<?xml version="1.0" encoding="utf-8" ?> <rss version="2.0" xml:base="https://mendelspod.com/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd"> <channel> <title>Mendelspod Podcast</title>
 <description>Mendelspod was founded in 2011 by Theral Timpson and Ayanna Monteverdi to advance life science research, connecting people and ideas. Influenced by the thinking tools developed by Eli Goldgratt, the founders bring a unique approach to media in the life sciences. With help from our advisors around the industry, Mendelspod goes beyond quick sound bites to create a space for probing conversations and deep insight into the topics and trends which shape the industry&#039;s future and therefore our future as a species.</description>
 <link>https://mendelspod.com/</link>
 <atom:link rel="self" href="https://mendelspod.com/feed.xml" />
 <language>en</language>
 <category>Science &amp; Medicine</category>
 <itunes:image href="http://mendelspod.com/sites/default/files/mendelspod_itunes_cover.jpg" />
 <copyright>© Copyright 2014 Mendelspod.com. All rights reserved. Los Gatos, California</copyright>
 <managingEditor>theral@mendelspod.com (Theral Timpson)</managingEditor>
 <webMaster>online@chempetitive.com (Chempetitive Group)</webMaster>
 <generator>Drupal 7</generator>
 <ttl>60</ttl>
 <pubDate>Wed, 04 Jan 2023 20:50:48 -0600</pubDate>
 <lastBuildDate>Mon, 09 Jan 2023 13:19:58 -0600</lastBuildDate>
 <itunes:category text="Science &amp; Medicine"> <itunes:category text="Natural Sciences" />
</itunes:category>
 <itunes:author>managingEditor</itunes:author>
 <itunes:explicit>clean</itunes:explicit>
 <itunes:owner> <itunes:email>theral@verizon.net</itunes:email>
</itunes:owner>
 <item> <title>Paul Freemont on Synthetic Biology in the UK</title>
 <link>https://mendelspod.com/podcasts/paul-freemont-synthetic-biology-uk/</link>
 <description>To begin the year, we head across the pond for an outlook on the thriving community of synthetic biology in the United Kingdom.

Paul Freemont was a co-author of the UK&#039;s synthetic biology roadmap and co-directs SynbiCITE, the national center for the commercialization of synthetic biology.   A few years ago the government put an initial investment of $300 million pounds into the field, and &quot;everything was going swimmingly well,&quot; says Paul.  &quot;Then COVID happened.&quot;</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Paul%20Freemont%202023%20Show.mp3" length="52691446" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/paul-freemont-synthetic-biology-uk/</guid>
 <pubDate>Wed, 04 Jan 2023 20:50:48 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Paul%2BFreemont.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>The Bioengineered Hangover Cure:  Changing the Conversation around GMOs with Zack Abbott of ZBiotics</title>
 <link>https://mendelspod.com/podcasts/bioengineered-hangover-cure-changing-conversation-around-gmos-zack-abbott-zbiotics/</link>
 <description>Our goal with today’s show was twofold:  bring you a practical holiday gift idea and to take you into the world of a synthetic biology entrepreneur.  Our guest:  Zack Abbott, CEO of ZBiotics.

Zack is a scientist turned businessman who is on a mission to change the conversation around GMOs.  His first product is a genetically engineered probiotic that alleviates the morning-after hangover by breaking down acetaldehyde.  Zack says he chose this product because it’s something consumers can choose to take—unlike a medicine that’s necessary like insulin.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Zack%20Abbot%202022%20Show.mp3" length="54107408" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/bioengineered-hangover-cure-changing-conversation-around-gmos-zack-abbott-zbiotics/</guid>
 <pubDate>Wed, 21 Dec 2022 22:28:19 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/zack-abbott.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Lance Baldo of Freenome on their Approach to Early Cancer Detection</title>
 <link>https://mendelspod.com/podcasts/lance-baldo-freenome-their-approach-early-cancer-detection/</link>
 <description>When excitement around early cancer detection first surfaced, we heard about the “pan-cancer” test that would look for any and all cancers, and early.  Now that we’re some years into it, the approach is turning out to be more of a narrow one.  Which cancer will we likely see targeted first with an FDA cleared test?  Colorectal, according to today’s guest.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Lance%20Baldo%20Show%202022%20Show.mp3" length="50303027" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/lance-baldo-freenome-their-approach-early-cancer-detection/</guid>
 <pubDate>Wed, 07 Dec 2022 20:57:04 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Lance%2BBaldo.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>What Is the Current State of COVID? with Mara Aspinall, Rockefeller Foundation</title>
 <link>https://mendelspod.com/podcasts/what-current-state-covid-mara-aspinall-rockefeller-foundation/</link>
 <description>Winter is here.  In America, we&#039;re just back from the Thanksgiving holiday when many of us travel and get together.  And so far there is no great COVID surge this year. 
Or is there?
Today&#039;s guest says there likely is, and we don&#039;t know it because of the most significant shift in our pandemic response: at-home testing.  </description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Mara%20Aspinall%202022%20Show.mp3" length="40939182" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/what-current-state-covid-mara-aspinall-rockefeller-foundation/</guid>
 <pubDate>Mon, 28 Nov 2022 22:02:50 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Mara-G.-Aspinall.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> Proteomics at Scale Empowers Genomics in New Ways: Dale Yuzuki, Olink</title>
 <link>https://mendelspod.com/podcasts/proteomics-scale-empowers-genomics-new-ways-dale-yuzuki-olink/</link>
 <description>It’s the age of multi omics.  Or multi comics, if you don&#039;t catch spell check.  A few weeks ago at the annual meeting of the American Society for Human Genetics, we were pleased to find not only genomics companies but some proteomics outfits finding a home.  As we chatted with one of these, Olink Proteomics,  we were blown away to hear that they were announcing the publication of 1,000 scientific papers.  It wasn’t so long ago that genomics companies were boasting this kind of milestone.  Has proteomics finally achieved scale?</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Dale%20Yuzuki%20Show%202022%20Show.mp3" length="36666794" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/proteomics-scale-empowers-genomics-new-ways-dale-yuzuki-olink/</guid>
 <pubDate>Mon, 21 Nov 2022 22:10:40 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Dale%20Yuzuki.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Is PGx Having a Moment?  Kristine Ashcraft, Invitae</title>
 <link>https://mendelspod.com/podcasts/pgx-having-moment-kristine-ashcraft-invitae/</link>
 <description>Pharmacogenomic testing, or PGx, is considered low-hanging fruit,  a no-brainer for the application of genetic testing in the clinic.  And some may think it is small fruit.  Not so, says today’s guest, Kristine Ashcraft.

&quot;Currently we lose a life every two minutes in the United States to non-optimized medications,” says Kristine in today’s show.  She has spent over twenty years working to see pharmacogenomic testing adopted into standard-of-care medicine. Kristine serves today as the Medical Affairs Director for PGx at the genetic testing company Invitae.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Kristine%20Ashcraft%20Show%202022.mp3" length="40234355" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/pgx-having-moment-kristine-ashcraft-invitae/</guid>
 <pubDate>Wed, 09 Nov 2022 21:43:59 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Kristine-Ashcraft.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Christian Henry on Revio, Onso and the New Vision at PacBio</title>
 <link>https://mendelspod.com/podcasts/christian-henry-revio-onso-and-new-vision-pacbio/</link>
 <description>Last week with a crowd of 1,200 customers in a Los Angeles nightclub, sequencing company Pacific Bioscience launched two new sequencers, both long and short read, Revio and Onso.  It was a night of great technology, music, and anticipation.  Their customers have waited a long time for this moment.  Revio offers long read whole genomes at scale for under $1,000.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Christian%20Henry%202022%20Show.mp3" length="51453960" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/christian-henry-revio-onso-and-new-vision-pacbio/</guid>
 <pubDate>Thu, 03 Nov 2022 01:05:45 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Christian%20Henry%20Revio%20Launch.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Paul Kruszka of GeneDx/Sema4 on Groundbreaking Newborn Sequencing Study</title>
 <link>https://mendelspod.com/podcasts/paul-kruszka-genedxsema4-groundbreaking-newborn-sequencing-study/</link>
 <description>Last week, during the first International Conference on Newborn Sequencing, a landmark study to sequence the genomes of 100,000 newborns was announced.  Called the GUARDIAN study, the project is the brainchild of Wendy Chung, Professor of Pediatrics at Columbia University.  The study will take place in New York State and is somewhat similar to an ongoing project in the U.K. being done by Genomics England.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Paul%20Kruszka%202022%20Show.mp3" length="24901156" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/paul-kruszka-genedxsema4-groundbreaking-newborn-sequencing-study/</guid>
 <pubDate>Thu, 13 Oct 2022 00:23:22 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Paul%20Kruszka.jpeg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Terry Lo of Vizgen on Spatial Genomics</title>
 <link>https://mendelspod.com/podcasts/terry-lo-vizgen-spatial-genomics/</link>
 <description>Today spatial biology company, Vizgen, makes their debut on on the program.

When Vizgen CEO Terry Lo was first involved in developing what we now call spatial biology at Perkin Elmer, he admits that he never thought it would have a genomics side to it.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Terry%20Lo%20Show%202022%20Show.mp3" length="32712289" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/terry-lo-vizgen-spatial-genomics/</guid>
 <pubDate>Tue, 27 Sep 2022 10:58:27 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Terry-Lo-CEO-Vizgen_0.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> Invitae’s Data Manager, Farid Vij, on New Genome Management Platform</title>
 <link>https://mendelspod.com/podcasts/invitaes-data-manager-farid-vij-new-genome-management-platform/</link>
 <description>One thinks of Invitae as a leading genetic testing company that has worked to improve clinical quality while bringing prices down.  And they are, and they have.  But after listening to today&#039;s show, you will see that their vision is bigger than that.

Farid Vij is the President and General Manager of Data at Invitae.  A year ago Invitae bought a company he co-founded called Ciitizen which was focused on providing patients with access to their complete medical records.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Farid%20Vij%20Show%202022.mp3" length="32380257" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/invitaes-data-manager-farid-vij-new-genome-management-platform/</guid>
 <pubDate>Wed, 21 Sep 2022 21:07:58 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/farid-vij-headshot.png" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>A New Tool in the Genomics Kit with Ivan Liachko of Phase Genomics</title>
 <link>https://mendelspod.com/podcasts/new-tool-genomics-kit-ivan-liachko-phase-genomics/</link>
 <description>Have you ever heard of proximity ligation?   We knew of it in research form back in the day, but not that it had been commercialized until this summer.   It’s not every day we come across a powerful new genomics tool on this program.  Which begs the question, where have Ivan Liachko and his company, Phase Genomics, been hiding?

The company received a grant this summer from the Bill Gates Foundation as well as the NIH to pursue phage therapeutics.  That’s using viruses to go after bacterial infections, particularly those which are developing antibiotic resistance.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Ivan%20Liachko%20Show%202022%20Show.mp3" length="43405440" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/new-tool-genomics-kit-ivan-liachko-phase-genomics/</guid>
 <pubDate>Wed, 14 Sep 2022 12:26:59 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/ivan_headshot.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Satellite Bio out with a New Tissue Based Approach to Regenerative Medicine</title>
 <link>https://mendelspod.com/podcasts/satellite-bio-out-new-tissue-based-approach-regenerative-medicine/</link>
 <description>Satellite Bio is named descriptively for the way its platform works.  Out of stealth in the past few months with what you might call a middle ground approach to generative medicine between stem cell therapy and organ transplant, the company takes its name from the tissue therapy constructs they surgically implant in patients.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/David%20Lennon%20Show%202022.mp3" length="31882154" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/satellite-bio-out-new-tissue-based-approach-regenerative-medicine/</guid>
 <pubDate>Wed, 24 Aug 2022 23:08:11 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Dave%20Lennon%20square_0.jpeg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>The Revolution in Single Molecule Sequencing Continues: Vijay Ramani, UCSF</title>
 <link>https://mendelspod.com/podcasts/revolution-single-molecule-sequencing-continues-vijay-ramani-ucsf/</link>
 <description>A new generation of biologists is pushing the limits of third-generation sequencing, furthering the technology&#039;s development and defining new applications to answer biology’s most pressing questions.

This is the express goal for the lab of Vijay Ramani, assistant professor at UCSF in the department of Biophysics and Biochemistry. Vijay also has an appointment in the Institute of Data Science and Biotechnology at the Gladstone Institute, and in 2019 he was named to the Forbes 30 under 30 rising stars in healthcare list.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Vijay%20Ramani%202022%20Show.mp3" length="44050729" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/revolution-single-molecule-sequencing-continues-vijay-ramani-ucsf/</guid>
 <pubDate>Wed, 17 Aug 2022 22:40:06 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/vijay-ramani-headshot.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Will Hwang of Mass General on Discovery of Novel Pancreatic Cancer Cell Subtype</title>
 <link>https://mendelspod.com/podcasts/will-hwang-mass-general-discovery-novel-pancreatic-cancer-cell-subtype/</link>
 <description>In our age of specialization, today’s guest, Dr. Will Hwang of Massachusetts General, went against the trend and received three bachelor degrees in different fields.

Or is this the new trend?

Will says that despite the diversity of pursuits, there was a thread that ran throughout his life as a student.  He always liked to look at things at the fundamental unit.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Will%20Whang%202022%20Show.mp3" length="34391624" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/will-hwang-mass-general-discovery-novel-pancreatic-cancer-cell-subtype/</guid>
 <pubDate>Wed, 10 Aug 2022 22:41:49 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Will%20Hwang.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> Lee Cronin on Origin of Life, Genomics, Aliens and More</title>
 <link>https://mendelspod.com/podcasts/lee-cronin-origin-life-genomics-aliens-and-more/</link>
 <description>While we’re able to sit outside on a warm summer’s night under the ocean of stars, let us contemplate some of the bigger questions. 
We’re very excited to start out our twelfth season of the podcast with the chemist, Lee Cronin, from the University of Glasgow.   Lee published an &lt;a href=&quot;https://www.nature.com/articles/s41467-021-23258-x&quot;&gt;original and fundamental theory&lt;/a&gt; about the universe in the weeks after we taped which has profound implications for the question about the origin of life and could have some interesting applications in genomics.  </description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Lee%20Cronin%202022%20Show.mp3" length="42395272" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/lee-cronin-origin-life-genomics-aliens-and-more/</guid>
 <pubDate>Mon, 01 Aug 2022 00:51:01 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/lee_cronin_sq.jpeg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Going Beyond Time Barriers:  Arutha Kulasinghe on the Power of New Spatial Biology Tools</title>
 <link>https://mendelspod.com/podcasts/going-beyond-time-barriers-arutha-kulasinghe-power-new-spatial-biology-tools/</link>
 <description>Arutha Kulasinghe was pumped for the AGBT (Advances in Genome Biology and Technology) Conference this year.  He is the Principal Investigator for the Clinical-oMx Lab at the University of Queensland.  Dr. Kulasinghe has pioneered spatial transcriptomics using digital spatial profiling approaches in the Asia-Pacific region, contributing to world-first studies for lung, head, and neck cancer and COVID-19.   Not gathering last year due to the pandemic, the AGBT conference has became a kind of revival for genome biologists.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Arutha%20Kulasinghe%202022%20Show.mp3" length="37659533" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/going-beyond-time-barriers-arutha-kulasinghe-power-new-spatial-biology-tools/</guid>
 <pubDate>Thu, 07 Jul 2022 00:51:24 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/arutha_kulasinghe.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Eric Green on the Future of the NHGRI</title>
 <link>https://mendelspod.com/podcasts/eric-green-future-nhgri/</link>
 <description>Dr. Eric Green has been the Director of the National Human Genome Research Institute (NHGRI) at the National Institutes of Health (NIH) since 2009.  Two years ago, he and his colleagues at the Institute came up with a strategic plan for the next ten years.  Today we discuss the plan with the director and get his outlook on the future of human genomics.

Dr. Green says human genomics can be roughly divided into four chapters.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Eric%20Green%202022%20Show.mp3" length="47382861" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/eric-green-future-nhgri/</guid>
 <pubDate>Mon, 27 Jun 2022 22:58:22 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Erik%20Green.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>We Have to Get Sequencing Back to Moore’s Law:  Gilad Almogy, Ultima Genomics</title>
 <link>https://mendelspod.com/podcasts/we-have-get-sequencing-back-moore%E2%80%99s-law-gilad-almogy-ultima-genomics/</link>
 <description>There was a tweet thread at the end of the recent Advances in Genome Biology and Technology (AGBT) conference where researchers took a moment of silence for all the sequencing companies that have announced big plans at the conference and then died.  It was clearly aimed at this year’s sequencing tools entrant and buzz-generating Ultima Genomics.  The company emerged from stealth the week before AGBT announcing the $100 genome with a purse of $600 million backed by funders including Khosla Ventures, Andreessen, and Founders Fund.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Gilad%20Almogy%202022%20Show.mp3" length="53663369" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/we-have-get-sequencing-back-moore%E2%80%99s-law-gilad-almogy-ultima-genomics/</guid>
 <pubDate>Wed, 22 Jun 2022 23:31:19 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Gilad%20Almogy.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> RNA Therapeutics:  A New Paradigm for Drug Development? Tim Mercer, BASE Lab, U of Queensland</title>
 <link>https://mendelspod.com/podcasts/rna-therapeutics-new-paradigm-drug-development-tim-mercer-base-lab-u-queensland/</link>
 <description>Has the pandemic unleashed the molecule of RNA to be the new future of drug development?

Tim Mercer is the Director of the BASE Lab at the University of Queensland which has recently become one of Australia’s leading national facilities for the manufacture and research of RNA technologies.  Tim is the next guest in our series on enzymatic DNA synthesis which he says is &quot;a quantum shift” in our ability to synthesize DNA.

Tim then goes on to explore the future of mRNA vaccines and other RNA therapeutics.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Tim%20Mercer%20Show%202022.mp3" length="43231282" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/rna-therapeutics-new-paradigm-drug-development-tim-mercer-base-lab-u-queensland/</guid>
 <pubDate>Thu, 16 Jun 2022 00:33:30 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Tim%20Mercer.jpeg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>The System is Working.  We Need More Engagement, Says ClinVar Champion Heidi Rehm of Mass General in Her Update on the State of Genomic Medicine in 2022</title>
 <link>https://mendelspod.com/podcasts/system-working-we-need-more-engagement-says-clinvar-champion-heidi-rehm-mass-general-her/</link>
 <description>Heidi Rehm’s talents for genomics are legendary.  Our field has devoured them like a hungry beast.

Discovering an appreciation for the natural logic of genetics in her early school years, Heidi would later learn she was good at the standardization of genomic databases for clinical use. This would make her a pioneering superstar of genomic medicine.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Heidi%20Rehm%202022%20Show.mp3" length="52522453" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/system-working-we-need-more-engagement-says-clinvar-champion-heidi-rehm-mass-general-her/</guid>
 <pubDate>Thu, 09 Jun 2022 10:00:52 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Heidi%20Rehm.jpeg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>The Promise of Exosomes Now Realized, Says Paul Billings, CEO, Biological Dynamics</title>
 <link>https://mendelspod.com/podcasts/promise-exosomes-now-realized-says-paul-billings-ceo-biological-dynamics/</link>
 <description>The area of early cancer detection continues to become ever more exciting these days. Each month more companies add liquid biopsies to their product offering as new technologies advance and are able to recognize cancer with increased sensitivity and specificity, particularly from cell-free DNA in the blood.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Paul%20Billings%202022%20Show.mp3" length="49907628" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/promise-exosomes-now-realized-says-paul-billings-ceo-biological-dynamics/</guid>
 <pubDate>Wed, 01 Jun 2022 19:04:02 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Paul_R_Billings.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>5-Base Sequencing:  Jonas Korlach and Tomi Pastinen</title>
 <link>https://mendelspod.com/podcasts/5-base-sequencing-jonas-korlach-and-tomi-pastinen/</link>
 <description>Pacific Biosciences has introduced a new method for detecting DNA methylation simultaneously with DNA sequencing.  They are calling it 5-base sequencing.

Today on the program, Jonas Korlach, PacBio’s Chief Scientific Officer, and Tomi Pastinen, the Director of the Genomic Medicine Center at Children’s Mercy Research Institute in Kansas City join us to describe the new breakthrough and connect it to clinical possibilities.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Jonas%20Korlach%20and%20Tomi%20Pastinen%202022.mp3" length="40719862" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/5-base-sequencing-jonas-korlach-and-tomi-pastinen/</guid>
 <pubDate>Wed, 25 May 2022 10:46:22 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/the-role-of-dna-methylation-in-human-disease-355520-1280x720.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> More Cancer Patients Die from Infections than Cancer, Says Alec Ford, CEO of Karius</title>
 <link>https://mendelspod.com/podcasts/more-cancer-patients-die-infections-cancer-says-alec-ford-ceo-karius/</link>
 <description>Alec Ford is passionate about his message.  No wonder.  There&#039;s an astounding fact in cancer medicine that is little known and could make a big difference.  More cancer patients are dying from infections than they are from their cancers.  And Alec&#039;s company has the technology to do something about it.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Alec%20Ford%20Show%202022.mp3" length="43416480" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/more-cancer-patients-die-infections-cancer-says-alec-ford-ceo-karius/</guid>
 <pubDate>Wed, 18 May 2022 09:53:38 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Alec%20Ford.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Some of the Lowest Hanging Fruits in Precision Medicine: Michelle Whirl-Carrillo on Pharmacogenomics</title>
 <link>https://mendelspod.com/podcasts/some-lowest-hanging-fruits-precision-medicine-michelle-whirl-carrillo-pharmacogenomics/</link>
 <description>One of the underrated but true successes of precision medicine has been pharmacogenomics.   Beginning in the ’90s with the approval of the drug Herceptin for HER2 positive breast cancer, tailoring drugs to genotype has been one of the less controversial areas of our field and will only continue to build on the early promise of sequencing the human genome.

Today we talk Michelle Whirl-Carrillo, Director of PharmGKB, a one-stop go-to for pharmacogenomics data that has been funded by the NIH since 2000.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Michelle%20Whirl-Carrillo%202022%20Show.mp3" length="38495532" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/some-lowest-hanging-fruits-precision-medicine-michelle-whirl-carrillo-pharmacogenomics/</guid>
 <pubDate>Mon, 09 May 2022 21:31:10 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Michelle%20Whirl-Carrillo.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>John Nelson of GE Research Talks Vaccines on Demand, Enzymatic Synthesis, and the Era of Writing DNA</title>
 <link>https://mendelspod.com/podcasts/john-nelson-ge-research-talks-vaccines-demand-enzymatic-synthesis-and-era-writing-dna/</link>
 <description>Today we talk with John Nelson, Senior Principal Scientist at GE Research and veteran in the field of DNA synthesis.  On January 7th, 2020, two weeks before the first cases of the coronavirus were reported in the U.S, John and a team of scientists and engineers proposed a new project to DARPA called NOW, or Nucelic Acids on Demand Worldwide.  The goal of the project, now fully underway, is to deliver DNA-based vaccines anywhere in the world in three days.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/john%20Nelson%202022%20Show.mp3" length="44119353" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/john-nelson-ge-research-talks-vaccines-demand-enzymatic-synthesis-and-era-writing-dna/</guid>
 <pubDate>Wed, 13 Apr 2022 22:04:17 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/John%20Nelson_0.png" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> A New Generation Comfortable Doing a Thousand Things at a Time Is Reinventing Life Science Says Joe Beechem of NanoString</title>
 <link>https://mendelspod.com/podcasts/new-generation-comfortable-doing-thousand-things-time-reinventing-life-science-says-joe/</link>
 <description>“I’ve seen a lot of revolutions.  Now we’re at the beginning of spatial biology, and I think it has the chance to transform life science similar to next gen sequencing, but even more.  It’s going to have more ramifications that spread through more disciplines than any of the revolutions I’ve seen in a while.”</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Joe%20Beechem%202022%20Show.mp3" length="49223530" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/new-generation-comfortable-doing-thousand-things-time-reinventing-life-science-says-joe/</guid>
 <pubDate>Wed, 06 Apr 2022 21:36:31 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Joe%20Beechem.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Enabling a New Age of Unbiased Proteomics Discovery: Omid Farokhzad, Seer Inc.</title>
 <link>https://mendelspod.com/podcasts/enabling-new-age-unbiased-proteomics-discovery-omid-farokhzad-seer-inc/</link>
 <description>Are we now entering the age of proteomics the way we did with genomics thirty years ago?

We were told we should talk to today’s guest by four people in one week.  He’s Omid Farokhzad, CEO and Founder of Seer Inc.  When we did, we understood why.

Seer offers its customers the chance to “see the proteome in a way that’s never been possible before.”  So what does that mean?</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Omid%20Farokhzad%202022%20Show.mp3" length="53827355" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/enabling-new-age-unbiased-proteomics-discovery-omid-farokhzad-seer-inc/</guid>
 <pubDate>Wed, 30 Mar 2022 20:41:59 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Omid_Farokhzad.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>The Rise of MRD Testing and the Field of Fragmentomics with Sugganth Daniel, Invitae</title>
 <link>https://mendelspod.com/podcasts/rise-mrd-testing-and-field-fragmentomics-sugganth-daniel-invitae/</link>
 <description>&quot;There&#039;s an entire field of fragmentomics with a whole lot of people working on it.  The DNA which is shed into the bloodstream has a certain length.   The length of ctDNA is shorter than cfDNA, and depending on where the cancer cell is located, the fragment size and pattern is different.  So you can actually deduce information about the tissue of origin from the fragment length and pattern.  And that&#039;s just the beginning.&quot;</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Sugganth%20Daniel%20Show%202022.mp3" length="43247961" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/rise-mrd-testing-and-field-fragmentomics-sugganth-daniel-invitae/</guid>
 <pubDate>Wed, 16 Mar 2022 23:40:01 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Sugganth%20Daniel.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>The Invention of Enzymatic DNA Synthesis with Sylvain Gariel, DNA Script</title>
 <link>https://mendelspod.com/podcasts/invention-enzymatic-dna-synthesis-sylvain-gariel-dna-script/</link>
 <description>The DNA synthesis space is seeing some real creativity and disruption this past year.  One newcomer, in particular, is shaking things up.

Sylvain Gariel is the co-founder and chief operating officer of DNA Script, who has recently launched the world’s first benchtop enzymatic DNA synthesizer.  In today&#039;s show, Sylvain, co-inventor of the new system, tells how he met his co-inventors at a French gas company and came to invent a whole new way of writing DNA.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Sylvain%20Gariel%20Show%202022.mp3" length="38395098" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/invention-enzymatic-dna-synthesis-sylvain-gariel-dna-script/</guid>
 <pubDate>Wed, 02 Mar 2022 21:09:38 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Sylvain%20Gariel%20DNA%20Script%20Headshot.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> Akoya Biosciences Launches New Integrated Spatial Platform: Our First Interview with CEO Brian McKelligon</title>
 <link>https://mendelspod.com/podcasts/akoya-biosciences-launches-new-integrated-spatial-platform-our-first-interview-ceo-brian/</link>
 <description>Even though Brian McKelligon calls himself a rookie CEO,  he comes to the top position at Akoya Biosciences with a veteran’s resume.  His path to one of spatial biology’s hottest companies in 2022 worked him up the ranks of some of the top names in life science tools:  Affymetrix, Ingenuity, Ion Torrent, and 10X Genomics.  Last year Brian led Akoya through an IPO and this year the company has launched a new integrated product line called the Phenocycler-Fusion which they are calling the fastest single-cell spatial biology system on the market.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Brian%20McKelligon%20Show.mp3" length="35882650" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/akoya-biosciences-launches-new-integrated-spatial-platform-our-first-interview-ceo-brian/</guid>
 <pubDate>Wed, 23 Feb 2022 19:38:24 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Brian-McKelligon.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> Harlan Robins on How T-cell Focused COVID Vaccines Can Move Us Toward Endemicity</title>
 <link>https://mendelspod.com/podcasts/harlan-robins-how-t-cell-focused-covid-vaccines-can-move-us-toward-endemicity/</link>
 <description>Harlan Robins is the Chief Scientific Officer at Adaptive Biotechnologies in Seattle.  In 2014, Harlan and his brother Chad co-founded Adaptive as a spinout from the Fred Hutchinson Cancer Center where Harlan had served as the head of computational biology.   Adaptive has been developing what they call &quot;immune medicine&quot; mainly in the area of cancer.  When the corona virus pandemic hit, they came out with the world’s first T cell-based COVID diagnostic.  The test has garnered them a lot of data on T cell response to COVID.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Harlan%20Robins%20Show%202022.mp3" length="31287168" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/harlan-robins-how-t-cell-focused-covid-vaccines-can-move-us-toward-endemicity/</guid>
 <pubDate>Wed, 16 Feb 2022 12:25:41 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Harlan%20Robins%5B1%5D.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Twist Bioscience:  A New Kind of DNA Synthesis Company</title>
 <link>https://mendelspod.com/podcasts/twist-bioscience-new-kind-dna-synthesis-company/</link>
 <description>“DNA is changing everything for the better,” says today’s guest, Emily Leproust, CEO of Twist Bioscience. Twist has emerged at the heart of what a New York Times Magazine write-up recently headlined &lt;a href=&quot;https://www.nytimes.com/2021/11/24/magazine/gene-synthesis.html&quot; target=&quot;_blank&quot;&gt;The Gene Synthesis Revolution&lt;/a&gt;. </description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Emily%20Leproust%202022%20Show_0.mp3" length="51667088" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/twist-bioscience-new-kind-dna-synthesis-company/</guid>
 <pubDate>Wed, 09 Feb 2022 21:10:10 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Emily%20Leproust_1.png" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Going High Resolution with 10X Genomics:  Michael Schnall-Levin</title>
 <link>https://mendelspod.com/podcasts/going-high-resolution-10x-genomics-michael-schnall-levin/</link>
 <description>Working at the Broad Institute early in his career, Michael Schnall Levin was discovering he was a biologist at heart.  He’d begun his studies in physics then done his PhD in mathematics.  But he&#039;d wanted “to do math that had an application in the real world.”  It was at the Broad that Michael came in contact with the new tools that were revolutionizing biology.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Michael%20Schnall-Levin%202022%20Show.mp3" length="48111396" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/going-high-resolution-10x-genomics-michael-schnall-levin/</guid>
 <pubDate>Wed, 26 Jan 2022 21:11:13 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/michael-schnall-levin.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>George Church and Ben Lamm on the Launch of Colossal Biosciences</title>
 <link>https://mendelspod.com/podcasts/george-church-and-ben-lamm-launch-colossal-biosciences/</link>
 <description>According to scientists, 30,000 species per year are going extinct.  That’s 6 an hour, 150 per day.  Up to one half of all species could be extinct by 2050.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/George%20and%20Ben%20Colossal%202022.mp3" length="29994723" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/george-church-and-ben-lamm-launch-colossal-biosciences/</guid>
 <pubDate>Thu, 20 Jan 2022 05:57:46 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/ben_george.jpeg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> We Might Be the Comeback Kids of the Universe:  Chris Mason on His Plan for the Next 500 Years</title>
 <link>https://mendelspod.com/podcasts/we-might-be-comeback-kids-universe-chris-mason-his-plan-next-500-years/</link>
 <description>Chris Mason is back on the program for our end-of-year special. He’s Professor of Genomics, Physiology, and Biophysics at Weill Cornell School of Medicine and the author of such an outstanding book that we had to have him on the program a second time this year.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Chris%20Mason%20Next%20500%20Yrs%20Show_0.mp3" length="63393671" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/we-might-be-comeback-kids-universe-chris-mason-his-plan-next-500-years/</guid>
 <pubDate>Tue, 21 Dec 2021 03:03:56 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Book%20Next%20500%20Yrs.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> Invitae and PacBio CEOs Share Details of Clinical Sequencing Partnership</title>
 <link>https://mendelspod.com/podcasts/invitae-and-pacbio-ceos-share-details-clinical-sequencing-partnership/</link>
 <description>In a joint interview, Sean George, CEO of diagnostics firm, Invitae, and Christian Henry, CEO of sequencing tools company, Pacific Biosciences, say that “it was clear in the first five minutes of a phone call that they shared a vision for doing something big together.”

What comes through the interview is that this partnership is built on a big vision: speeding up the adoption of whole genome sequencing into clinical medicine as the preferred method for genetic testing.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Sean%20and%20Christian%202021%20Show_0.mp3" length="65304375" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/invitae-and-pacbio-ceos-share-details-clinical-sequencing-partnership/</guid>
 <pubDate>Tue, 07 Dec 2021 00:40:03 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Sean%20and%20Christian.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Building on the Knowledge Base of Developer Community,  LuminexPLORE Lab Offers Custom Insights: Jackie Surls, Director</title>
 <link>https://mendelspod.com/podcasts/building-knowledge-base-developer-community-luminexplore-lab-offers-custom-insights-jackie/</link>
 <description>There are some technologies that become so ubiquitous in biomedical research that their name turns synonymous with their use.  This has been the case for the Luminex xMAP platform and multiple biomarker analysis.   The product has been applied in just about every area of life sciences including infectious disease, STD, organ transplant rejection, vaccine development, cancer research, immunodeficiency, animal testing, agriculture, and others.  (xMAP is a research use only product and not for use in diagnostic procedures.)</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Jackie%20Surls%20Show%202021_0.mp3" length="27364519" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/building-knowledge-base-developer-community-luminexplore-lab-offers-custom-insights-jackie/</guid>
 <pubDate>Tue, 30 Nov 2021 02:59:33 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/jacqueline-surls.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>DNA Script Takes DNA Synthesis Back to the Bench with Enzymatic Tech: Thomas Ybert, CEO</title>
 <link>https://mendelspod.com/podcasts/dna-script-takes-dna-synthesis-back-bench-enzymatic-tech-thomas-ybert-ceo/</link>
 <description>DNA is a multibillion-dollar industry in 2021 and satisfies many life science applications, including drugs, reagents, siRNA, PCR, diagnostics, synthetic biology, and many others.  Enzymatic DNA synthesis, or EDS, is a new approach to manufacturing DNA that is much more efficient and user-friendly and could disrupt the current market.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Thomas%20Ybert%20Show%202021.mp3" length="33616577" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/dna-script-takes-dna-synthesis-back-bench-enzymatic-tech-thomas-ybert-ceo/</guid>
 <pubDate>Wed, 17 Nov 2021 10:06:47 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Thomas%20Ybert%20DNA%20Script%20High%20Res%20Headshot.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Tumor Evolution in Context with Christina Curtis	</title>
 <link>https://mendelspod.com/podcasts/tumor-evolution-context-christina-curtis/</link>
 <description>If one was going to be a cancer researcher, surely one would want to be Christina Curtis.  She’s an associate professor of oncology and genetics at Stanford, and she studies tumor evolution.  She’s the Darwin of cancer research.

Because scientists can’t see human tumors evolve in real life, in Christina&#039;s lab she creates what she calls &quot;virtual tumors that recapitulate the size and spatial properties of an actual tumor.  And evaluating patient data,” she says,  &quot;we have found that metastatic seeding could happen very early.  That these tumors were born to be bad.”</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Christina%20Curtis%202021%20Show.mp3" length="36776146" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/tumor-evolution-context-christina-curtis/</guid>
 <pubDate>Thu, 11 Nov 2021 10:19:13 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Christina%20Curtis.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>The History of mRNA Vaccines with Elie Dolgin</title>
 <link>https://mendelspod.com/podcasts/history-mrna-vaccines-elie-dolgin/</link>
 <description>&quot;Scientists have been putting RNA into cells through a lipid delivery system for 44 years,” says Elie Dolgin. “And that’s ultimately the vaccine that has gone into millions of arms.”
Elie is the author of a recent piece in Nature magazine, &lt;a href=&quot;https://www.nature.com/articles/d41586-021-02483-w&quot; target=&quot;_blank&quot;&gt;The Tangled History of mRNA Vaccines&lt;/a&gt;.  He joins us to talk about his quest to uncover the winding journey that led to the cure that is moving the world forward.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Elie%20Dolgin%202021%20Show.mp3" length="58493161" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/history-mrna-vaccines-elie-dolgin/</guid>
 <pubDate>Wed, 03 Nov 2021 21:59:42 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Elie%20Dolgin.jpeg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> Hundreds of Thousands of Biological Molecules Undiscovered in Plant Chemical Space Says Founder of New Drug Discovery Company</title>
 <link>https://mendelspod.com/podcasts/hundreds-thousands-biological-molecules-undiscovered-plant-chemical-space-says-founder-new/</link>
 <description>“Why do plants make a host of chemicals they don’t use?  One answer that has always intrigued me is that, unlike us, they can’t walk up and walk away from an environment they don’t like.  Evolution has honed this space for over 400 million years.”</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Viswa%20Colluru%202021%20Show.mp3" length="38346237" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/hundreds-thousands-biological-molecules-undiscovered-plant-chemical-space-says-founder-new/</guid>
 <pubDate>Mon, 01 Nov 2021 21:11:49 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Viswa%20Colluru.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> Quantitative Pathology with David Rimm, Yale</title>
 <link>https://mendelspod.com/podcasts/quantitative-pathology-david-rimm-yale/</link>
 <description>David Rimm, Professor of Pathology at Yale, was doing spatial biology since before it was called that.  He’s known for counting.  And he’s been going beyond—beneath?--the model of the cell in biology for years.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/David%20Rimm%202021%20Show.mp3" length="34696129" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/quantitative-pathology-david-rimm-yale/</guid>
 <pubDate>Mon, 25 Oct 2021 17:26:11 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/David_Rimm_2_0.png" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>The State of Comprehensive Genomic Profiling at One of America’s Largest Health Systems with Carlo Bifulco</title>
 <link>https://mendelspod.com/podcasts/state-comprehensive-genomic-profiling-one-america%E2%80%99s-largest-health-systems-carlo-bifulco/</link>
 <description>Carlo Bifulco joins us today.  He’s an Italian who helped persuade one of America’s largest not-for-profit health systems that providing more genomic information to cancer patients early on was the right thing.  With 52 hospitals, over 1,000 physician clinics, more than 120,000 caregivers serving communities across seven states—Alaska, California, Montana, New Mexico, Oregon, Texas, and Washington—Providence and Carlo have quite a task ahead.  We ask Carlo what is the state of comprehensive genomic profiling at Providence today?
</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Carlo%20Bifulco%202021%20Show.mp3" length="34837733" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/state-comprehensive-genomic-profiling-one-america%E2%80%99s-largest-health-systems-carlo-bifulco/</guid>
 <pubDate>Mon, 18 Oct 2021 21:41:01 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Carlo%20Bifulco.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Inside the World of Genome Engineering at Amyris with Kirsten Benjamin, VP of R&amp;D</title>
 <link>https://mendelspod.com/podcasts/inside-world-genome-engineering-amyris-kirsten-benjamin-vp-rd/</link>
 <description>If a company knows genome engineering, that would be Emeryville based Amyris, the Bay Area&#039;s crown jewel for synthetic biology.  Founded back in 2003, the company first worked on creating biofuels from yeast.  Today they have retooled their platform to produce a diversified line of consumer products that have not only rewarded their bottom line but point the world to a model of sustainable consumer goods.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Kirsten%20Benjamin%202021%20Show-Rerun.mp3" length="33006927" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/inside-world-genome-engineering-amyris-kirsten-benjamin-vp-rd/</guid>
 <pubDate>Mon, 04 Oct 2021 12:50:47 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Kirsten%20Benjamin_Amyris.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Clinical Genetics 2021 Highlights: Laura Hercher, Host of the Beagle Landed Podcast</title>
 <link>https://mendelspod.com/podcasts/clinical-genetics-2021-highlights-laura-hercher-host-beagle-landed-podcast/</link>
 <description>Laura Hercher, host of our sister podcast, &lt;a href=&quot;https://beaglelanded.com&quot; target=&quot;_blank&quot;&gt;The Beagle Has Landed&lt;/a&gt;, joins us today to compare notes. Her gig is much more focused on the clinical side of genomics. Genetic counselors are her core audience. Today we do a highlights show looking back over the Beagle&#039;s past year.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Laura%20Hercher%202021%20Show.mp3" length="48797288" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/clinical-genetics-2021-highlights-laura-hercher-host-beagle-landed-podcast/</guid>
 <pubDate>Tue, 21 Sep 2021 10:17:36 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/laura%20hercher_0.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> A New Way to Phenotype Life:  Chris Mason Talks Spatial Biology, His New Book</title>
 <link>https://mendelspod.com/podcasts/new-way-phenotype-life-chris-mason-talks-spatial-biology-his-new-book/</link>
 <description>Chris Mason, Professor of Physiology and Biophysics and prolific genomics researcher at Weill Cornell Medicine, joins us to talk about what he’s doing with the new generation of spatial biology tools.
The first papers we dive into are his work on COVID. Chris says the spatial tools have shown us the ravages of the coronavirus on the body like nothing we’ve seen before, i.e. the tissue damage from the cytokine storms and “the long term perturbations such as seeing cells far apart that were usually hanging out together.”</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Chris%20Mason%202021%20Show.mp3" length="38289357" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/new-way-phenotype-life-chris-mason-talks-spatial-biology-his-new-book/</guid>
 <pubDate>Mon, 09 Aug 2021 21:27:13 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Chris%20Mason_1.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>The Impact of Spatial Technology on Childhood Cancers with David Steffin, Texas Children&#039;s</title>
 <link>https://mendelspod.com/podcasts/impact-spatial-technology-childhood-cancers-david-steffin-texas-childrens/</link>
 <description>David Steffin is a cancer researcher and physician at Texas Children&#039;s whose particular focus is on pediatric cancers. He begins today’s program with some interesting numbers.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/David%20Steffin%20Show%202021.mp3" length="34912895" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/impact-spatial-technology-childhood-cancers-david-steffin-texas-childrens/</guid>
 <pubDate>Mon, 02 Aug 2021 22:28:36 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/david-steffin.jpeg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Robert Green: Newborn Sequencing Is the Goal Here in the U.S.</title>
 <link>https://mendelspod.com/podcasts/robert-green-newborn-sequencing-goal-here-us/</link>
 <description>&quot;If you go to a scientific meeting, even with the greatest critics, and you ask, how many people in this audience believe that your entire genome will be part of your everyday medical care in fifty years, every person will raise their hand.  So the only questions we’re debating are: how do we get there, how soon can we get there, and what evidence base must we have in place before we get there?  What’s really exciting to me is getting there sooner rather than later.  If we get there 20 years sooner, we are saving thousands of people&#039;s lives.”</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Robert%20Green%20Show%202021.mp3" length="44704850" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/robert-green-newborn-sequencing-goal-here-us/</guid>
 <pubDate>Thu, 29 Jul 2021 10:41:44 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/RobertGreen.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>The Studies Are In—Optical Mapping Can Replace Traditional Cytogenetics Tests</title>
 <link>https://mendelspod.com/podcasts/studies-are-%E2%80%94optical-mapping-can-replace-traditional-cytogenetics-tests/</link>
 <description>We’re all aware of the way that next gen sequencing has changed many tests in the clinical laboratory.  But some testing has held stubbornly resistant to change.  This has been the case in cytogenetics, or the analysis of chromosomes.  That is now changing thanks to a technology that is making inroads where next gen sequencing could not.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Alex%20Hoischen%20Show%202021.mp3" length="24273092" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/studies-are-%E2%80%94optical-mapping-can-replace-traditional-cytogenetics-tests/</guid>
 <pubDate>Mon, 12 Jul 2021 11:31:09 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Alex%20Hoischen.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> Amy Sturm of Geisinger on FH Testing and New Implementation Science</title>
 <link>https://mendelspod.com/podcasts/amy-sturm-geisinger-fh-testing-and-new-implementation-science/</link>
 <description>&quot;We have all of these evidence based tools and evidence based methods, but the problem is it can take upwards of 20 plus years to be truly implemented into care where healthcare providers are using them and patients are receiving them.  And this includes medications and diagnostic tools and other types of treatment or screening.”</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Amy%20Sturm%202021%20Show.mp3" length="41486386" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/amy-sturm-geisinger-fh-testing-and-new-implementation-science/</guid>
 <pubDate>Wed, 07 Jul 2021 11:26:33 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/amy_sturm_0.jpeg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Out of the Reductionist Trap:  Brad Gray of NanoString on Spatial Biology</title>
 <link>https://mendelspod.com/podcasts/out-reductionist-trap-brad-gray-nanostring-spatial-biology/</link>
 <description>One of the hottest new trends in biomedical research today is what is known as spatial biology--the ability to capture tissues in a 3D context. It was named &lt;a href=&quot;https://www.nature.com/articles/s41592-020-01042-x&quot; target=&quot;_blank&quot;&gt;Method of the Year&lt;/a&gt; by Nature Magazine in 2020.
And one of the first automated instruments launched in this market was the GeoMx Digital Spatial Profiler by NanoString. CEO Brad Gray is here to tell us the story of the birth of the DSP and the revolution of 3D biology. What will these new tools enable for the basic and translational researcher?
</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Brad%20Gray%202021%20Show.mp3" length="33535969" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/out-reductionist-trap-brad-gray-nanostring-spatial-biology/</guid>
 <pubDate>Wed, 19 May 2021 15:19:12 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Brad%20Gray_0.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Precision Oncology at the Community Level with Lee Schwartzberg</title>
 <link>https://mendelspod.com/podcasts/precision-oncology-community-level-lee-schwartzberg/</link>
 <description>When Lee Schwartzberg did his training as an oncologist some thirty years ago at Memorial Sloan Kettering in New York, he had a dream.  And after training, he set off to make that dream a reality: to bring the resources, expertise, and research that one enjoys at a major research hospital cancer center to the community level.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Lee%20Schwartzberg%202021%20Show.mp3" length="47254565" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/precision-oncology-community-level-lee-schwartzberg/</guid>
 <pubDate>Wed, 05 May 2021 20:16:44 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/lee-schwartzberg-.png" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Daniel Kraft on the Digitome and COVID</title>
 <link>https://mendelspod.com/podcasts/daniel-kraft-digitome-and-covid/</link>
 <description>“The new drug is the engaged individual,” says today’s guest, Daniel Kraft.
Daniel is the founder of Exponential Medicine where he has championed digital health and the explosion of wearable technologies.  He&#039;s also hosting the new &lt;a href=&quot;https://cvshealth.com/news-and-insights/programs/healthy-conversations&quot; target=&quot;_blank&quot;&gt;Healthy Conversations&lt;/a&gt; podcast--go check it out!  There you will find interviews with the innovator’s of today’s medical culture, including shows with former FDA Director, Scott Gottlieb, and genomic medicine guru, Eric Topol.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Daniel%20Kraft%20Show%202021.mp3" length="43189960" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/daniel-kraft-digitome-and-covid/</guid>
 <pubDate>Mon, 19 Apr 2021 18:29:26 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Daniel%20Kraft%20Headshot%202017.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Orchid Health Is 1st in the World to Offer Whole Genome Couple&#039;s Report</title>
 <link>https://mendelspod.com/podcasts/orchid-health-first-world-offer-whole-genome-couples-report/</link>
 <description>First comes love, then comes marriage; then comes the genomic couple&#039;s report.  Isn&#039;t that how the line goes?
Perhaps that&#039;s a how it will begin to go.
Today&#039;s guest is the founder of Orchid Health, which as of this week is offering the world’s first risk prediction &lt;a href=&quot;https://www.orchidhealth.com&quot; target=&quot;_blank&quot;&gt;couple’s report&lt;/a&gt;. Based on whole genome sequencing from a saliva sample that expectant parents take from home, the report will tell them their genetic risk for the major diseases, including brain, heart, cancer, diabetes, and inflammatory bowel.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Noor%20Saddiqui%20Show%202021.mp3" length="47720020" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/orchid-health-first-world-offer-whole-genome-couples-report/</guid>
 <pubDate>Tue, 06 Apr 2021 21:09:37 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Noor%20Saddiqui.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>PacBio and Labcorp Team Up on a Global Pan-Pathogen Surveillance Network</title>
 <link>https://mendelspod.com/podcasts/pacbio-and-labcorp-team-global-pan-pathogen-surveillance-network/</link>
 <description>Will there be a fourth surge of COVID here in the U.S.?  Already that we’re asking the question and it’s not an inevitability is a good sign.  It’s become a race between vaccination clinics and viral variants.

The U.S. was a bit slow to this race, but we are catching up.  Viral surveillance has become a key part of any nation’s pandemic strategy.   This past month, PacBio and Labcorp announced a partnership that brings the tool of long read sequencing to this effort.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Brian%20Caveney%20and%20Jonas%20Korlach%202021%20Show.mp3" length="42161982" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/pacbio-and-labcorp-team-global-pan-pathogen-surveillance-network/</guid>
 <pubDate>Wed, 31 Mar 2021 20:23:50 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Brian%26Jonas.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Will High Sensitivity Proteomics Enable a New Paradigm in Precision Health? with Kevin Hrusovsky, Quanterix</title>
 <link>https://mendelspod.com/podcasts/will-high-sensitivity-proteomics-enable-new-paradigm-precision-health-kevin-hrusovsky/</link>
 <description>Kevin Hrusovosky’s career has been dedicated to transforming medicine from reactive “sick care” to preventative personalized care.  A serial entrepreneur, he currently serves as the CEO of Quanterix, a company which has just nabbed $700 million and is raising the bar on proteomics testing.

“Genomics can tell you what your predisposition is,” he says in today’s interview, “proteomics can tell you the earliest moment you are in a disease cascade.”</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Kevin%20Hrusovsky%202021%20Show.mp3" length="49044603" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/will-high-sensitivity-proteomics-enable-new-paradigm-precision-health-kevin-hrusovsky/</guid>
 <pubDate>Tue, 23 Mar 2021 18:46:34 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Kevin%20Hrusovsky.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>A Liquid Biopsy Technology that Doesn&#039;t Degrade the Sample:  Raj Krishnan of Biological Dynamics</title>
 <link>https://mendelspod.com/podcasts/liquid-biopsy-technology-doesnt-degrade-sample-raj-krishnan-biological-dynamics/</link>
 <description>Raj Krishnan has a good story, and probably a good product.  More data will tell.  He&#039;s the CEO of Biological Dynamics, a new liquid biopsy company that is able to detect biomarkers in not only blood but other biological fluids.  And the company&#039;s products are good for not only cancer but Alzheimer&#039;s and other disease areas as well.

Raj comes to precision medicine from electrical engineering.  You don&#039;t hear that very often.  One day in his lab while working on his PhD he had a classic eureka! moment.  That unexpected discovery for which every scientist longs.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Raj%20Krishnan%202021%20Show.mp3" length="41999233" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/liquid-biopsy-technology-doesnt-degrade-sample-raj-krishnan-biological-dynamics/</guid>
 <pubDate>Wed, 10 Mar 2021 21:47:19 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Raj%20Krishnan%20headshot%20%281%29.png" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>The Future of Big Biology:  Bionano at AGBT</title>
 <link>https://mendelspod.com/podcasts/future-big-biology-bionano-agbt/</link>
 <description>

Mendelspod was live this week at AGBT 2021 where Theral interviewed CEO Erik Holmlin and CMO Alka Chaubey of Bionano Genomics on Tuesday.  The topic was the future of big biology.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Bionano%20AGBT%20Show%202021.mp3" length="67847191" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/future-big-biology-bionano-agbt/</guid>
 <pubDate>Wed, 03 Mar 2021 21:21:04 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/BionanoAGBT.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> Playing Catch Up--Viral Surveillance in the U.S. with Will Lee of Helix</title>
 <link>https://mendelspod.com/podcasts/playing-catch-viral-surveillance-us-will-lee-helix/</link>
 <description>How fast is the coronavirus mutating?  Why is the U.K. variant, or B.1.1.7, more transmissible than original strains of the virus?   Is viral surveillance the weak spot in the U.S.&#039;s fight against the pandemic?</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Will%20Lee%202021%20Show.mp3" length="35093591" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/playing-catch-viral-surveillance-us-will-lee-helix/</guid>
 <pubDate>Tue, 16 Feb 2021 11:02:58 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/will%20lee.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>The Coronavirus, A Year On with Carl Zimmer</title>
 <link>https://mendelspod.com/podcasts/coronavirus-year-carl-zimmer/</link>
 <description>It’s been a year since the coronavirus breached American shores. Here to look back with some perspective is New York Times science writer, Carl Zimmer. Carl has authored thirteen books on science, including Planet of Viruses which includes an essay titled, &quot;Predicting the Next Plague.&quot;
</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Carl%20Zimmer%202021%20Show.mp3" length="41252873" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/coronavirus-year-carl-zimmer/</guid>
 <pubDate>Wed, 27 Jan 2021 22:17:57 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Carl%20Zimmer.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Spatial Biology Enables The Cancer Immunome Project</title>
 <link>https://mendelspod.com/podcasts/spatial-biology-enables-cancer-immunome-project/</link>
 <description>We’ve all heard of and perhaps worked with data from The Cancer Atlas Project.  Now, with the help of new spatial biology tools, researchers at the Mayo Clinic are developing what they call The Cancer Immunome Project.  This is a comprehensive effort to fully characterize the immune system and how it interacts with and fights off cancer.

Today we talk with  J C Villasboas, a physician-scientist at Mayo who co-started the project.  He’s also Director of Mayo’s Immune Monitoring Core Facility.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/J%20C%20Villasboas%202021%20Show_0.mp3" length="40828643" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/spatial-biology-enables-cancer-immunome-project/</guid>
 <pubDate>Thu, 21 Jan 2021 11:30:47 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/J%20C%20Villasboas.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>The CRISPR Saga with Kevin Davies</title>
 <link>https://mendelspod.com/podcasts/crispr-saga-kevin-davies/</link>
 <description>A discovery here. A paper there. An important paper gets passed over. A fortuitous encounter in a coffee shop among two ambitious scientists. A yogurt company just being a yogurt company. Science moves forward in fits and starts.
By the time we read the headline in the paper, “breakthrough of the year,” it can have an inevitable quality about it. Then, in a few years, the historian comes and shows us just how random, messy, and, yes, how beautiful is the business of science.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Kevin%20Davies%202020%20Show.mp3" length="65248302" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/crispr-saga-kevin-davies/</guid>
 <pubDate>Tue, 22 Dec 2020 11:31:18 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Kevin-Davies-2020.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>PacBio’s Never Been Stronger:  New CEO, Christian Henry, Shares His Vision</title>
 <link>https://mendelspod.com/podcasts/pacbio%E2%80%99s-never-been-stronger-new-ceo-christian-henry-shares-his-vision/</link>
 <description>At the beginning of the year, we were all holding our breath for the future of PacBio.  And by all, I mean all.  It seems everyone has been rooting for this sequencing technology company.

And why?  It’s simple.  Pretty much everyone is in agreement that they have the highest quality reads on the market.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Christian%20Henry%202020%20Show.mp3" length="42756654" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/pacbio%E2%80%99s-never-been-stronger-new-ceo-christian-henry-shares-his-vision/</guid>
 <pubDate>Tue, 15 Dec 2020 12:07:46 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Iu5YVCVk_400x400.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Keith Robison on the State of Sequencing: 2020 Edition</title>
 <link>https://mendelspod.com/podcasts/keith-robison-state-sequencing-2020-edition/</link>
 <description>We speak directly with the Oracle today.  It&#039;s Keith Robison, blogger at Omics Omics.   Your All Knowingness, we ask, what has happened in the world of sequencing technology this year?

“The companies may need a mulligan,” he quips and laughs.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Keith%20Robison%202020%20Show.mp3" length="62889161" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/keith-robison-state-sequencing-2020-edition/</guid>
 <pubDate>Tue, 17 Nov 2020 10:40:07 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Keith%20Robison.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Halloween with Nathan and Laura:  The Spooky and Creepy of Genomics</title>
 <link>https://mendelspod.com/podcasts/halloween-nathan-and-laura-spooky-and-creepy-genomics/</link>
 <description>Our October Review show is a Halloween special this year.  Join us around the campfire amidst the sounds of howling wolves as Nathan, Laura, and Count Theracula recall some of their creepiest and spookiest times in the world of genomics.

It&#039;s Mendelspod&#039;s Haunted House of the Genome.
</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Halloween%202020_1.mp3" length="64148864" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/halloween-nathan-and-laura-spooky-and-creepy-genomics/</guid>
 <pubDate>Fri, 30 Oct 2020 13:33:41 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/bat.jpg_0.png" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>When and Why Whole Genome Sequencing Should Be Standard of Care:  Stephen Kingsmore of Rady Children’s</title>
 <link>https://mendelspod.com/podcasts/when-and-why-whole-genome-sequencing-should-be-standard-care-stephen-kingsmore-rady/</link>
 <description>There’s an urgency about Stephen Kingsmore.  Which is not to say he’s in a rush.

He’s the CEO of the Rady’s Children’s Genomics Institute.  He and his team have two world records to their name for the incredible speed of diagnosing a rare disease using whole genome sequencing.  The latest is 19.5 hours.

Dr. Kingsmore feels they can even shave time off that.  They’re shooting for a new record of somewhere around 12 hours.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Stephen%20%20Kingsmore%202020%20Show.mp3" length="40699491" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/when-and-why-whole-genome-sequencing-should-be-standard-care-stephen-kingsmore-rady/</guid>
 <pubDate>Mon, 26 Oct 2020 20:51:58 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/stephen%20kingsmore.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Limited Genetic Diversity Affects Us All</title>
 <link>https://mendelspod.com/podcasts/limited-genetic-diversity-affects-us-all/</link>
 <description>Diversity’s in the news these days. It&#039;s not just political correctness. Let’s look deeper into our field at how limited diversity in genetics is affecting all of us.
If you are a member of a minority population and you go into a cancer clinic seeking help, some of the genetic tests on offer may not work for you because of your ethnic background. Not only is this wrong on a social justice level. It turns out it&#039;s just bad science.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Diversity%20in%20Genetics.mp3" length="35818759" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/limited-genetic-diversity-affects-us-all/</guid>
 <pubDate>Wed, 21 Oct 2020 21:30:36 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/genetic%20diversity.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Genomics England Making Significant Strides in System Built on Trust in NHS</title>
 <link>https://mendelspod.com/podcasts/genomics-england-making-significant-strides-system-built-trust-nhs/</link>
 <description>“In an era where we look at these surveys about trust and everything’s going off the cliff,  everyone still trusts the NHS.  It’s so deep in the British psyche.&quot;</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Chris%20Wigley%202020%20Show.mp3" length="44369330" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/genomics-england-making-significant-strides-system-built-trust-nhs/</guid>
 <pubDate>Wed, 07 Oct 2020 22:16:30 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Chris-Wigley-1.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>September 2020 Review with Nathan and Laura: Vaccine Choice, Dwarfism, Research Volunteerism</title>
 <link>https://mendelspod.com/podcasts/september-2020-review-nathan-and-laura-vaccine-choice-dwarfism-research-volunteerism/</link>
 <description>We take a deep dive into a core genomics question that is somewhat philosophical today: “what is a disease, or disability?” This month we heard about a new experimental drug for dwarfism called vosoritide that raised questions for parents of dwarfism. If the drug could make their children taller, would they give it to them? Laura asks “can we put forth a medication for a condition saying those who take it are better off getting rid of it and not be saying those who are not getting it are unacceptable to have these different lives?&quot;</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/September%20Review%20Show%202020.mp3" length="59367062" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/september-2020-review-nathan-and-laura-vaccine-choice-dwarfism-research-volunteerism/</guid>
 <pubDate>Fri, 02 Oct 2020 01:33:41 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Dwarfism.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> Bob Nussbaum on the State of Genetic Testing: 2020 Edition</title>
 <link>https://mendelspod.com/podcasts/bob-nussbaum-state-genetic-testing-2020-edition/</link>
 <description>From a career at NIH where he was Chief of the Genetic Disease Branch to academic Chief of Medical Genetics at UCSF to his current business title of Chief Medical Officer at InVitae, Bob Nussbaum has been a central figure in the field of genetic testing.  A chief among chiefs.  Today he gives our State of Genetic Testing: 2020 Edition.

Our approach is to ask Bob to weigh into the recent debates that have come up this past year.  And they can be summarized into one question.  Even one word. &quot;Expanded.&quot;</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Bob%20Nussbaum%20Show%202020.mp3" length="38084575" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/bob-nussbaum-state-genetic-testing-2020-edition/</guid>
 <pubDate>Tue, 22 Sep 2020 14:24:13 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/bob-nussbaum.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>SynBioBeta 2020 with John Cumbers</title>
 <link>https://mendelspod.com/podcasts/synbiobeta-2020-john-cumbers/</link>
 <description>Synthetic biology was surging like perhaps no other bio-based industry when the pandemic struck, and it has had some unique weapons in its arsenal for aiding in the fight against COVID. There are the leading vaccine makers such as Moderna using synthetic biology, as well as antibody technology and CRISPR based testing. But many of the surging trends from the last year have only been made more urgent this year: small molecules, food tech, synthetic materials.
Living with a pandemic is making humans more aware of our scientific dependence.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/John%20Cumbers%202020%20Show.mp3" length="35575949" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/synbiobeta-2020-john-cumbers/</guid>
 <pubDate>Mon, 14 Sep 2020 19:23:28 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/john-cumbers-synbiobeta.jpeg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Mapping Intracellular Context:  Garry Nolan on Spatial Biology</title>
 <link>https://mendelspod.com/podcasts/mapping-intracellular-context-garry-nolan-spatial-biology/</link>
 <description>First it was all about biomarkers. Then panels of biomarkers. But biology is complicated. Why does one patient respond to an immuno therapy when another which shares the same biomarker does not?
Welcome to the age of spatial biology.
Garry Nolan joins us today. He&#039;s a professor in the Department of Pathology at Stanford who&#039;s career has been a journey of seeing intracellular happenings more and more in context. Check out this cool analogy from &lt;a href=&quot;https://www.cell.com/cell/fulltext/S0092-8674(20)30870-9&quot;&gt;a new paper&lt;/a&gt; his lab put out in Cell.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Garry%20Nolan%202020%20Show.mp3" length="32363638" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/mapping-intracellular-context-garry-nolan-spatial-biology/</guid>
 <pubDate>Tue, 08 Sep 2020 21:24:04 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Garry%20Nolan%202020.jpeg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>August 2020 Review: Radical Shift on LDT Policy, First Pan-Cancer Liquid Biopsies, and New Alzheimer’s Test</title>
 <link>https://mendelspod.com/podcasts/august-2020-review-radical-shift-ldt-policy-first-pan-cancer-liquid-biopsies-and-new/</link>
 <description>After a long break, the world&#039;s first genomics pundits are back for the season.  And they are calm and collected in the face of the strorm on Pennsylvania Ave.   We&#039;re sixty days from an election.  How serious should we be taking politicization of the COVID vaccine, this radical shift on LDTs at the FDA?

We also discuss some regular approvals and on rejection that sent the industry reeling with disappointment.  Then it&#039;s on to Laura&#039;s, Nathan&#039;s, and Theral&#039;s picks for science of the month.

Welcome back!
</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/August%202020%20Review%20Show.mp3" length="48531645" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/august-2020-review-radical-shift-ldt-policy-first-pan-cancer-liquid-biopsies-and-new/</guid>
 <pubDate>Mon, 31 Aug 2020 22:11:04 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Foundation%20Medicine%20FoundationOne%20Liquid%202%20resized.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Using CRISPR Genome Editing Tools, Willow Biosciences out with First Synthetic Cannabinoid</title>
 <link>https://mendelspod.com/podcasts/using-crispr-genome-editing-tools-willow-biosciences-out-first-synthetic-cannabinoid/</link>
 <description>We see this new ingredient appearing advertised and in products everywhere.  On the billboards, in the new shops next to our favorite restaurant, on the counters at the barbershop and when we pick up our prescriptions at the pharmacy.

C-B-D.

It has to do with the ongoing revolution that’s happening around the country—around the world—regarding the deregulation of marijuana.  But there’s another revolution that will change our consumption of cannabinoids.  That of synthetic biology.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Chris%20Savile%202020%20Show.mp3" length="29224718" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/using-crispr-genome-editing-tools-willow-biosciences-out-first-synthetic-cannabinoid/</guid>
 <pubDate>Wed, 26 Aug 2020 13:28:57 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Chris%20Savile.jpeg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>The Pros and Cons of Expanded Carrier Screening with Mary Norton, UCSF</title>
 <link>https://mendelspod.com/podcasts/pros-and-cons-expanded-carrier-screening-mary-norton-ucsf/</link>
 <description>Mary Norton is a perinatologist and clinical geneticist at UCSF who says that in the age when we are diagnosing ever more rare diseases, adding to the carrier screening panel can be a good thing, but it’s complicated.

But it can be a good thing.

But it’s complicated.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Mary%20Norton%202020%20Show.mp3" length="31573050" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/pros-and-cons-expanded-carrier-screening-mary-norton-ucsf/</guid>
 <pubDate>Tue, 16 Jun 2020 10:39:57 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Mary%20Norton.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Is This A Unique Time for Science?  We Ask Sci-fi Writer Kim Stanley Robinson</title>
 <link>https://mendelspod.com/podcasts/unique-time-science-we-ask-sci-fi-writer-kim-stanley-robinson/</link>
 <description>Has this pandemic presented a unique moment for science in our history? Or is it just a strange and temporary moment of science fiction? Or both?
Sci-fi author Kim Stanley Robinson (The Mars Trilogy, The Ministry of the Future) recently penned &lt;a href=&quot;https://www.newyorker.com/culture/annals-of-inquiry/the-coronavirus-and-our-future&quot; target=&quot;_blank&quot;&gt;an essay&lt;/a&gt; in the New Yorker about how the virus has “changed our imaginations” and created a new “structure of feeling.”</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Kim%20Stanley%20Robinson%20June%202020%20Show.mp3" length="45772297" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/unique-time-science-we-ask-sci-fi-writer-kim-stanley-robinson/</guid>
 <pubDate>Sat, 13 Jun 2020 12:30:50 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/KSRemail_0.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>May 2020 with Nathan and Laura: Vaccine News, Notre Dame Argument, COVID Genetic Targets</title>
 <link>https://mendelspod.com/podcasts/may-2020-nathan-and-laura-vaccine-news-notre-dame-argument-covid-genetic-targets/</link>
 <description>Happy summertime! We had positive news this month about an mRNA vaccine from Moderna. We also saw how during a pandemic, the process of science is especially abnormal. Nathan says let&#039;s be happy about the good news. Laura&#039;s ringing with alarm bells, sensing conflicts of interest right and left.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/May%202020%20Review%20Show.mp3" length="46470543" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/may-2020-nathan-and-laura-vaccine-news-notre-dame-argument-covid-genetic-targets/</guid>
 <pubDate>Sun, 31 May 2020 23:43:47 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Moderna%20mRNA.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Matt Loose on &quot;Read Until&quot; or Adaptive Sequencing</title>
 <link>https://mendelspod.com/podcasts/matt-loose-adaptive-sequencing/</link>
 <description>Back before the world turned upside down,  you know, all those years ago--early this February--a paper popped up on bioRxiv called, “Nanopore adaptive sequencing for mixed samples, whole exome capture and targeted panels.&quot;  It’s an interesting paper.

In the paper, the authors, led by Matt Loose from the DeepSeq lab at the University of Nottingham, describe a method unique to nanopore sequencing where one can do &quot;selective sequencing of single molecules in real time by individually reversing the voltage across specific nanopores.”</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Matt%20Loose%202020%20Show.mp3" length="39101934" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/matt-loose-adaptive-sequencing/</guid>
 <pubDate>Wed, 27 May 2020 19:34:34 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/matt%20loose.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>The Current State of Coronavirus Vaccines with Jeff Stein, Cidara Therapeutics</title>
 <link>https://mendelspod.com/podcasts/current-state-coronavirus-vaccines-jeff-stein-cidara-therapeutics/</link>
 <description>What is the key to getting a coronavirus vaccine?  “Manufacturing,” says today’s guest, Jeff Stein of Cidara Therapeutics.

Jeff joined us just last fall to talk about his company’s exciting new technology, an immunotherapy, that is a universal flu preventative and therapy.  Yes, you read that right.  A universal flu preventative.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Jeff%20Stein%202020%20Show.mp3" length="35832988" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/current-state-coronavirus-vaccines-jeff-stein-cidara-therapeutics/</guid>
 <pubDate>Thu, 21 May 2020 09:27:28 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Jeff%20Stein%20New.jpeg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>April 2020 Review with Nathan and Laura:  Ioannidis Scandal, Antibody Testing, Ethics Questions</title>
 <link>https://mendelspod.com/podcasts/april-2020-review-nathan-and-laura-ioannidis-scandal-antibody-testing-ethics-questions/</link>
 <description>Our commentators, Nathan Pearson of Root and Laura Hercher of Sarah Laurence College, join us to look back on month two of the first modern pandemic.

We begin with a scandal that rocked the Twitter science community and talk about how science itself may be having a big moment.  Will this be a silver lining for this strange year?

Then it’s on to antibody testing.  What would a good antibody test need to do?  And will there be tough ethical questions when some “have their immunity papers” and go back to work while others do not?</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/April%202020%20Review%20Show_0.mp3" length="39823683" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/april-2020-review-nathan-and-laura-ioannidis-scandal-antibody-testing-ethics-questions/</guid>
 <pubDate>Thu, 30 Apr 2020 22:44:13 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/AntibodyTest.jpeg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Lab Director Speaks to the Challenges of COVID-19 Testing: Elaine Lyon, HudsonAlpha</title>
 <link>https://mendelspod.com/podcasts/lab-director-speaks-challenges-covid-19-testing-elaine-lyon-hudsonalpha/</link>
 <description>Why have diagnostic tests for the Coronavirus been slow on the scene?  What have been the challenges for lab directors?  Were they scientific?  Were they regulatory?  Were they scaling challenges?  Are they still scaling challenges?  Supply chain problems?

Elaine Lyon worked for many years at the molecular genetics lab at ARUP at the University of Utah and is now the Clinical Services Lab Director at Hudson Alpha.  In both of these jobs she has designed and overseen the design of many diagnostic tests.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Elaine%20Lyon%202020%20Show.mp3" length="32388218" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/lab-director-speaks-challenges-covid-19-testing-elaine-lyon-hudsonalpha/</guid>
 <pubDate>Tue, 14 Apr 2020 10:45:38 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/ElaineLyon_1.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>FDA in the Time of Coronavirus: Understanding the New VALID Act with Turna Ray, GenomeWeb</title>
 <link>https://mendelspod.com/podcasts/fda-time-coronavirus-understanding-new-valid-act-turna-ray-genomeweb/</link>
 <description>After the virus reached American shores, was the FDA quick enough to allow companies and labs to develop their own tests without restrictive oversight?  The question sparked a sweeping new bill in congress, the VALID Act that could overhaul FDA oversight of diagnostics altogether—something that has been clamored for for a generation.

Turna Ray has been covering the FDA and diagnostics for GenomeWeb since 2006.  She has recently written a piece on the new VALID Act that includes responses from various members of the community.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Turna%20Ray%202020%20Show.mp3" length="33611208" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/fda-time-coronavirus-understanding-new-valid-act-turna-ray-genomeweb/</guid>
 <pubDate>Tue, 07 Apr 2020 11:57:18 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Turna%20Ray.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>March 2020 Review with Nathan &amp; Laura:  Corona Gets Personal, Where Are the Tests?, the VALID Act, Some non-Corona Science</title>
 <link>https://mendelspod.com/podcasts/march-2020-review-nathan-laura-corona-gets-personal-where-are-tests-valid-act-some-non/</link>
 <description>Laura comes to us from her flat in New York, Nathan is stuck in San Diego, but they are here and ready to discuss what a month ago was a warning and now is a full blown world crisis.  What have they faced personally?  What are their thoughts on testing?  And what are some of their early big picture reactions as to how this will all go down?

We make some time for some Corona-free science as well.
</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/March%202020%20Review%20Show.mp3" length="38629150" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/march-2020-review-nathan-laura-corona-gets-personal-where-are-tests-valid-act-some-non/</guid>
 <pubDate>Thu, 02 Apr 2020 11:38:39 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Corona-Time.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>90% Go Undiagnosed, Says Geisinger’s Amy Sturm of FH Patients</title>
 <link>https://mendelspod.com/podcasts/90-go-undiagnosed-says-geisinger%E2%80%99s-amy-sturm-fh-patients/</link>
 <description>More than one in two hundred people have an inherited form of heart disease.   But most don’t know it.

Often on Mendelspod we talk about cancer genomics, but in the area of cardio, too, genetic testing can save lives.

Amy Sturm is the Director of Genomic Counseling and Screening Program at Geisinger Health Systems.  There she has led the effort to return the results of cardio genetic tests to over 1,000 patients.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Amy%20Sturm%202020%20Show.mp3" length="38157158" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/90-go-undiagnosed-says-geisinger%E2%80%99s-amy-sturm-fh-patients/</guid>
 <pubDate>Thu, 26 Mar 2020 12:01:48 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/amy_sturm.jpeg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Lisa Alderson on Her Telegenetics Firm, Genome Medical, Also Speaks to the DTC Downturn</title>
 <link>https://mendelspod.com/podcasts/lisa-alderson-her-telegenetics-firm-genome-medical-also-speaks-dtc-downturn/</link>
 <description>Lisa Alderson has been helping to build genetic testing companies for a while.  In 2016 she co-founded her own company, Genome Medical, a tele-genomics firm to help patients and providers understand genetic testing results.

Anyone in the genetic testing industry will know that Genome Medical’s offering addresses a burning need.   As Lisa remarks in today’s show, genetics is complicated.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Lisa%20Alderson%202020%20Show.mp3" length="37784256" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/lisa-alderson-her-telegenetics-firm-genome-medical-also-speaks-dtc-downturn/</guid>
 <pubDate>Tue, 10 Mar 2020 11:24:13 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Lisa%20Alderson.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>February 2020 Review with Nathan and Laura:  Coronavirus, Medicare for All, and Live from AGBT</title>
 <link>https://mendelspod.com/podcasts/february-2020-review-nathan-and-laura-coronavirus-medicare-all-and-live-agbt/</link>
 <description>What do we actually know about the novel coronavirus, we ask our two monthly commentators at the outset of February’s review show.  Then, speaking of pandemics, as Bernie fever sweeps America, we explore the charge that Medicare for All means an end to innovation.

Laura gives an update on the status of the genetic counseling bill, and Nathan comes to us live from AGBT with highlights from Marco Island.
</description>
 <author>online@cglife.com (cglife)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/February%202020%20Review%20Show.mp3" length="51834105" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/february-2020-review-nathan-and-laura-coronavirus-medicare-all-and-live-agbt/</guid>
 <pubDate>Fri, 28 Feb 2020 11:00:16 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/SARS-CoV-2.png" />
 <itunes:author> online@cglife.com (cglife)
</itunes:author>
</item>
 <item> <title>Pouria Sanae on the DTC Slowdown and His New Precision Health Testing Platform</title>
 <link>https://mendelspod.com/podcasts/pouria-sanae-dtc-slowdown-and-his-new-precision-health-testing-platform/</link>
 <description>“To be fully honest, I think some of these tests are scary tests.  I’ve had the luxury of testing myself . . . some of this needs to have the physician and the genetic counselor involved.”

That’s Pouria Sanae, a newcomer to our field via Yahoo and Helix.  He’s also a Swede which gives him a fresh perspective on American genomic culture.  Last month Pouria and his co-founders launched ixlayer, a new platform that integrates many of the players in the genomic medicine space:  DTC companies, clinical labs, and physician/providers.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Pouria%20Sanae%202020%20Show.mp3" length="26660343" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/pouria-sanae-dtc-slowdown-and-his-new-precision-health-testing-platform/</guid>
 <pubDate>Thu, 13 Feb 2020 11:19:41 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Pouria%20Sanae.jpeg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>January 2020 Review:  Genetic Counselors vs ACMG, 23andMe Layoffs, Privacy</title>
 <link>https://mendelspod.com/podcasts/january-2020-review-genetic-counselors-vs-acmg-23andme-layoffs-privacy/</link>
 <description>23andMe lays off over 100 employees.  Illumina comes to the JP Morgan empty-handed.  Has Precision Medicine seen it’s heyday already?  Or are we gearing up for another wave of innovation?  Nathan and Laura are again ready for the tough questions of genomics.

We begin with the current spat between genetic counselors and the ACMG.  Like, . . . huh?
</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/January%202020%20Review%20Show%20with%20Nathan%20and%20Laura_0.mp3" length="42213265" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/january-2020-review-genetic-counselors-vs-acmg-23andme-layoffs-privacy/</guid>
 <pubDate>Fri, 31 Jan 2020 11:29:03 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Unite%21.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>End-of-Decade Review, What&#039;s Next? with Nathan and Laura</title>
 <link>https://mendelspod.com/podcasts/end-decade-review-whats-next-nathan-and-laura/</link>
 <description>It&#039;s our special look back over the entire decade which has Nathan and Laura firing on all fours.  Not only do we discover their genomic highlights of the last ten years--ups and downs-- they also pull out their special &quot;future glasses&quot; and come up with a provocative list for the next ten.  You don&#039;t want to miss this.

But first, we do cover December and that kerfuffle over the George Church dating app.  And the genomics of income--really?  Did you go for that?

Theral, Nathan, and Laura for an extended broadcast.  Happy 2020!
</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Dec%202019%20Review%20Show.mp3" length="64994241" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/end-decade-review-whats-next-nathan-and-laura/</guid>
 <pubDate>Fri, 27 Dec 2019 08:04:29 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/GenomicsDecadeImage.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Ewan Birney on Race, UK Genomics</title>
 <link>https://mendelspod.com/podcasts/ewan-birney-race-uk-genomics/</link>
 <description>Our end-of-year special guest is one of the U.K.’s top genomicists, Ewan Birney, Co-Director of the European Bioinformatics Institute at EMBL. He is also the non-Executive Director for Genomics England.  Ewan&#039;s perhaps best known for his work with the ENCODE consortium.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Ewan%20Birney%20Show%202019.mp3" length="36251803" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/ewan-birney-race-uk-genomics/</guid>
 <pubDate>Tue, 17 Dec 2019 12:48:57 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Ewan%20Birney.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>November 2019 with Nathan and Laura: Happy Birthday CRISPR Babies, 23andMe for Embryo Selection, and Golden Rice, Almost</title>
 <link>https://mendelspod.com/podcasts/november-2019-nathan-and-laura-happy-birthday-crispr-babies-23andme-embryo-selection-and/</link>
 <description>The gene edited babies, Lulu and Nana, turn one.  Laura Hercher says it feels like it’s been five years.  Nathan says, “Happy Birthday.”

Along with our genomics headline party this month, we also discuss a comment that came in from our last show which leads us to the question, can we discuss science without discussing politics?

It’s Nathan, Laura and Theral for almost a full hour sifting through November’s news.
</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/November%202019%20Show.mp3" length="36565909" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/november-2019-nathan-and-laura-happy-birthday-crispr-babies-23andme-embryo-selection-and/</guid>
 <pubDate>Mon, 02 Dec 2019 12:14:15 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Golden%20Rice.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Learning from the Field&#039;s Mistakes, Ancestry.com Rolls out Physician Ordered Health Testing</title>
 <link>https://mendelspod.com/podcasts/learning-fields-mistakes-ancestrycom-rolls-out-physician-ordered-health-testing/</link>
 <description>Just in time for Black Friday, Ancestry.com has launched new health testing.   Thanksgiving week  (the company calls the shopping holidays the “Turkey Five”) has been kind to what is the largest DNA testing company in the world.  Back in 2017, their ancestry test competed with the Instapot for Amazon’s top sellers on the biggest shopping day of the year.  To date Ancestry has sold over 15 million DNA tests.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Sarah%20South%202019%20Show_0.mp3" length="35358648" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/learning-fields-mistakes-ancestrycom-rolls-out-physician-ordered-health-testing/</guid>
 <pubDate>Mon, 25 Nov 2019 20:34:35 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/SarahSouth.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>The Gene Edited Babies Saga - A Year Later with Hank Greely</title>
 <link>https://mendelspod.com/podcasts/gene-edited-babies-saga-year-later-hank-greely/</link>
 <description>On November 25th, 2018, the world was shocked to find out a Chinese scientist, He Jiankui, had edited the germline of twin girls-and the twins had been born.  Many in the scientific community remember that Sunday afternoon well as the story broke on MIT&#039;s Tech Review,  &quot;EXCLUSIVE: Chinese scientists are creating CRISPR babies.&quot;

Today’s guest can even tell you what he had for dinner that Sunday and just what was his reaction. &quot;Holy Shit!&quot;</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Hank%20Greely%202019%20Show.mp3" length="37229652" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/gene-edited-babies-saga-year-later-hank-greely/</guid>
 <pubDate>Fri, 22 Nov 2019 10:33:40 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Hank.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Improving Quantitative Evidence for Genetic Tests: Carlos Araya, Invitae</title>
 <link>https://mendelspod.com/podcasts/improving-quantitative-evidence-genetic-tests-carlos-araya-invitae/</link>
 <description>Warning:  the first part of this story can sound quite typical.  Three co-founders with backgrounds in genomics and AI found a Stanford spinout.  Their goal: to bring the tools of AI and computational modeling to unlock the medical secrets of the genome and deliver those to patients.  They call this company, Jungla—Spanish for “jungle”—naming not only their adventure, but the whole problem.   Then things get interesting.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Carlos%20Araya%202019%20Show-auphonic_0.mp3" length="33772354" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/improving-quantitative-evidence-genetic-tests-carlos-araya-invitae/</guid>
 <pubDate>Thu, 14 Nov 2019 12:30:37 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Carlos%20Araya.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>The Meteoric Rise of Twist Bioscience and the Wild Demand for DNA:  Emily Leproust, CEO</title>
 <link>https://mendelspod.com/podcasts/meteoric-rise-twist-bioscience-and-wild-demand-dna-emily-leproust-ceo/</link>
 <description>In 2013 Twist Bioscience was a newcomer to a market that most of us thought was saturated, cornered, commoditized—that of synthetic DNA.  But Emily Leproust and her co-founders saw something different.  They saw &quot;a big market with unhappy customers.”  Today, with a radically disruptive technology, they are market dominant.   Twist is a publicly traded company whose stock has doubled already once since they IPOd last year.  Imagine, a DNA synthesis company going public!  And then seeing their stock perform so well.  This is tricky for the most hyped of tech or biotech startups.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Emily%20Leproust%202019%20Show.mp3" length="36203194" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/meteoric-rise-twist-bioscience-and-wild-demand-dna-emily-leproust-ceo/</guid>
 <pubDate>Thu, 07 Nov 2019 12:00:16 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Emily%20Leproust.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>October 2019 Review with Nathan and Laura: Prime Editing, Vertex Win, and ASHG</title>
 <link>https://mendelspod.com/podcasts/october-2019-review-nathan-and-laura-prime-editing-vertex-win-and-ashg/</link>
 <description>Our Halloween show this year summarizing October’s genomics news has more tricks and treats than spooks and scares.  It’s Nathan and Laura back to sift through a big month of happenings from the cool CRISPR upgrade to Inscripta’s bold move in gene editing to Ancestry.com’s shift into health testing.

It’s all here, right now, on Mendelspod.
</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Oct%202019%20Review%20Complete%20Show.mp3" length="35576754" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/october-2019-review-nathan-and-laura-prime-editing-vertex-win-and-ashg/</guid>
 <pubDate>Fri, 01 Nov 2019 11:12:49 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Prime%20Editing.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Should We Increase Panel Testing for All Breast Cancer Patients?</title>
 <link>https://mendelspod.com/podcasts/should-we-increase-panel-testing-all-breast-cancer-patients/</link>
 <description>It’s a hot question in the field today.  Recently several studies arguing for increased testing for all breast cancer patients have been published in leading oncology journals.

Peter Beitsch is a breast cancer surgeon in Dallas Texas and co-author of one such study in the Journal of Clinical Oncology.     He says that NCCN guidelines were created when tests were much more expensive and in an outdated context and that many patients are going under-diagnosed today.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Universal%20Testing%20for%20Breast%20Cancer%20Patients%20%20-%202019%20Show.mp3" length="36065992" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/should-we-increase-panel-testing-all-breast-cancer-patients/</guid>
 <pubDate>Thu, 24 Oct 2019 11:46:40 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Breast%20Cancer%20figure.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Genomics Going from a Passive to an Active Science: John Stuelpnagel on the “Write” Revolution</title>
 <link>https://mendelspod.com/podcasts/genomics-going-passive-active-science-john-stuelpnagel-write-revolution/</link>
 <description>Not many people have had quite the same view on the genomics revolution as John Stuelpnagel.  He co-founded Illumina, Ariosa, and Fabric Genomics (formerly Omicia).  And he’s the Chairman of Fabric, 10X Genomics, and Inscripta.  And not all had the foresight John did that biology would turn out to be so complex.

John is our guest today to preview and describe what he calls the new “writing” phase of genomics, which he says is already underway.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/John%20Stuelpnagel%202019%20Show.mp3" length="32985201" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/genomics-going-passive-active-science-john-stuelpnagel-write-revolution/</guid>
 <pubDate>Tue, 22 Oct 2019 10:10:06 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/John-Stuelpnagel.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Why Isn’t Personalized Medicine Being Mentioned by the Presidential Contenders?  Ed Abrahams on Drug Pricing, Genetic Testing, and the State of the Industry in 2019</title>
 <link>https://mendelspod.com/podcasts/why-isnt-personalized-medicine-being-mentioned-presidential-contenders-ed-abrahams-drug/</link>
 <description>Ed Abrahams has a message for Nancy Pelosi about HR 3.  That’s the new bill in the House to reduce drug pricing.

Ed is the President of the Personalized Medicine Coalition, an advocacy organization in Washington representing our industry which will soon announce a new caucus in congress devoted to personalized medicine.  Ed joins us today and says to Pelosi, there’s a better way, a more American way to reduce drug costs.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Ed%20Abrahams%202019%20Show_0.mp3" length="39292887" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/why-isnt-personalized-medicine-being-mentioned-presidential-contenders-ed-abrahams-drug/</guid>
 <pubDate>Tue, 15 Oct 2019 11:13:00 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/ed%20abrahams_0.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Karen Miga on the Next Era of Genomics</title>
 <link>https://mendelspod.com/podcasts/karen-miga-next-era-genomics/</link>
 <description>&quot;Welcome to the era of T2T genomics,” tweeted UCSC’s Karen Miga on August 16th of this year.  Then she linked to a paper on bioRxiv that begins:

&quot;After nearly two decades of improvements, the current human reference genome (GRCh38) is the most accurate and complete vertebrate genome ever produced. However, no one chromosome has been finished end to end, and hundreds of unresolved gaps persist.”</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Karen%20Miga%202019%20Show.mp3" length="27891536" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/karen-miga-next-era-genomics/</guid>
 <pubDate>Mon, 07 Oct 2019 17:14:41 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Karen%20Miga.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>September 2019 Review with Nathan and Laura: Same-Sex Genetics, Mosquitos, and Another DTC Scandal</title>
 <link>https://mendelspod.com/podcasts/september-2019-review-nathan-and-laura-same-sex-genetics-mosquitos-and-another-dtc-scandal/</link>
 <description>After the summer break, Nathan and Laura, stir from their beach slumbers, to again offer their anything but sleepy opinions on the latest genomics headlines.
</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Sept%202019%20Review%20Complete%20Show.mp3" length="34145503" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/september-2019-review-nathan-and-laura-same-sex-genetics-mosquitos-and-another-dtc-scandal/</guid>
 <pubDate>Mon, 30 Sep 2019 21:54:30 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Same%20Sex%20Gene.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>We Can See Tumor Heterogeneity.  Now What? We Ask Cathy Smith, UCSF</title>
 <link>https://mendelspod.com/podcasts/we-can-see-tumor-heterogeneity-now-what-we-ask-cathy-smith-ucsf/</link>
 <description>Cathy Smith counts herself among the Gleevec Generation after the landmark targeted cancer therapy.  She’s an optimist who believes in the possibilities of precision medicine.

“We are outsmarting cancer,”  she says.

Cathy is an Assistant Professor of Hematology/Oncology at UCSF where she is also an MD treating patients.  Her area of expertise is in acute myeloid leukemia or AML.  She joins us today to discuss a recent group paper and collaboration using new technology to track and monitor cancer evolution at the single cell level.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Cathy%20Smith%202019%20Show_0.mp3" length="28469623" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/we-can-see-tumor-heterogeneity-now-what-we-ask-cathy-smith-ucsf/</guid>
 <pubDate>Tue, 17 Sep 2019 12:24:13 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Cathy%20Smith.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Hallelujah!  A Universal Flu Preventative and Therapy with  Jeff Stein, Cidara</title>
 <link>https://mendelspod.com/podcasts/hallelujah-universal-flu-preventative-and-therapy-jeff-stein-cidara/</link>
 <description>As another summer winds down, another flu season approaches.  Yuuuk.  When will we be able to stop living in fear of that crowded plane flight in winter months or waking up congested and wondering . . . dreading, “am I coming down with a cold?”

Yes, we get that annual flu vaccine shot, but each year we still get the bug.  Until now, a real universal flu vaccine has eluded drug makers, and having the flu goes on being just part of life.  But it doesn&#039;t have to be.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Jeff%20Stein%202019%20Show.mp3" length="22295106" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/hallelujah-universal-flu-preventative-and-therapy-jeff-stein-cidara/</guid>
 <pubDate>Thu, 12 Sep 2019 09:57:58 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Jeff%20Stein.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>&#039;The Movement:&#039; John Cumbers Previews the Rapidly Growing SynBioBeta 2019</title>
 <link>https://mendelspod.com/podcasts/movement-john-cumbers-previews-rapidly-growing-synbiobeta-2019/</link>
 <description>Synthetic biology is experiencing a second renaissance and the place to be this October 1-3 is at the &lt;a href=&quot;https://synbiobeta.com&quot; target=&quot;_blank&quot;&gt;SynBioBeta conference&lt;/a&gt; in San Francisco.
For those of you who are going, today’s show is your preview. For those of you who need a nudge, just listen to what conference founder, John Cumbers, has conjured up in this biggest and most diverse lineup yet.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/John%20Cumbers%202019%20Show.mp3" length="38569185" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/movement-john-cumbers-previews-rapidly-growing-synbiobeta-2019/</guid>
 <pubDate>Mon, 02 Sep 2019 19:48:25 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/John-Cumbers-2019.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Anya Prince on Our Current Vulnerability to Genetic Discrimination</title>
 <link>https://mendelspod.com/podcasts/anya-prince-our-current-vulnerability-genetic-discrimination/</link>
 <description>Some Americans still resist genetic testing for fear they will be discriminated against by insurance companies.  Why?

in 2008, Congress passed GINA, the Genetic Information Nondiscrimination Act, to protect us from insurance companies choosing to include us or not for policies based on the genes we came with.    Then in 2010, Congress passed the ACA, or Affordable Care Act, and with it protection against preexisting conditions.  This includes genetic predispositions.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Anya%20Prince%202019%20Show.mp3" length="31725095" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/anya-prince-our-current-vulnerability-genetic-discrimination/</guid>
 <pubDate>Tue, 13 Aug 2019 10:16:10 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Anya%20Prince.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Do Long Reads Hold Answers for Alzheimer’s? with Mark Ebbert, Mayo</title>
 <link>https://mendelspod.com/podcasts/do-long-reads-hold-answers-alzheimers-mark-ebbert-mayo/</link>
 <description>It’s the kind of plot that makes great science.

There are genes that have been hiding in plain sight, undetected until now.  They’ve gone unseen, that is, by short read sequencing.  Today’s guest and his colleagues call them “camouflage genes,” and a couple in particular may play functional roles in Alzheimer’s disease.

Mark Ebbert is an Assistant Professor of Neuroscience at the Mayo Clinic where he is using long read sequencing technology and computational biology to study neurodegenerative diseases, including Alzheimer’s and ALS.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Mark%20Ebbert%202019%20Show_0.mp3" length="34803111" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/do-long-reads-hold-answers-alzheimers-mark-ebbert-mayo/</guid>
 <pubDate>Wed, 31 Jul 2019 22:22:51 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Mark%20Ebbert.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>With Nanopore Sensing Beyond Sequencing, Ontera Takes &#039;Lab&#039; to the Field</title>
 <link>https://mendelspod.com/podcasts/nanopore-sensing-beyond-sequencing-ontera-takes-lab-field/</link>
 <description>We’ve interviewed several CEOs over the years since the Theranos fiasco who avoided any mention of the blighted company whenever the comparison came up.  But today’s guest, Murielle Thinard McLane, the CEO of Ontera, jumped at the chance before Theral could get to it.

&quot;Some people might say, well that&#039;s the Theranos model.  They (Theranos) didn&#039;t get it wrong.  The demand for a fast, comprehensive point-of-care solution near the patient is there.  Where they got it wrong is that you need a technology that is sound to do that!&quot;</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Murielle%20Thinard%20McLane%202019%20Show.mp3" length="27089327" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/nanopore-sensing-beyond-sequencing-ontera-takes-lab-field/</guid>
 <pubDate>Thu, 25 Jul 2019 11:32:30 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/murielle.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Mark Chaisson on Two New Structural Variation Papers</title>
 <link>https://mendelspod.com/podcasts/mark-chaisson-two-new-structural-variation-papers/</link>
 <description>If you’re not on the long read sequencing train, you’re not landing in the world of genomics.

A new paper out begins, &quot;Structural variants contribute greater diversity at the nucleotide level between two human genomes than another form of genetic variation.”</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Mark%20Chaisson%202019%20Show_1.mp3" length="29889652" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/mark-chaisson-two-new-structural-variation-papers/</guid>
 <pubDate>Wed, 17 Jul 2019 12:41:06 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Mark%20Chaisson%20300.JPG" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Early Cancer Detection: Is This Company Ahead of Grail?</title>
 <link>https://mendelspod.com/podcasts/early-cancer-detection-company-ahead-grail/</link>
 <description>The great promise of liquid biopsy technology is in early cancer detection.    That is, it&#039;s the great future promise.  Right?   This past month at the annual cancer conference, ASCO, we heard about one such flagship company announcing just which technology they were going to use to do it--DNA methylation.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Richard%20Brand%202019%20Show_0.mp3" length="34556010" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/early-cancer-detection-company-ahead-grail/</guid>
 <pubDate>Mon, 08 Jul 2019 22:59:43 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Richard%20Brand.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>June 2019 Review with Nathan and Laura: Gene Patents, Grail, Dr. Lynch</title>
 <link>https://mendelspod.com/podcasts/june-2019-review-nathan-and-laura-gene-patents-grail-dr-lynch/</link>
 <description>Nathan and Laura join Theral for our final review show before the summer break.  Have you already headed out on vacation?  Take us along and stay current with the top stories in genomics.

This month it&#039;s gene patents (yes, Congress is really reviving that debate), another gene therapy with another astronomical price tag, and remembering Dr. Henry Lynch of Lynch Syndrome fame.
</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/June%202019%20Review%20Show.mp3" length="35974899" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/june-2019-review-nathan-and-laura-gene-patents-grail-dr-lynch/</guid>
 <pubDate>Sun, 30 Jun 2019 21:45:27 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/gene%20patents.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Should Genomic Screening Be Standard of Care? with Adam Buchanan, Geisinger</title>
 <link>https://mendelspod.com/podcasts/should-genomic-screening-be-standard-care-adam-buchanan-geisinger/</link>
 <description>Those of us watching every shift in the level of adoption of genomic medicine have our eyes closely glued to Geisinger Health System in Pennsylvania.

Adam Buchanan is the Co-Director of Geisinger’s MyCode Genomic Screening and Counseling program, and today we talk to him about the rationale of making genomic screening part of routine medical care.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Adam%20Buchanan%202019%20Show.mp3" length="36203957" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/should-genomic-screening-be-standard-care-adam-buchanan-geisinger/</guid>
 <pubDate>Mon, 24 Jun 2019 23:04:35 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/adam%20buchanan.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>May 2019 Review with Nathan and Laura: Gene Therapies, DTC Shifts, Gender and Sports</title>
 <link>https://mendelspod.com/podcasts/may-2019-review-nathan-and-laura-gene-therapies-dtc-shifts-gender-and-sports/</link>
 <description>Our two reigning champions are back for a month packed with news.  It’s Nathan Pearson of Root and Laura Hercher of Sarah Laurence College and Host of The Beagle Has Landed Podcast daring to go where no genomics commentators have gone before.
</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/May%202019%20Review%20Show%20-auphonic.mp3" length="37283428" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/may-2019-review-nathan-and-laura-gene-therapies-dtc-shifts-gender-and-sports/</guid>
 <pubDate>Fri, 31 May 2019 11:45:45 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/TMIB-Theral%20square.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Toward the Human Pan Genome with Adam Phillippy, NHGRI</title>
 <link>https://mendelspod.com/podcasts/toward-human-pan-genome-adam-phillippy-nhgri/</link>
 <description>Storylines repeat in genome science every decade or so.  The human genome is complete.  No.  Now it&#039;s complete.  Or, in the 90&#039;s, it was first announced that the first chromosome was sequenced.   We have the same story for you today--breaking news from a paper that has not even been published yet: the first “complete” assembly of a human chromosome, end to end, telomere to telomere.

So what’s going on?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Adam%20Phillippy%202019%20Show_0.mp3" length="38009860" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/toward-human-pan-genome-adam-phillippy-nhgri/</guid>
 <pubDate>Thu, 23 May 2019 09:18:59 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Adam%20Phillippy.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Laura Hercher on the DTC Genetic Testing Landscape</title>
 <link>https://mendelspod.com/podcasts/laura-hercher-dtc-genetic-testing-landscape/</link>
 <description>&quot;DTC is now too big of an arena to put everything in the same bucket.”
This was a line from Laura Hercher, one of our monthly commentators a couple shows back. The statement made its way around Twitter, so we thought we’d have Laura back to the program and ask her to come up with some more buckets.
It turns out it’s not that easy.  Direct-to-consumer genetic testing is a dynamic and complex space in 2019, a mishmash that quite defies easy categorization.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Laura%20Hercher%202019%20Show_0.mp3" length="35456538" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/laura-hercher-dtc-genetic-testing-landscape/</guid>
 <pubDate>Thu, 16 May 2019 10:13:25 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/laura%20hercher%202019.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Arcadia Biosciences Pivots to Bring Us Non-GMO, High Fiber GoodWheat and Better Cannabis</title>
 <link>https://mendelspod.com/podcasts/arcadia-biosciences-pivots-bring-us-non-gmo-high-fiber-goodwheat-and-better-cannabis/</link>
 <description>Today we&#039;re joined by Matt Plavan, President of Arcadia Specialty Genomics.
The last time we talked with someone from Arcadia Bioscience, a biotech company working on plant genomics in Davis, California, they were confronting GMO regulatory hurdles.
Which was a pity. They had created these great new strains of rice and soybeans, among other crops, that were being held from market due to regulations in Southeast Asia. This at a time when world population is . . . well, you know what its doing.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Matt%20Plavan%202019%20Show.mp3" length="31171693" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/arcadia-biosciences-pivots-bring-us-non-gmo-high-fiber-goodwheat-and-better-cannabis/</guid>
 <pubDate>Thu, 09 May 2019 10:05:04 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Matt%20Plavan%201.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>April 2019 Review with Nathan and Laura: uBiome Raided by FBI, PRS for Obesity, and a Gene Therapy Cure</title>
 <link>https://mendelspod.com/podcasts/april-2019-review-nathan-and-laura-ubiome-raided-fbi-prs-obesity-and-gene-therapy-cure/</link>
 <description>April was a tough month for some genomics companies.  The FBI raided the offices of uBiome and two other pioneers in the field failed.  Are there broader implications?

Nathan and Laura have returned to first give us some facts and then to throw their hats in the ring.

Lots happened this month in the world of DNA.  Tune in and catch it all.
</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/April%202019%20Review%20Show.mp3" length="35709023" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/april-2019-review-nathan-and-laura-ubiome-raided-fbi-prs-obesity-and-gene-therapy-cure/</guid>
 <pubDate>Thu, 02 May 2019 08:40:49 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/FBI-UBiome.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>The Era of the Social Genome with Rodrigo Martinez, Veritas Genetics</title>
 <link>https://mendelspod.com/podcasts/era-social-genome-rodrigo-martinez-veritas-genetics/</link>
 <description>Two years ago Veritas Genetics began offering whole genome sequencing for a thousand dollars. It was a significant milestone—and still is!—not only for what it means about the company providing the genomes but also what it means about the demand for such a product.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Rodrigo%20Martinez%202019%20Show.mp3" length="35521113" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/era-social-genome-rodrigo-martinez-veritas-genetics/</guid>
 <pubDate>Thu, 18 Apr 2019 09:30:41 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Rodrigo%20Martinez.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Reassessing Alzheimer’s with Larry Goldstein, UCSD</title>
 <link>https://mendelspod.com/podcasts/reassessing-alzheimers-larry-goldstein-ucsd/</link>
 <description>There are drug trial failures.  And there are drug trial failures.

The recent move by drug giant Biogen to halt their Alzheimer’s drug has not only been a setback for the company—their stock fell precipitously on the news—it’s also been a major setback for the whole research community focused on this disease.  The Biogen trial was one of the last of the major drug companies with high hopes for a significant therapeutic step forward for the neurodegenerative disease.  The last five years has seen one big pharma players after another throw in the towel.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Larry%20Goldstein%202019%20Show.mp3" length="35625204" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/reassessing-alzheimers-larry-goldstein-ucsd/</guid>
 <pubDate>Mon, 08 Apr 2019 20:15:08 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Larry%20Goldstein.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Family Surprises Care of the Home DNA Test with Brianne Kirkpatrick</title>
 <link>https://mendelspod.com/podcasts/family-surprises-care-home-dna-test-brianne-kirkpatrick/</link>
 <description>You order a $99 home DNA test for some holiday pleasure.  It’s a bit of fun.  Right?

Until it turns your life upside down.  Which is when you contact a professional.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Brianne%20Kirkpatrick%202019%20Show.mp3" length="29107199" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/family-surprises-care-home-dna-test-brianne-kirkpatrick/</guid>
 <pubDate>Wed, 03 Apr 2019 22:11:30 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/BrianneKirkpatrick.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>March 2019 with Nathan and Laura: Old Envelopes, Wooly Mammoth DNA, and the Night King </title>
 <link>https://mendelspod.com/podcasts/march-2019-nathan-and-laura-old-envelopes-wooly-mammoth-dna-and-night-king/</link>
 <description>From recovering DNA on hundred year old envelopes to bringing it to life from 28,000 year old wooly mammoth samples, it&#039;s our genomics version of March Madness.  Join Theral, Nathan and Laura for another monthly look back over the headlines.
</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/March%202019%20with%20Nathan%20and%20Laura.mp3" length="36955407" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/march-2019-nathan-and-laura-old-envelopes-wooly-mammoth-dna-and-night-king/</guid>
 <pubDate>Thu, 28 Mar 2019 20:41:53 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/old%2Bletter.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Single Cell Analysis Shows Important New Detail in Key Clinical Study of AML: Koichi Takahashi, MD Anderson</title>
 <link>https://mendelspod.com/podcasts/single-cell-analysis-shows-important-new-detail-key-clinical-study-aml-koichi-takahashi-md/</link>
 <description>The history of biomedicine goes something like this:


A new tool is invented.  2.  New tool is used in research labs to generate new data and new hypotheses.  There is new science.   3. New tool is used in clinical setting to confirm this new science with real patients.   4.  Then new tool is adopted into clinical use.


All the buzz these days, single cell DNA analysis instruments have just made it into step three.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Koichi%20Takahashi%202019%20Show_0.mp3" length="32186068" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/single-cell-analysis-shows-important-new-detail-key-clinical-study-aml-koichi-takahashi-md/</guid>
 <pubDate>Wed, 20 Mar 2019 21:58:49 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/koichi_takahashi.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Science Communication in a Post Fact World with Erik Clausen</title>
 <link>https://mendelspod.com/podcasts/science-communication-post-fact-world-erik-clausen/</link>
 <description>&quot;That’s fake news!”

We hear it all the time.  And often it is said about scientific facts, for example, recent studies or evidence of global warming.  Or the safeness of vaccines.  But has the problem with “fake news” been that much of an issue in the life science industry?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Erik%20Clausen%202019%20Show.mp3" length="28986659" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/science-communication-post-fact-world-erik-clausen/</guid>
 <pubDate>Wed, 06 Mar 2019 17:15:55 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/erik%20clausen%20b%26w.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>February 2019 Review with Nathan and Laura: Family Surprises, IQ Profiling, and Chinese Surveillance</title>
 <link>https://mendelspod.com/podcasts/february-2019-review-nathan-and-laura-family-surprises-iq-profiling-and-chinese/</link>
 <description>Our two favorite commentators are back for our February 2019 month-in-review show, and to give our own twist to Valentine&#039;s Day celebrations we take on the topic of family surprises due to DNA testing.  This is a phenomenon taking the world by storm in 2019.  The Boston Globe had a great headline this past week, &quot;First came the home DNA kits. Now come the support groups.&quot;</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/February%202019%20Review%20Show%20with%20Nathan%20and%20Laura-1.mp3" length="36624402" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/february-2019-review-nathan-and-laura-family-surprises-iq-profiling-and-chinese/</guid>
 <pubDate>Thu, 28 Feb 2019 20:21:04 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Paternity%20Test.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Heretic No Longer?  Meet Michael Joyner, Precision Medicine’s Critic-in-Chief</title>
 <link>https://mendelspod.com/podcasts/heretic-no-longer-meet-michael-joyner-precision-medicines-critic-chief-0/</link>
 <description>In 2016, after President Obama announced the Cancer Moonshot in the State of the Union, a very outspoken physician researcher from the Mayo Clinic penned an open letter to Vice President Biden criticizing the project and proposing the money be better spent other ways. It included these lines:</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Michael%20Joyner%202019%20Show%20%281%29.mp3" length="19475855" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/heretic-no-longer-meet-michael-joyner-precision-medicines-critic-chief-0/</guid>
 <pubDate>Tue, 26 Feb 2019 11:40:20 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Michael%20Joyner.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>The Internet of Biology Revolution-For Real This Time, with Brett Goldsmith, Cardea</title>
 <link>https://mendelspod.com/podcasts/internet-biology-revolution-real-time-brett-goldsmith-cardea/</link>
 <description>Talk to anyone who’s been around diagnostics or blood sampling for long, and they’ll tell you that nanotechnology is nothing new.
Today’s guest, Brett Goldsmith, the Chief Technology Officer at Cardea, says he was involved in the nano revolution that was and then wasn’t 20 years ago. (The older veterans among us might date it back even further, to forty years ago.) So what are Brett and Cardea buzzing about early this year in a new &lt;a href=&quot;https://www.nature.com/articles/s41598-019-38700-w&quot; target=&quot;_blank&quot;&gt;Nature paper&lt;/a&gt;?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Brett%20Goldsmith%202019%20Show.mp3" length="36129794" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/internet-biology-revolution-real-time-brett-goldsmith-cardea/</guid>
 <pubDate>Tue, 05 Feb 2019 19:26:19 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Brett%20Goldsmith.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>January 2019 Review with Nathan and Laura: Cloning, CRISPRing, DTC, and Paleogenomic Overreach</title>
 <link>https://mendelspod.com/podcasts/january-2019-review-nathan-and-laura-cloning-crispring-dtc-and-paleogenomic-overreach/</link>
 <description>Nathan and Laura are back for the first time this year for a wild trip past cloned CRISPRd monkeys and the first gene drive in mammals. (Just that?)  But first we have to deal with our hangover from the end of last year.

We talk DTC and end with a discussion of the ancient DNA controversy.
</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/January%202019%20Review%20Show%20with%20Nathan%20and%20Laura.mp3" length="27923843" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/january-2019-review-nathan-and-laura-cloning-crispring-dtc-and-paleogenomic-overreach/</guid>
 <pubDate>Thu, 31 Jan 2019 20:42:57 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/ancient%20DNA.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Cara O&#039;Neill of the Cure Sanfilippo Foundation Tells Her Story</title>
 <link>https://mendelspod.com/podcasts/cara-oneill-cure-sanfilippo-foundation-tells-her-story/</link>
 <description>You’re a mother, and life is typical.  You’re also a pediatrician.  Then one day you hear that your daughter is autistic.  OK.  Then you get the news that, no, it’s not autism but a very rare disease called Sanfilippo Syndrome.  From your training as a pediatrician you quickly think back and remember the MPS rare diseases, but nothing else prepares you for what’s ahead.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Cara%20O%27Neill%202019%20Show.mp3" length="31519469" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/cara-oneill-cure-sanfilippo-foundation-tells-her-story/</guid>
 <pubDate>Mon, 28 Jan 2019 17:17:46 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/cara%20o%27neill.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> PregSource:  The NIH’s Crowdsourcing Project for Pregnancy Data with Caroline Signore</title>
 <link>https://mendelspod.com/podcasts/pregsource-nih%E2%80%99s-crowdsourcing-project-pregnancy-data-caroline-signore/</link>
 <description>There are hundreds of pregnancy apps available. So what is unique about the NIH’s new crowdsourcing project called PregSource?
“We think PregSource is different because we offer the security and reliability of having been developed at the NIH with the participation of well regarded organizations. We’ve developed the content with expert input at every stage. Their are no ads at PregSource. And, of course, we will never, ever share or sell the data with a commercial organization.”</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Caroline%20Signore%202019%20Show.mp3" length="29084717" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/pregsource-nih%E2%80%99s-crowdsourcing-project-pregnancy-data-caroline-signore/</guid>
 <pubDate>Thu, 24 Jan 2019 13:24:21 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Caroline%20Signore.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Meet Christian, Janos, and the New World of 3D Oncology</title>
 <link>https://mendelspod.com/podcasts/meet-christian-janos-and-new-world-3d-oncology/</link>
 <description>Today we engage in a rare discussion between a startup founder who is going beyond sequencing and working directly with cancer patient cells in 3D cultures and with one of his customers, the husband of a cancer patient.

Meet Christian Regenbrecht, the CEO of CPO or Cellular Phenomics and Oncology based in Berlin, Germany and Janos Flosser, a fund manager who invests in technology from Copenhagen, Denmark.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Christian%20and%20Janos%20Show%202019.mp3" length="32362741" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/meet-christian-janos-and-new-world-3d-oncology/</guid>
 <pubDate>Wed, 16 Jan 2019 19:26:14 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/tumor%20cells.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Has Computational Modeling for Cancer Genomics &quot;Arrived?&quot; with Shirley Liu, Dana Farber</title>
 <link>https://mendelspod.com/podcasts/has-computational-modeling-cancer-genomics-arrived-shirley-liu-dana-farber/</link>
 <description>It’s the question of the moment  Are we living in the age of AI?  Or is it still just hype?

When it comes to the latest research in immuno therapy, computational modeling is helping to answer key open questions, such as which patients might respond to which drugs.

&quot;If you were to ask me last year about deep learning, I would probably say, aaah, most of the algorithms that are published are not really answering the important questions yet.  But I think this year I am converted.  We are starting to use deep learning, and we are starting to see interesting results.”</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Shirley%20Liu%202018%20Show.mp3" length="31918641" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/has-computational-modeling-cancer-genomics-arrived-shirley-liu-dana-farber/</guid>
 <pubDate>Tue, 08 Jan 2019 08:03:33 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Shirley%20Liu.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Amy Harmon of the NYT on Race &amp; Genetics, Women in Science</title>
 <link>https://mendelspod.com/podcasts/amy-harmon-nyt-race-genetics-women-science/</link>
 <description>At the end of the year, we like to speak with a journalist who covers genetics about some of their stories.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Amy%20Harmon%202018%20Show%20%281%29.mp3" length="20619967" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/amy-harmon-nyt-race-genetics-women-science/</guid>
 <pubDate>Thu, 27 Dec 2018 00:17:35 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Amy%20Harmon.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>CRISPR or Not, You Can&#039;t Genetically Enhance Humans, Says Sci-Fi Author Kim Stanley Robinson</title>
 <link>https://mendelspod.com/podcasts/crispr-or-not-you-cant-genetically-enhance-humans-says-sci-fi-author-kim-stanley-robinson/</link>
 <description>Designer babies.  The term means many things to many people.  To some it means kids only dressed in Gucci.

Some say that by doing pre-implantation genetic screening, we are already living in the age of designer babies.  Others have been holding out for that time when humans edit their own germline offering the new progeny not only disease repair, but also enhancements.  It&#039;s also argued there’s a third category in the middle there somewhere, a protection against disease in the future.  That’s what He Jiankui attempted.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Kim%20Stanley%20Robinson%202018%20Show.mp3" length="34354695" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/crispr-or-not-you-cant-genetically-enhance-humans-says-sci-fi-author-kim-stanley-robinson/</guid>
 <pubDate>Thu, 20 Dec 2018 12:19:37 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/KSR.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>The New World of Infectious Disease Diagnosis: Out in the Field with David Hong of Karius </title>
 <link>https://mendelspod.com/podcasts/new-world-infectious-disease-diagnosis-out-field-david-hong-karius/</link>
 <description>A one month old baby is admitted to a hospital with fever.  This is cause for serious alarm.  The child is put on broad spectrum antibiotics.  The infected area is drained and a culture run to try to identify the pathogen.   The cultures come back negative, the pathogen not identified.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/David%20Hong%202018%20Show.mp3" length="23639352" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/new-world-infectious-disease-diagnosis-out-field-david-hong-karius/</guid>
 <pubDate>Thu, 13 Dec 2018 10:20:25 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/David-Hong-Photo.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>California Life Science Industry Steps to New Heights - the 2019 Edition with Sara Radcliffe</title>
 <link>https://mendelspod.com/podcasts/california-life-science-industry-steps-new-heights-2019-edition-sara-radcliffe/</link>
 <description>Sara Radcliffe can be happy--extra happy.  She is the CEO of the California Life Sciences Association at a time when the state is breaking records, beating out every other state in category after category.    Today Sara discusses a &lt;a href=&quot;http://info.califesciences.org/2019report&quot; target=&quot;_blank&quot;&gt;new report&lt;/a&gt; the organization has released along with PWC detailing our sector’s explosive growth.  Jobs: check.   Wages and revenue:  check.  VC funding: check.  NIH funding: check.     California leads in all.   Big yaaaawn?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Sara%20Radcliffe%202018%20Show.mp3" length="23844567" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/california-life-science-industry-steps-new-heights-2019-edition-sara-radcliffe/</guid>
 <pubDate>Mon, 03 Dec 2018 22:30:14 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/CLSA%20%26%20PwC%202019%20California%20Life%20Sciences%20Industry%20Report%20Final.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Nathan and Laura on CRISPRed Babies and Other November 2018 Stories</title>
 <link>https://mendelspod.com/podcasts/nathan-and-laura-crispred-babies-and-other-november-2018-stories/</link>
 <description>What a week!  And a great time to have on our expert contributors, genomicist Nathan Pearson and genetic counselor Laura Hercher, to talk about what is reportedly a first in history: babies born with a gene altered.   They&#039;ll be called Lulu and Nana.

So just how pissed, scared, shocked, and curious are we after three days?</description>
 <author>online@cglife.com (cglife)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/November%202018%20with%20Nathan%20and%20Laura%20Show%20%281%29.mp3" length="20012492" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/nathan-and-laura-crispred-babies-and-other-november-2018-stories/</guid>
 <pubDate>Thu, 29 Nov 2018 09:21:03 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/0-19.jpg" />
 <itunes:author> online@cglife.com (cglife)
</itunes:author>
</item>
 <item> <title>Ellen Matloff on a New Digital Genetic Counseling Product for DTC Customers</title>
 <link>https://mendelspod.com/podcasts/ellen-matloff-new-digital-genetic-counseling-product-dtc-customers/</link>
 <description>If Mendelspod had an annual Product of the Year award, we&#039;d certainly be liking for 2018 the one featured today, a digital genetic counseling product for direct-to-consumer genetic testing.

Hats are off to Ellen Matloff, a genetic counselor formerly at Yale who saw the DTC boom coming a few years ago, busted out of academia, started My Gene Counsel, and last month launched her first digital product.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Ellen%20Matloff%202018%20Show.mp3" length="30332333" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/ellen-matloff-new-digital-genetic-counseling-product-dtc-customers/</guid>
 <pubDate>Thu, 15 Nov 2018 09:16:40 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/ellen-matloff-my-gene-counsel-ceo.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Connecting the Dots for a Community of Rare Disease Patients:  Terri Klein, MPS Society</title>
 <link>https://mendelspod.com/podcasts/connecting-dots-community-rare-disease-patients-terri-klein-mps-society/</link>
 <description>The MPS Society is a rare organization.  Not just because it is an umbrella for the rare diseases that have in common lysosomal storage malfunction.  But because it is one of the largest rare disease organizations in the world.

Terri Klein is the CEO leading the MPS Society.  She says the group has over three thousand members on their roster.  This brings some strength and resources in an area where low numbers intensifies an uphill battle.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Terri%20Klein%202018%20Show.mp3" length="32874226" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/connecting-dots-community-rare-disease-patients-terri-klein-mps-society/</guid>
 <pubDate>Wed, 07 Nov 2018 21:44:31 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Terri%20Klein.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Keith Robison and Shawn Baker on Illumina Buyout of PacBio</title>
 <link>https://mendelspod.com/podcasts/keith-robison-and-shawn-baker-illumina-buyout-pacbio/</link>
 <description>Just hours after Illumina announced their buyout of Pacific Biosciences, Theral sits down with longtime sequencing Omics Omics blogger, Keith Robison, and the Chief Science Officer at sequencing marketplace, AllSeq, Shawn Baker, to discuss the news which has taken the industry by surprise.

A special thanks to our sponsor, Sage Science, and the quick decision on this show.
</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Keith%20and%20Shawn%20on%20Illumina%20Buyout%20of%20PacBio.mp3" length="26803371" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/keith-robison-and-shawn-baker-illumina-buyout-pacbio/</guid>
 <pubDate>Fri, 02 Nov 2018 11:50:49 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Illumina-pacbio.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>October 2018 Review with Nathan and Laura:  ASHG Does Race, Parents Do Gene Therapy, Unsung Demons</title>
 <link>https://mendelspod.com/podcasts/october-2018-review-nathan-and-laura-ashg-does-race-parents-do-gene-therapy-unsung-demons/</link>
 <description>As an election nears, the question of race and genetics has been front and center.  It even prompted ASHG to take the unusual step of making a group wide statement.   The three of us agree: scientists should talk more about the race question with non-scientists.

Two papers in Tech Review this month show that the world of people buying cures and disease prevention through gene editing isn’t around the corner, it’s here.  Now what about those who can’t afford it?  One of the papers was written by our very own Laura Hercher.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/October%202018%20with%20Nathan%20and%20Laura%20Show_0.mp3" length="39316641" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/october-2018-review-nathan-and-laura-ashg-does-race-parents-do-gene-therapy-unsung-demons/</guid>
 <pubDate>Wed, 31 Oct 2018 20:20:17 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/race%20and%20genetics.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>A Point-of-Care CBC Test Based on a Few Drops of Blood—Is This the Real Thing? with Danny Levner, Sight Diagnostics</title>
 <link>https://mendelspod.com/podcasts/point-care-cbc-test-based-few-drops-blood%E2%80%94-real-thing-danny-levner-sight-diagnostics/</link>
 <description>Time is health.  Take certain blood cancers, for instance.  When a patient is seen in a doctor’s office, they are then sent to a central lab for testing, and the results can take a few days.  With blood cancer patients, these few days can be vital.

For years a holy grail in diagnostics has been to get diagnostic tests to the point-of-care based on just a few drops of the patient’s blood that could give immediate results.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Danny%20Levner%202018%20Show.mp3" length="27207686" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/point-care-cbc-test-based-few-drops-blood%E2%80%94-real-thing-danny-levner-sight-diagnostics/</guid>
 <pubDate>Thu, 25 Oct 2018 11:12:33 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Danny%20Levner.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>It’s a Gold Rush in Single Cell Genomics, Says Joachim Schultze, U of Bonn</title>
 <link>https://mendelspod.com/podcasts/it%E2%80%99s-gold-rush-single-cell-genomics-says-joachim-schultze-u-bonn/</link>
 <description>The title says it all here.  Herr Professor Schultze directs a major facility that he calls a single cell genomics platform.  They have most of the single cell technologies available and partner with labs from all over the world on research.

Advances in single cell technologies are changing basic research and also delivering results for translational work in everything from immunology to obesity.

“Biology will never be the same again,” says Joachim.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Joachim%20Schultze%20Show%202018.mp3" length="28965938" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/it%E2%80%99s-gold-rush-single-cell-genomics-says-joachim-schultze-u-bonn/</guid>
 <pubDate>Mon, 15 Oct 2018 16:54:35 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Joachim%20Schultze.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>A Market Solution for Biospecimen Quality Standards with Matt McLoughlin, Scientist.com</title>
 <link>https://mendelspod.com/podcasts/market-solution-biospecimen-quality-standards-matt-mcloughlin-scientistcom/</link>
 <description>We ran a series this summer highlighting one of the major issues in biomedical research: that the collection, storage, and procurement of biospecimen samples lacks any across-the-board governing standards.  Various institutions adopt their own regulations resulting in a checkerboard of quality assurance, and by extension, an unknown effect on the outcomes of research.  Our first guest called it “garbage in, garbage out.” (See links below.)  This should send shudders through anyone doing research with any human tissue sample.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Matt%20McLoughlin%202018%20Show_0.mp3" length="32111318" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/market-solution-biospecimen-quality-standards-matt-mcloughlin-scientistcom/</guid>
 <pubDate>Mon, 01 Oct 2018 21:56:11 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Matthew%20McLoughlin%2C%20BSc%20.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>September 2018 with Nathan and Laura:  Studying the Same Genes and the Matt Fender Story</title>
 <link>https://mendelspod.com/podcasts/september-2018-nathan-and-laura-studying-same-genes-and-matt-fender-story/</link>
 <description>And here we were thinking it was a slow month!

We have two big stories today:  first  this philosophy of biology question about whether it’s a bad thing that we’ve been stuck circling the wagons ‘round the same ole genes.  Is it just an economic question?  Or is it that these are the most active genes, and so we need a meritocracy, as Nathan puts forth?</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/September%202018%20with%20Nathan%20and%20Laura%20Show-New.mp3" length="38174872" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/september-2018-nathan-and-laura-studying-same-genes-and-matt-fender-story/</guid>
 <pubDate>Fri, 28 Sep 2018 16:06:14 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Matt%20Fender_0.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Single Cell Sequencing Tailor Made for Nephrology, Says Vivek Bhalla, Stanford</title>
 <link>https://mendelspod.com/podcasts/single-cell-sequencing-tailor-made-nephrology-says-vivek-bhalla-stanford/</link>
 <description>Vivek Bhalla is used to the question, what’s a nephrologist?  When we admitted we’d never had one on the program, he made his own admission, saying that the kinds of people who became nephrologists are the kinds of people who don’t seek out the limelight.

But Vivek, an assistant professor of medicine at Stanford, is changing that and speaking out on behalf of his profession.  And he’s very excited about what single cell sequencing has done for the study of the kidney.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Vivek%20Bhalla%20Show%202018.mp3" length="23516236" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/single-cell-sequencing-tailor-made-nephrology-says-vivek-bhalla-stanford/</guid>
 <pubDate>Thu, 20 Sep 2018 10:23:47 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Vivek%20Bhalla.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>It’s the Social Factors, Stupid!  Lisa Suennen on Healthcare, Her Career, Digital Health Investing, and . . . Just Being Herself</title>
 <link>https://mendelspod.com/podcasts/it%E2%80%99s-social-factors-stupid-lisa-suennen-healthcare-her-career-digital-health-investing-and/</link>
 <description>She&#039;s been a highly sought after venture funder and knowledge broker in the field of digital health.  STAT News wrote that upwards of 1,500 pitches crossed her desk last year at GE Ventures.  But as of a couple weeks ago, it&#039;s a desk at which she&#039;s no longer sitting.  So what&#039;s she up to next?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Lisa%20Suennen%202018%20Show.mp3" length="30056291" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/it%E2%80%99s-social-factors-stupid-lisa-suennen-healthcare-her-career-digital-health-investing-and/</guid>
 <pubDate>Thu, 13 Sep 2018 10:10:13 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Lisa%20Suennen.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Concerned About DTC Test Quality?  Ask Two Questions, Says Daryl Pritchard, PMC</title>
 <link>https://mendelspod.com/podcasts/concerned-about-dtc-test-quality-ask-two-questions-says-daryl-pritchard-pmc/</link>
 <description>We like talking to the folks at the Personalized Medicine Coalition (PMC).  They have many stakeholders and multifaceted speakers on a wide range of topics.  Recently they’re open to talking more about DTC testing—as are most of the traditional diagnostics community.  (In our most popular program of the year, CEO of Invitae, Sean George &lt;a href=&quot;https://mendelspod.com/podcasts/genetic-testing-dead-long-live-genetic-testing-sean-george-invitae/&quot;&gt;said&lt;/a&gt; back in May that the clinical community must “coop” with the rapidly growing DTC movement.)</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Daryl%20Pritchard%202018%20Show-auphonic.mp3" length="31065454" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/concerned-about-dtc-test-quality-ask-two-questions-says-daryl-pritchard-pmc/</guid>
 <pubDate>Wed, 05 Sep 2018 09:37:46 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/darylpritchard.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>August 2018 Review with Nathan and Laura: The polygenic month</title>
 <link>https://mendelspod.com/podcasts/august-2018-review-nathan-and-laura-polygenic-month/</link>
 <description>It’s our first show back after the summer break, and nothing has got us all buzzing about genomics again like a polygenic risk score.  It even has Laura Hercher talking about the Human Genome Project doing some delivering, god forbid.

CRISPR has had a rough summer.  But still . . . it is CRISPR.

Is Burning Man still cool, we were asked last weekend.  Don&#039;t know.  Don&#039;t care.  We asked back, is 23andMe still cool?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/August%202018%20with%20Nathan%20and%20Laura%20Show.mp3" length="32084535" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/august-2018-review-nathan-and-laura-polygenic-month/</guid>
 <pubDate>Fri, 31 Aug 2018 08:48:24 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/polygenic%20risk.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>An International Perspective on How to Improve Biobanking with Kirstin Goldring</title>
 <link>https://mendelspod.com/podcasts/international-perspective-how-improve-biobanking-kirstin-goldring/</link>
 <description>For the next episode in our summer series on human tissue sample quality and biobanking, we turn to a veteran biobanker in the U.K. who managed several projects there including the U.K. Parkisons’ Disease Society Brain Bank at Imperial College.

Today we talk to Kirstin Goldring, Principal Scientist at Astra Zeneca where she’s in charge of Human Biological Sample Strategy and Governance. Kirstin is a counselor at the European Society for Biopreservation and Biobanking and also a member of ISBER or the International Society for Biorepositories.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Kirstin%20Goldring%202018%20Show.mp3" length="21834031" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/international-perspective-how-improve-biobanking-kirstin-goldring/</guid>
 <pubDate>Tue, 21 Aug 2018 10:38:03 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Kirstin%20Goldring.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>A Seqster Preview with Founder Ardy Arianpour</title>
 <link>https://mendelspod.com/podcasts/seqster-preview-founder-ardy-arianpour/</link>
 <description>As long as we’ve been doing clinical genetics, the goal has been to marry up the genetic data with phenotypic data in the electronic medical records.    This has been achieved with some success and with a few of the best genetic markers at some of the leading healthcare providers:  Geisinger, Rady Children&#039;s, Brigham and Women’s—to name a few. But it hasn’t happened at scale, at least not in this country.  Some of the national health services around the world are making the dream more of a reality, for example in Iceland and the U.K.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Ardy%20Arianpour%202018%20Show.mp3" length="25733265" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/seqster-preview-founder-ardy-arianpour/</guid>
 <pubDate>Thu, 16 Aug 2018 10:11:11 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/ArdyArianpour.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Detective Stories from the Genomic War Room with Ramesh Hariharan</title>
 <link>https://mendelspod.com/podcasts/detective-stories-genomic-war-room-ramesh-hariharan/</link>
 <description>A book like this only comes around once in a while—one never knows from which corner.  This time it was written by the CTO of a next gen sequencing data analytics company.

“Every one of these cases was intense.  It was just so fascinating that I had to put it down in a book and tell the story.  There’s so much in biology that boggles your mind and makes you wonder.”</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Ramesh%20Hariharan%202018%20Show_0.mp3" length="33723103" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/detective-stories-genomic-war-room-ramesh-hariharan/</guid>
 <pubDate>Thu, 26 Jul 2018 09:07:56 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Ramesh%20Hariharan.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Should Biobanking Come Under CLIA?  Shannon McCall, Duke</title>
 <link>https://mendelspod.com/podcasts/should-biobanking-come-under-clia-shannon-mccall-duke/</link>
 <description>When former President Obama’s team released the paperwork for what’s become the All of Us Research Program, in the part about biobanking, the wording specified that the biobanks applying for the grants be “CLIA compliant.”</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Shannon%20McCall%202018%20Show.mp3" length="29954358" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/should-biobanking-come-under-clia-shannon-mccall-duke/</guid>
 <pubDate>Tue, 17 Jul 2018 08:31:33 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Shannon%20McCall.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Pharma Stepping Up, Footing the Bill for Genetic Testing &amp; Counseling: Jordanna Mora, Alnylam</title>
 <link>https://mendelspod.com/podcasts/pharma-stepping-footing-bill-genetic-testing-counseling-jordanna-mora-alnylam/</link>
 <description>It seems to be human nature to value and pay up to hundreds of thousands of dollars for a little white pill that we can drop on the floor--and granted, can do wonders for us, but we want to pay nothing or very little to be told what is wrong with us so that we might know which little white pill to use in the first place.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Jordanna%20Mora%202018%20Show.mp3" length="16639668" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/pharma-stepping-footing-bill-genetic-testing-counseling-jordanna-mora-alnylam/</guid>
 <pubDate>Tue, 12 Jun 2018 09:55:00 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Jordanna%20Mora%201.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Are We Asking Too Much of Genomics in Cancer Research?  Tony Letai, Dana Farber</title>
 <link>https://mendelspod.com/podcasts/are-we-asking-too-much-genomics-cancer-research-tony-letai-dana-farber/</link>
 <description>It’s a question we’ve asked on the program before.  Are we over relying on the genomics route getting us to biomedical research paradise?  Should we be putting more eggs in other baskets?

After combing through lots of clinical trials data, Tony Letai of Dana Farber and the Broad, &lt;a href=&quot;https://www.nature.com/articles/nm.4389&quot; target=&quot;_blank&quot;&gt;found&lt;/a&gt; that a majority of cancer patients have not benefited from precision medicine.  On today’s show he says we need to rethink our approach to cancer research and treatment.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Tony%20Letai%202018%20Show.mp3" length="29146925" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/are-we-asking-too-much-genomics-cancer-research-tony-letai-dana-farber/</guid>
 <pubDate>Thu, 07 Jun 2018 10:07:23 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/anthony-letai.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>I Won’t Rest Until We Have Quality Standards in Place for Biospecimens: Carolyn Compton, ASU</title>
 <link>https://mendelspod.com/podcasts/i-won%E2%80%99t-rest-until-we-have-quality-standards-place-biospecimens-carolyn-compton-asu/</link>
 <description>She’s a force of nature, and she’s back on Mendelspod.  A decade ago, Carolyn Compton was hired by the NCI to solve a problem that has plagued the world of not just cancer research, but all of biomedical research.  To this day, there are no standards in place for the acquisition, collection, storage, and delivery of human biological samples used for research.  The leader of the NIH has acknowledged that this is a major part of biology’s non-reproducibility problem.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Carolyn%20Compton%202018%20Show_0.mp3" length="27123470" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/i-won%E2%80%99t-rest-until-we-have-quality-standards-place-biospecimens-carolyn-compton-asu/</guid>
 <pubDate>Tue, 05 Jun 2018 08:34:50 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/CarolynSquare.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>May 2018 with Nathan and Laura: The Free Exome, California Database, and Mosaicism</title>
 <link>https://mendelspod.com/podcasts/may-2018-nathan-and-laura-free-exome-california-database-and-mosaicism/</link>
 <description>Nathan Pearson and Laura Hercher are back for a look over a busy month of headlines.

May took us into the era of the free genome as Geisinger planted the genomic medicine flag on an even higher peak.  And did you know California was keeping a genetic database for every baby born?

Meh. . . says Laura.  Every state does it.  Old news.

And mosaicism is old scientific news, says Nathan, but he likes the way Carl Zimmer brings it to light in a new book.  Nathan and Laura then go above and beyond with their own elucidation.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/May%202018%20with%20Nathan%20and%20Laura%20Show_0.mp3" length="31309521" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/may-2018-nathan-and-laura-free-exome-california-database-and-mosaicism/</guid>
 <pubDate>Fri, 01 Jun 2018 09:40:16 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Geisinger%20with%20Flag.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Has Diagnostic Testing Plateaued?  Alka Chaubey, Greenwood Genetic Center</title>
 <link>https://mendelspod.com/podcasts/has-diagnostic-testing-plateaued-alka-chaubey-greenwood-genetic-center/</link>
 <description>If you’ve been in the field of genetic testing then you know about the Greenwood Genetic Center.  With an address on Mendel Circle in Greenwood, South Carolina, this non profit diagnostic testing laboratory has basically written the book on diagnosing and understanding genetic disorders.  Chances are, too, that you know the director of their cytogenetics lab and our guest today, Alka Chaubey.  Her hunger for meeting new people and learning new science is matched only by her desire to share the Greenwood legacy.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Alka%20Chuabey%202018%20Show.mp3" length="24902976" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/has-diagnostic-testing-plateaued-alka-chaubey-greenwood-genetic-center/</guid>
 <pubDate>Thu, 24 May 2018 09:23:41 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/AlkaChaubey_0.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>A New Way for DTC?  Nathan Pearson, Root Deep Insight</title>
 <link>https://mendelspod.com/podcasts/new-way-dtc-nathan-pearson-root-deep-insight/</link>
 <description>You know him, but do you know what he does for a day job?

Over the past two years, Nathan Pearson has dazzled us with his broad knowledge of the genomics space on our regular monthly reviews.  Today we’re talking to Nathan about his new company that he soft launched last December, Root Deep Insight, a venture into what he calls “direct-to-lay folk genetics.”</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Nathan%20Pearson%202018%20Show.mp3" length="63415764" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/new-way-dtc-nathan-pearson-root-deep-insight/</guid>
 <pubDate>Thu, 17 May 2018 09:36:17 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Nathan-Pearson%20-%20new.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Genetic Testing in the Age of Trump: Hank Greely, Stanford</title>
 <link>https://mendelspod.com/podcasts/genetic-testing-age-trump-hank-greely-stanford/</link>
 <description>&quot;In a world turned upside down, this is an area where I don’t think he’s had much effect.   I don’t think he knows how to spell “DNA.”&quot;

So begins Hank Greely in today’s interview on genetic testing in the age of Trump.  Hank is a Professor of Law and, by courtesy, Professor of Genetics at Stanford.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Hank%20Greely%202018%20Show.mp3" length="39203887" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/genetic-testing-age-trump-hank-greely-stanford/</guid>
 <pubDate>Wed, 09 May 2018 22:06:52 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Hank%20Greely%20standing.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Genetic Testing is Dead, Long Live Genetic Testing:  Sean George of Invitae </title>
 <link>https://mendelspod.com/podcasts/genetic-testing-dead-long-live-genetic-testing-sean-george-invitae/</link>
 <description>A few years ago they were the new kid on the block, and now they are a leader of mainstream genetic testing.  Last year their revenue and profit were significantly up.

And yet in today’s interview, CEO Sean George does not sound like someone sitting back on his laurels.  In fact, he says his business model has got to change.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Sean%20George%202018%20Show.mp3" length="37415853" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/genetic-testing-dead-long-live-genetic-testing-sean-george-invitae/</guid>
 <pubDate>Thu, 03 May 2018 09:57:26 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Sean%20George_0.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>April 2018 with Nathan and Laura:  Golden State Killer and the Cancer Prediction Space</title>
 <link>https://mendelspod.com/podcasts/april-2018-nathan-and-laura-golden-state-killer-and-cancer-prediction-space/</link>
 <description>After decades on the loose, it’s cool the cops finally caught him.  But is it cool how they caught him?

Nathan Pearson and Laura Hercher are back for April’s headlines.  AACR had some more good news about Keytruda, and we take a look at the cancer prediction space.

DNA Day, the first cannabis based therapy to be recommended for FDA approval, the Zuckerberg hearing—there’s lots in here today.
</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/April%202018%20with%20Nathan%20and%20Laura%20Show.mp3" length="29989334" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/april-2018-nathan-and-laura-golden-state-killer-and-cancer-prediction-space/</guid>
 <pubDate>Tue, 01 May 2018 08:23:17 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Golden-State-Killer.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Liquid Biopsy for Infectious Disease with Mickey Kertesz, Karius</title>
 <link>https://mendelspod.com/podcasts/liquid-biopsy-infectious-disease-mickey-kertesz-karius/</link>
 <description>Sequencing goes to the world of infectious disease.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Mickey%20Kertesz%202018%20Show.mp3" length="21328609" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/liquid-biopsy-infectious-disease-mickey-kertesz-karius/</guid>
 <pubDate>Mon, 23 Apr 2018 21:06:17 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Mickey%20Kertesz.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Nanopore Sequencing and the Future of Cancer Research with Chia-Lin Wei, JAX</title>
 <link>https://mendelspod.com/podcasts/nanopore-sequencing-and-future-cancer-research-chia-lin-wei-jax/</link>
 <description>We can all recognize that PacBio has laid down the railroad tracks in the frontier of long read sequencing.  What many are asking is just how close on their caboose is Oxford Nanopore?  And just what exactly will be the differences between the two technologies?

Chia-Lin Wei is the Director of Genome Technologies at the Jackson Laboratories.  When we called her up for today’s interview to talk about how she is using nanopore sequencing, she said, “I’ve been using nanopore for years, why the interest this year by the media?”</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Chia-Lin%20Wei%202018%20Show.mp3" length="25277954" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/nanopore-sequencing-and-future-cancer-research-chia-lin-wei-jax/</guid>
 <pubDate>Wed, 18 Apr 2018 09:11:13 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/chia-lin%20wei.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>A New Method for Long Reads:  Hanlee Ji of Stanford on Cancer Genomics Tech 2018</title>
 <link>https://mendelspod.com/podcasts/new-method-long-reads-hanlee-ji-stanford-cancer-genomics-tech-2018/</link>
 <description>Hanlee Ji is the Senior Associate Director of the Stanford Genome Technology Center as well as an oncologist at Stanford.  He’s also a clinical geneticist.  In other words, he doesn’t need to take off his glasses and spin around in a phone booth to be able to do about everything.

“I was in fellowship for a long time,” he says in todays interview.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Hanlee%20Ji%202018%20Show_0.mp3" length="29095094" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/new-method-long-reads-hanlee-ji-stanford-cancer-genomics-tech-2018/</guid>
 <pubDate>Mon, 09 Apr 2018 20:39:09 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Hanlee%20Ji.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>March 2018 in Genomics with Nathan &amp; Laura:  DTC BRCA and Revisiting All of Us</title>
 <link>https://mendelspod.com/podcasts/march-2018-genomics-nathan-laura-dtc-brca-and-revisiting-all-us/</link>
 <description>23andMe steals the headlines yet again.

“If somebody is worried about breast cancer susceptibility in their family, they should certainly not be using this test.”

That’s our monthly commentator and genetic counselor, Laura Hercher, talking about BRCA going DTC.  But wait a minute.  Then she says the test could be good in some instances.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/March%202018%20Review%20Show.mp3" length="19605773" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/march-2018-genomics-nathan-laura-dtc-brca-and-revisiting-all-us/</guid>
 <pubDate>Sun, 01 Apr 2018 08:23:31 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/All%20of%20Us.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>With More Tools in the Box, Lon Cardon Says We’re in a New Age of Drug Development</title>
 <link>https://mendelspod.com/podcasts/more-tools-box-lon-cardon-says-we%E2%80%99re-new-age-drug-development/</link>
 <description>“I think the field has just really come to life over the last five or seven years.  We’ve got all this sequence data.  We’ve got the population data.  We’ve got gene editing.  I’ve been at this thirty plus years, and we haven’t had a culmination of technology and data like this before.  I think everyone has to be excited in some way or other.”</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Lon%20Cardon%202018%20Show.mp3" length="25421371" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/more-tools-box-lon-cardon-says-we%E2%80%99re-new-age-drug-development/</guid>
 <pubDate>Wed, 21 Mar 2018 09:15:02 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/lon-cardon.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Personalized Medicine in the Trump Era with Edward Abrahams</title>
 <link>https://mendelspod.com/podcasts/personalized-medicine-trump-era-edward-abrahams/</link>
 <description>The Personalized Medicine Coalition advocates for a wide group of constituents, including scientists, health care providers, entrepreneurs, payers, and patients.  Which is why we’ve often wondered how the organization can be absolutely clear in their priorities.

Today, PMC President Edward Abrahams joins us to answer that question.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Edward%20Abrahams%202018%20Show.mp3" length="29966454" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/personalized-medicine-trump-era-edward-abrahams/</guid>
 <pubDate>Wed, 14 Mar 2018 21:19:00 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/ed_abrahams.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Eric Schadt and Sema4 Try the Consumer Model with Newborn Screening Panel</title>
 <link>https://mendelspod.com/podcasts/eric-schadt-and-sema4-try-consumer-model-newborn-screening-panel/</link>
 <description>&quot;We like to refer to it as consumer initiated, but physician supervised,” says Eric Schadt today when asked if his new test is direct-to-consumer.

Eric is the Dean for Precision Medicine at the Icahn School of Medicine at Mount Sinai in New York and since 2016 has served as CEO of Sema4, a spinoff that he founded out of the Mount Sinai Health System.  Sema4 launched a newborn screening panel, Sema4 Natalis, in February of this year covering over 190 disorders.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Eric%20Schadt%202018%20Show.mp3" length="36940652" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/eric-schadt-and-sema4-try-consumer-model-newborn-screening-panel/</guid>
 <pubDate>Tue, 06 Mar 2018 10:56:31 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Eric%20Schadt%20Light.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>February 2018 in Genomics with Nathan &amp; Laura:  23andMe Goes for the Gold, Trump Year One</title>
 <link>https://mendelspod.com/podcasts/february-2018-genomics-nathan-laura-23andme-goes-gold-trump-year-one/</link>
 <description>Booking 26 million viewers, the voice of Warren buffet, the endorsements of Olympians Joey Cheek and Tara Lipinski—this company was going for the gold with their ads during the Olympics this year.  Of course, we’re talking of the direct-to-consumer genetic testing company, 23andMe.  What was the take of our monthly commentators, Nathan Pearson of Root and Laura Hercher of Sarah Lawrence College?

Also, for all the doomsday predictions, has Donald Trump been any worse after one year for our industry than the biohacker?

Join us for this month’s look back over the headlines.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/February%202018%20Review%20Show%20with%20Nathan%20and%20Laura.mp3" length="18038066" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/february-2018-genomics-nathan-laura-23andme-goes-gold-trump-year-one/</guid>
 <pubDate>Thu, 01 Mar 2018 10:50:11 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/olympics.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>State of Sequencing 2018 with Keith Robison, Omics! Omics! Blogger</title>
 <link>https://mendelspod.com/podcasts/state-sequencing-2018-keith-robison-omics-omics-blogger/</link>
 <description>Sequencing geeks are fresh off the trail from AGBT, and it’s time for our annual look at the sequencing tools space.  This year we sit down with the longtime &lt;a href=&quot;http://omicsomics.blogspot.com&quot; target=&quot;_blank&quot;&gt;Omics! Omics!&lt;/a&gt; blogger, Keith Robison, who not only can answer all your questions about the topic, he even knows which sequencer you’re using right now, and in which department.

Keith jauntily runs through the Big 3--Illumina, Pac-Bio, and Oxford Nanopore--and has a few odds and ends to say about the &quot;niche developers.&quot;</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Keith%20Robison%202018%20Show.mp3" length="34329642" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/state-sequencing-2018-keith-robison-omics-omics-blogger/</guid>
 <pubDate>Tue, 20 Feb 2018 10:01:07 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Keith%20Omics.JPG" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> Direct RNA-Seq Project Shows Nanopore Sequencing Can Reveal New Insights into Basic Biology:  Winston Timp, JHU</title>
 <link>https://mendelspod.com/podcasts/direct-rna-seq-project-shows-nanopore-sequencing-can-reveal-new-insights-basic-biology/</link>
 <description>Nanopore sequencing has arrived.  Passing test after test this past year--including one we discuss today--this technology which was being hyped decades ago is delivering on its promise.

Winston Timp joins us today.  He&#039;s an assistant professor at Johns Hopkins and one of the leaders on a recent large scale project to directly sequence RNA on an array of nanopores.  Winston&#039;s is the first in a series of shows we&#039;ve lined up with users of Oxford Nanopore&#039;s technology.

Why RNA-seq?  Hasn’t this been done for years?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Winston%20Timp%202018%20Show.mp3" length="26776542" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/direct-rna-seq-project-shows-nanopore-sequencing-can-reveal-new-insights-basic-biology/</guid>
 <pubDate>Tue, 06 Feb 2018 09:59:26 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Winston%20Timp.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>January 2018 Review Show with Nathan and Laura: CRISPR vs The Immune System, Biotech Math, and MinION&#039;s Big Test</title>
 <link>https://mendelspod.com/podcasts/january-2018-review-show-nathan-and-laura-crispr-vs-immune-system-biotech-math-and-minions/</link>
 <description>Some stocks are up on news of big biotech mergers, but others are down on hearing of the latest difficulties of gene therapy.  One thing’s for sure—blood diseases are where it’s at.

Speaking of the latest difficulties, we start our January review by going back to that paper out of Stanford about a new obstacle to using CRISPR as a new drug platform.  It’s called the human immune system.  Major roadblock or small warning light?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/January%202018%20Mendelspod%20Review%20Show%20with%20Nathan%20and%20Laura.mp3" length="26531613" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/january-2018-review-show-nathan-and-laura-crispr-vs-immune-system-biotech-math-and-minions/</guid>
 <pubDate>Wed, 31 Jan 2018 21:23:35 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/MinION.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Going Beyond the Liver with RNAi:  Chris Anzalone of Arrowhead Pharma</title>
 <link>https://mendelspod.com/podcasts/going-beyond-liver-rnai-chris-anzalone-arrowhead-pharma/</link>
 <description>Fifteen years ago, folks in the industry were buzzing about RNAi the way they talk about CRISPR today.  Then things went quiet for the technology, at least in the news.  Until last year.

In September of 2017, Alnylam Pharmaceuticals, the leader in the RNAi space, announced such positive phase III study results that most experts in the business expect an FDA approval soon.  It will be the first for an RNAi drug.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Chris%20Anzalone%202018%20Show.mp3" length="20681454" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/going-beyond-liver-rnai-chris-anzalone-arrowhead-pharma/</guid>
 <pubDate>Tue, 23 Jan 2018 11:03:51 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Chris-Anzalone350x350.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Vice Chancellor Keith Yamamoto on UCSF’s Role in Medicine Today</title>
 <link>https://mendelspod.com/podcasts/keith-yamamoto-ucsfs-role-medicine-today/</link>
 <description>A major chapter in the history of medicine has been written by UC San Francisco.  They are writing the next for precision medicine.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Keith%20Yamamoto%202018%20Show.mp3" length="28168882" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/keith-yamamoto-ucsfs-role-medicine-today/</guid>
 <pubDate>Mon, 15 Jan 2018 08:29:15 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/KeithYamamoto.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>The Global Business of Reproductive Genetic Testing with Gary Harton, Igenomix</title>
 <link>https://mendelspod.com/podcasts/global-business-reproductive-genetic-testing-gary-harton-igenomix/</link>
 <description>Reproductive testing is one of the hottest fields in which genetics is going mainstream, a field hurdling us rapidly into the future.  It’s an area we’ll be following closely in 2018.

Gary Harton serves as the Chief Operating Officer in the US for Igenomix, a company in the reproductive testing space with a vast global presence.  The company has labs in the US, Japan, India, Turkey, Rome, Brazil, Mexico, Canada, and are headquartered in Valencia, Spain.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Gary%20Harton%202018%20Show.mp3" length="40980268" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/global-business-reproductive-genetic-testing-gary-harton-igenomix/</guid>
 <pubDate>Thu, 11 Jan 2018 10:18:28 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Gary%20Harton.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>The State of Genomics 2018 with Nathan, Laura, and Misha</title>
 <link>https://mendelspod.com/podcasts/state-genomics-2018-nathan-laura-and-misha/</link>
 <description>Our first show of the year is an outlook on genomics for 2018.  To do this we’re joined by our regular commentators, Nathan Pearson and Laura Hercher, and also by a special guest to mix things up a bit, Misha Angrist, Associate Professor at Duke University and Editor in Chief of Genome Magazine.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/State%20of%20Genomics%202018%20Show.mp3" length="39620346" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/state-genomics-2018-nathan-laura-and-misha/</guid>
 <pubDate>Sun, 07 Jan 2018 22:23:21 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Genomics2018.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Sharon Begley of STAT News </title>
 <link>https://mendelspod.com/podcasts/sharon-begley-stat-news/</link>
 <description>Sharon Begley joins us for our last show of the year to look back over some of the year’s top stories.  She’s the senior science writer at STAT News where she covers genetics, cancer, neuroscience and other fields of biomedical research.   Prior to joining STAT, Sharon was the senior health and science correspondent at Reuters, the science columnist at the Wall Street Journal, and the science editor at Newsweek.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Sharon%20Begley%202017%20Show.mp3" length="33931772" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/sharon-begley-stat-news/</guid>
 <pubDate>Tue, 19 Dec 2017 11:48:36 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Sharon%20Begley.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>A New “Middle Way” for Genomics, with Physical Chemist, Yuval Ebenstein</title>
 <link>https://mendelspod.com/podcasts/new-middle-way-genomics-physical-chemist-yuval-ebenstein/</link>
 <description>“I love low tech,” says today’s guest.

It’s not your typical catch phrase for 2017.   But then today’s guest is not your typical genome scientist.

A professor in the Department of Chemical Physics at Tel Aviv University in Israel where he runs the NanoBioPhotonix Lab, Yuval Ebenstein came to the genome from an unusual direction.  As a physical chemist he started working with DNA as “just a material.”</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Yuval%20Ebenstein%202017%20Show.mp3" length="29239825" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/new-middle-way-genomics-physical-chemist-yuval-ebenstein/</guid>
 <pubDate>Tue, 12 Dec 2017 19:37:52 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Yuval%20Ebenstein.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> Sara Demy on Biotech CEOs</title>
 <link>https://mendelspod.com/podcasts/sara-demy-biotech-ceos/</link>
 <description>Our topic today:  biotech leadership.  What makes a good biotech CEO?  Are there unique issues to biotech and diagnostics that shape and demand a different kind of leadership?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Sara%20Demy%202017%20Show.mp3" length="28797449" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/sara-demy-biotech-ceos/</guid>
 <pubDate>Mon, 04 Dec 2017 16:40:45 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Sara%20Demy.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>November 2017 with Nathan and Laura:  The Stem Cell Story We’ve All Been Waiting For and a Sea Change for DTC Testing</title>
 <link>https://mendelspod.com/podcasts/november-2017-nathan-and-laura-stem-cell-story-weve-all-been-waiting-and-sea-change-dtc/</link>
 <description>It didn’t take long to come up with our lead story for November’s month in review show.  Looking at the pictures of the boy in Germany playing soccer after successful treatment of his rare skin disease is just the kind of images we had in mind when we first heard of stem cell therapies.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/November%202017%20Mendelspod%20Review%20Show%20with%20Nathan%20and%20Laura.mp3" length="23310987" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/november-2017-nathan-and-laura-stem-cell-story-weve-all-been-waiting-and-sea-change-dtc/</guid>
 <pubDate>Thu, 30 Nov 2017 20:02:12 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/boy%20with%20EB.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Seattle Startup Takes Precision Oncology to the Next Step:  Carla Grandori, CEO, SEngine</title>
 <link>https://mendelspod.com/podcasts/seattle-startup-takes-precision-oncology-next-step-carla-grandori-ceo-sengine/</link>
 <description>Carla Grandori was for thirty years a cancer researcher most recently at the Fred Hutch in Seattle.  She had her personal reasons for working on cancer, she tells us in today’s show.  Now, she’s the CEO and founder of SEngine, a startup offering something completely new for oncologists around the country.

Carla says she was motivated to step out of the research lab when two patients came to her personally and asked her, “can you study my cancer?”</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Carla%20Grandori%202017%20Show_0.mp3" length="25807564" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/seattle-startup-takes-precision-oncology-next-step-carla-grandori-ceo-sengine/</guid>
 <pubDate>Thu, 16 Nov 2017 09:17:39 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Carla%20Grandori%20MD%20PhD.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> Immuno Oncology 2017:  Looking Back, Looking Forward with Rachel Laing and Olivier Lesueur</title>
 <link>https://mendelspod.com/podcasts/immuno-oncology-2017-looking-back-looking-forward-rachel-laing-and-olivier-lesueur/</link>
 <description>Immuno oncology is now the dominant topic at Mendelspod. From shows with CEOs presenting new panels of predictive biomarker tests, to the firsts at the FDA with the CAR-T approvals as well as the first approval of a drug (Merck’s Keytruda) based on a common biomarker (MSI) rather than on a tumor type, to scientists discussing rare cells of the immune system, we had more podcasts on this topic than any other in 2017.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Immuno%20Oncology%20Review%20Show%202017.mp3" length="30335819" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/immuno-oncology-2017-looking-back-looking-forward-rachel-laing-and-olivier-lesueur/</guid>
 <pubDate>Tue, 14 Nov 2017 09:35:27 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Rachel%20%26%20Olivier.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Huh?  30 Million Americans Have a Rare Disease?  Howard Jacob on the State of Clinical Sequencing</title>
 <link>https://mendelspod.com/podcasts/huh-30-million-americans-have-rare-disease-howard-jacob-state-clinical-sequencing/</link>
 <description>Here’s a title for you.  Chief Genomics Officer.  Today’s guest is also the VP of Genomic Medicine and a faculty investigator at the HudsonAlpha Institute for Biotechnology.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Howard%20Jacob%202017%20Show.mp3" length="28342531" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/huh-30-million-americans-have-rare-disease-howard-jacob-state-clinical-sequencing/</guid>
 <pubDate>Wed, 08 Nov 2017 21:57:53 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Howard-Jacob.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>With their Own Manufacturing Facility, Seattle Children’s Goes Big into CAR-T, Rare Disease</title>
 <link>https://mendelspod.com/podcasts/their-own-manufacturing-facility-seattle-childrens-going-big-car-t/</link>
 <description>The past few months have seen the first approvals at the FDA for CAR-T cancer therapies.  But trials have been going on for years.  And not just by big pharma.

Today’s guest, Dr. Michael Jensen, is a researcher at  Seattle Children’s Hospital and started his first CAR-T cell trial back in 2002.

“It’s been a long road to get to the point where we understand enough about the science and physiology of this technology to make it work int he clinic,&quot; he tells us in today&#039;s interview.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Michael%20Jensen%20Show%202017.mp3" length="29124490" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/their-own-manufacturing-facility-seattle-childrens-going-big-car-t/</guid>
 <pubDate>Mon, 06 Nov 2017 20:32:39 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Michael%20Jensen.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>With Immuno Oncology Comes a New Focus on Rare Cells</title>
 <link>https://mendelspod.com/podcasts/immuno-oncology-comes-new-focus-rare-cells/</link>
 <description>Modena, Italy is the town where one of the world&#039;s rarest cars were first developed and built:  the Ferrari sports car.   It’s also home to one of the world’s oldest universities where today’s guest spends his time studying rare human cells.</description>
 <author>online@cglife.com (cglife)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Andrea%20Cossarizza%202017%20Show.mp3" length="26869880" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/immuno-oncology-comes-new-focus-rare-cells/</guid>
 <pubDate>Wed, 01 Nov 2017 14:26:12 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Andrea%20Cossarizza_0.jpg" />
 <itunes:author> online@cglife.com (cglife)
</itunes:author>
</item>
 <item> <title>We&#039;ve Become Too Single Variant Centric, Says Deanna Church on Genome Analysis </title>
 <link>https://mendelspod.com/podcasts/weve-become-too-single-variant-centric-says-deanna-church-genome-analysis/</link>
 <description>From 1999 to 2013, Deanna Church was a staff scientist at the NCBI where, for a time, she headed the Genome Reference Consortium.  This was the effort to continually update, improve and maintain the reference genome.  Then Deanna went into private industry, first to Personalis--a genome interpretation company, and now she’s Director of Applications at 10X Genomics--the tools company offering linked read sequencing technology.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Deanna%20Church%202017%20Show.mp3" length="24070433" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/weve-become-too-single-variant-centric-says-deanna-church-genome-analysis/</guid>
 <pubDate>Thu, 12 Oct 2017 09:32:18 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Deanna%20Church.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Clinicians Show High Demand for Single Cell Sequencing, Says Bobby Sebra of Mt. Sinai</title>
 <link>https://mendelspod.com/podcasts/clinicians-show-high-demand-single-cell-sequencing-says-bobby-sebra-mt-sinai/</link>
 <description>If today&#039;s guest were a super hero, he&#039;d be High Resolution Sequencing Man.

Bobby Sebra is the Director of Technology Development at the Icahn Institute of Genomics and Multiscale Biology at Mt Sinai in New York.  He has the complete arsenal of DNA sequencers in his lab.  He specializes in long read applications, and today he goes into several of those spaces, including infectious disease and oncology.

How has sequencing changed since we last had Bobby on a couple years ago, and how does he see it changing in the next two years?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Bobby%20Sebra%202017%20Show.mp3" length="27482815" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/clinicians-show-high-demand-single-cell-sequencing-says-bobby-sebra-mt-sinai/</guid>
 <pubDate>Thu, 05 Oct 2017 09:22:24 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/BobbySebra_0.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>September 2017 with Nathan and Laura: Venter Blunder, RNAi Returns, and Monthly Science Moments</title>
 <link>https://mendelspod.com/podcasts/september-2017-nathan-and-laura-venter-blunder-rnai-returns-and-monthly-science-moments/</link>
 <description>To honor Laura&#039;s pentametric thirst,
We write the summary today in verse.
 
Was it a quake that had no epicenter,
That silly paper out by J. Craig Venter?
 
And after years of silencing the market
Has RNAi at last knocked out its target?
 
Then Nathan gives to yuppies devil&#039;s choice.
Which one libs: gluten dough or GMOs?
 
</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/September%202017%20Mendelspod%20Review%20Show%20with%20Nathan%20and%20Laura.mp3" length="27732477" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/september-2017-nathan-and-laura-venter-blunder-rnai-returns-and-monthly-science-moments/</guid>
 <pubDate>Mon, 02 Oct 2017 11:52:24 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Venter%20Face.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Charting the Dark Matter of Cancer Genomes with Jim Broach</title>
 <link>https://mendelspod.com/podcasts/charting-dark-matter-cancer-genomes-jim-broach/</link>
 <description>We’ve heard a lot this year about the search for new structural variants and the hope that scientists will find new causal linkages for diseases such as cancer.  But will the genome still yield dramatic genetic signatures such as KRAS, BRAF and EGFR that have been so helpful in cancer treatment?

Today’s guest says, yes, and he’s on the trail.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Jim%20Broach%202017%20Show.mp3" length="26441680" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/charting-dark-matter-cancer-genomes-jim-broach/</guid>
 <pubDate>Tue, 26 Sep 2017 10:57:13 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/James%20Broach.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Why Childhood Cancers Need Their Own Gene Panel: Tim Triche</title>
 <link>https://mendelspod.com/podcasts/why-childhood-cancers-need-their-own-gene-panel-tim-triche/</link>
 <description>When we first talked with Tim Triche of LA Children&#039;s Hospital, we found out he was a bit of an outlier among cancer researchers.  He was an advocate for poking around in the non-coding RNA.

Today we welcome Tim back to the show to talk about a new gene panel that he has designed specifically for childhood cancers.  It’s a first of its kind and was modeled quite closely on the gene panel for the NCI’s MATCH trial.
The new panel has both a DNA and an RNA component, and the RNA side is by far the biggest.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Tim%20Triche%202017%20Show.mp3" length="26809293" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/why-childhood-cancers-need-their-own-gene-panel-tim-triche/</guid>
 <pubDate>Thu, 21 Sep 2017 09:32:01 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Triche_Timothy_06-18-10.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Exploring the Exome and the Future of Genomics with Jay Shendure</title>
 <link>https://mendelspod.com/podcasts/exploring-exome-and-future-genomics-jay-shendure/</link>
 <description>Back in 2009, University of Washington professor, Jay Shendure, wrote a &lt;a href=&quot;http://www.nature.com/ng/journal/v42/n1/abs/ng.499.html?foxtrotcallback=true&quot; target=&quot;_blank&quot;&gt;definitive paper&lt;/a&gt; offering up a roadmap for exome sequencing. Since then, the cost of sequencing has come down so far that many have debated whether or not to do whole genome sequencing vs. just the exome.  </description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Jay%20Shendure%202017%20Show.mp3" length="26706497" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/exploring-exome-and-future-genomics-jay-shendure/</guid>
 <pubDate>Tue, 12 Sep 2017 19:54:55 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Jay%20Shendure.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>August 2017 Review with Nathan and Laura:  CAR-T Cashes In, Embryos Edited in US, and the Invitae Incident</title>
 <link>https://mendelspod.com/podcasts/august-2017-review-nathan-and-laura-car-t-cashes-embryos-edited-us-and-invitae-incident/</link>
 <description>Back from summer vacation, Nathan and Laura are smoking hot as they look back over some exciting headlines.
The summer boiled over with plenty to talk about, but it was just this week that delivered most of the news for our discussion today. Novartis’ gene therapy based on CAR-T technology was approved Wednesday, making it the first gene therapy to be approved ever in the US. Analysts will be trying to figure out how high high is when it comes to the price tag, but Nathan and Laura explain why this therapy is a big deal for patients.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/August%202017%20Review%20Show.mp3" length="22117365" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/august-2017-review-nathan-and-laura-car-t-cashes-embryos-edited-us-and-invitae-incident/</guid>
 <pubDate>Fri, 01 Sep 2017 09:12:01 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/CAR-T%202.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>The First In-Human Gene Editing Trial in the U.S. - And It’s Not with CRISPR</title>
 <link>https://mendelspod.com/podcasts/first-human-gene-editing-trial-us-and-its-not-crispr/</link>
 <description>The challenge for the first ever in-human gene editing trial, according to today’s guest, is with the delivery to the body.

“At the moment, the easiest place to deliver your gene or genome editing is to the liver, using AAV which are viruses that seek out and go to the liver cells,&quot; says Sandy Macrae, the CEO of Sangamo Therapeutics.

Sangamo is known for two things: They have pioneered the commercialization of an older gene editing technology called Zinc Fingers.  And they have done a lot of work in the area of HIV.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Sandy%20Macrae%202017%20Show.mp3" length="28360628" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/first-human-gene-editing-trial-us-and-its-not-crispr/</guid>
 <pubDate>Tue, 08 Aug 2017 08:20:02 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Sandy%20Macrae.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Thermo, Pfizer, and Novartis Pull Off a First for NGS in Lung Cancer</title>
 <link>https://mendelspod.com/podcasts/thermo-pfizer-and-novartis-pull-first-ngs-lung-cancer/</link>
 <description>Today we get to bring you a feel good story, one of the major achievements so far in precision oncology.  Three large companies—Thermo Fisher, Pfizer, and Novartis—put aside their differences to come together for patients.

The patients are those who suffer from non-small cell lung cancer.  In June, the FDA approved for the first time an NGS panel with multiple genes for multiple drugs that treat this kind of cancer.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/A%20First%20for%20NGS%20in%20Lung%20Cancer%202017%20Show.mp3" length="27438737" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/thermo-pfizer-and-novartis-pull-first-ngs-lung-cancer/</guid>
 <pubDate>Thu, 03 Aug 2017 09:57:18 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Lung%20Cancer%20Biomarkers.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> Making Genetic Testing Mainstream Medicine with Sean George, Invitae</title>
 <link>https://mendelspod.com/podcasts/making-genetic-testing-mainstream-medicine-sean-george-invitae/</link>
 <description>Invitae appointed their co-founder Sean George as CEO earlier this year.  He joins us to share his bold vision for the field of genetic testing.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Sean%20George%202017%20Show.mp3" length="29171487" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/making-genetic-testing-mainstream-medicine-sean-george-invitae/</guid>
 <pubDate>Tue, 01 Aug 2017 09:47:50 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Sean%20George.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Need Better Standards for Your Clinical Assays?  NIST Can Help</title>
 <link>https://mendelspod.com/podcasts/need-better-standards-your-clinical-assays-nist-can-help/</link>
 <description>The life science tools space is flourishing.  Biomedical research output is at an all time high.  Today’s guest says there are over 40,000 papers published each year on cancer biomarkers.

But very few of those become commercialized tests.  Why?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Ken%20Cole%202017%20Show.mp3" length="25667983" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/need-better-standards-your-clinical-assays-nist-can-help/</guid>
 <pubDate>Thu, 27 Jul 2017 09:43:53 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Ken%20Cole.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Turning on Your DNA with Justin Kao, Helix</title>
 <link>https://mendelspod.com/podcasts/turning-your-dna-justin-kao-helix/</link>
 <description>They’re getting a lot of buzz this week.  We’re pleased to have Justin Kao, a co-founder of Helix on the program today for the first time.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Justin%20Kao%202017%20Show.mp3" length="36039862" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/turning-your-dna-justin-kao-helix/</guid>
 <pubDate>Tue, 25 Jul 2017 08:51:32 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Justin%20Kao.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Will This New Nano Technology Be the Microarray of Genomic Structural Variation?  Barrett Bready, Nabsys</title>
 <link>https://mendelspod.com/podcasts/will-new-nano-technology-be-microarray-genomic-structural-variation-barrett-bready-nabsys/</link>
 <description>Barrett Bready is back on the program.  He’s the CEO of Nabsys, a company with some new technology for genome mapping.

Originally Nabsys had been working to develop nanopore sequencing, but after a recent reboot has become focused on scaling up scientists&#039; ability to read structural genomic information.  Barrett compares Nabsys’ new multiplex technology for genome mapping to the improvement of arrays over single nucleotide (SNP) detection.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Barrett%20Bready%202017%20Show.mp3" length="22234862" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/will-new-nano-technology-be-microarray-genomic-structural-variation-barrett-bready-nabsys/</guid>
 <pubDate>Thu, 20 Jul 2017 11:30:46 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Barrett%20Bready%20New.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>George Church on What Comes After CRISPR</title>
 <link>https://mendelspod.com/podcasts/george-church-what-comes-after-crispr/</link>
 <description>George Church joins us today.  He’s the Robert Winthrop Professor of . . . . well, he’s George Church.  And he confirms that, yes, a movie called “Woolly&quot; is being made about his lab.  In the next breath, he reminds us (and himself?) that less than 1% of his press is about the woolly mammoth.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/George%20Church%202017%20Show.mp3" length="34211186" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/george-church-what-comes-after-crispr/</guid>
 <pubDate>Thu, 13 Jul 2017 09:07:12 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/George%20Church-closeup-time-100-gala-2017_0.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Is CRISPR Controversy Science or Spin?  June 2017 Review with Nathan and Laura</title>
 <link>https://mendelspod.com/podcasts/crispr-controversy-science-or-spin-june-2017-review-nathan-and-laura/</link>
 <description>It’s the end of the month--and the half year mark--so we open up today&#039;s monthly discussion with Nathan and Laura to include some of the headlines we’ve missed this year.

Last month a paper was published warning about the off target effects when using CRISPR.  Laura and Nathan agree the kerfuffle which exploded into this month was more about Wall Street than adding anything new to science.

Remember the technology we used before CRISPR?  Sangamo Biosciences launched the first ever “in vivo” (in human) trial for gene editing using Zinc Finger technology.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/June%202017%20Review%20Show.mp3" length="25845081" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/crispr-controversy-science-or-spin-june-2017-review-nathan-and-laura/</guid>
 <pubDate>Fri, 30 Jun 2017 09:26:35 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/gene%20editing.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>We Need a Google Maps for Metagenomics, Says Rob Knight, UCSD</title>
 <link>https://mendelspod.com/podcasts/we-need-google-maps-metagenomics-says-rob-knight-ucsd/</link>
 <description>When will we see the results of microbiome research in our every day lives?  And what will that look like?

Rob Knight joins us for the first time today.  He’s a professor at UC San Diego and Director of the Center for Microbiome Innovation.  He is well known for co-authoring a paper showing that the microbial populations in the guts of obese mice differentiate from those in lean mice.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Rob%20Knight%202017%20Show.mp3" length="23482039" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/we-need-google-maps-metagenomics-says-rob-knight-ucsd/</guid>
 <pubDate>Tue, 27 Jun 2017 09:25:49 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Rob%20Knight.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Move Over PDL1:  New Test Combo Adds RNAseq to Better Track Immune Escape</title>
 <link>https://mendelspod.com/podcasts/move-over-pdl1-new-test-combo-adds-rnaseq-better-track-immune-escape/</link>
 <description>Reports from ASCO, the nation’s biggest cancer conference, this year again were full of stunning stories about the success of older and new immuno therapies.  The race has never been hotter for biomarkers to target patient groups.  Most of this new class of drugs--which harnesses the immune system to go after the cancer--inhibit an immune checkpoint called programmed cell death protein 1 or PDL1.  So frontline cancer treatment these days typically includes a test for the PDL1 biomarker.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Mark%20Gardner%202017%20Show.mp3" length="22475477" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/move-over-pdl1-new-test-combo-adds-rnaseq-better-track-immune-escape/</guid>
 <pubDate>Thu, 22 Jun 2017 10:47:43 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Mark_Gardner_headshot2_HiRes.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> The Last Major Disease To Be Studied?  Ron Davis of Stanford Thinks So</title>
 <link>https://mendelspod.com/podcasts/last-major-disease-be-studied-ron-davis-stanford-thinks-so/</link>
 <description>Let’s say you’re a biomedical researcher looking for a place to make your mark.   You find out that there is still a major disease that affects more than 2 million people in the US, and we still know virtually nothing about this disease at the molecular level.  Wouldn&#039;t that stand out?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Ron%20Davis%202017%20Show.mp3" length="28793059" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/last-major-disease-be-studied-ron-davis-stanford-thinks-so/</guid>
 <pubDate>Thu, 15 Jun 2017 09:12:52 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Ron%20Davis%20Speaking.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>On Bioinformatics Data Sharing and Collaboration: Andrew Carroll, DNAnexus</title>
 <link>https://mendelspod.com/podcasts/bioinformatics-data-sharing-and-collaboration-andrew-carroll-dnanexus/</link>
 <description>What does it take to collaborate in genomics?

A platform, for one thing.  Over the past few years bioinformaticians have been speculating about a dominant &quot;go to” site that would serve the software needs of those in genomics.  Would it be a private company, a Google of genomics?  Or would it be a non profit consortium?  Would it be created at the government level?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Andrew%20Carroll%202017%20Show_0.mp3" length="31088279" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/bioinformatics-data-sharing-and-collaboration-andrew-carroll-dnanexus/</guid>
 <pubDate>Thu, 08 Jun 2017 10:02:29 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Andrew%20Carroll%20New.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Grail Merger, Genomic Autopsies, Overtreatment Alarm, and Controversy at Ancestry.com:  May 2017 Review with Nathan and Laura</title>
 <link>https://mendelspod.com/podcasts/grail-merger-genomic-autopsies-overtreatment-alarm-and-controversy-ancestrycom-may-2017/</link>
 <description>Is Grail already merging?  Genomic autopsies?  Does the House&#039;s new healthcare bill turn mere genetic risk into pre-conditions? Nathan and Laura are back to find meaning in the rush of May&#039;s headlines.

Laura cites a disturbing survey of over 2,000 women diagnosed with breast cancer that found half of them had unnecessary double mastectomies after genetic testing.  She says unabashedly, “In big letters, it’s an ADVERTSIMENT FOR GENETIC COUNSELING.”

Speaking of alarms, Nathan says attorney Joel Winston’s blog against Ancestry.com’s terms and conditions was fear mongering.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/May%202017%20Review%20Show.mp3" length="25105045" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/grail-merger-genomic-autopsies-overtreatment-alarm-and-controversy-ancestrycom-may-2017/</guid>
 <pubDate>Thu, 01 Jun 2017 09:38:55 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/genetic_counseling_breast_cancer_6.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Is Population Medicine Failing Us? Michel Accad</title>
 <link>https://mendelspod.com/podcasts/population-medicine-failing-us-michel-accad/</link>
 <description>Is health the same thing for an individual as it is for a population? This question goes to the foundation of how we practice medicine today and that of most of genomic research.
Michel Accad is a cardiologist in San Francisco and the author of a new book, &lt;a href=&quot;https://www.amazon.com/Moving-Mountains-Socratic-Challenge-Population/dp/1634320301&quot; target=&quot;_blank&quot;&gt;Moving Mountains: A Socratic Challenge to the Theory and Practice of Population Medicine&lt;/a&gt;, in which he uses Socrates to spar with Geoffrey Rose, a British physician and one of the architects of modern medicine.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Michel%20Accad%202017%20Show.mp3" length="27097882" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/population-medicine-failing-us-michel-accad/</guid>
 <pubDate>Thu, 25 May 2017 09:53:54 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Michel%20Accad_0.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Deep Omics Profiler, Mike Snyder, Now Turns to Wearables </title>
 <link>https://mendelspod.com/podcasts/deep-omics-profiler-mike-snyder-now-turns-wearables/</link>
 <description>Mike Snyder is well known in the genomics community for his iPOP (integrated personal omics profiling) study. Profiling himself with hundreds of thousands of measurements each day over a period of seven years and a group of a hundred others for about three years, he and his team at Stanford have shown that sequencing and other omics data can be used to predict Type II diabetes, cancer, heart problems and other disease. He’s also published numerous papers comparing NGS instruments. Now he is expanding iPOP with a whole new set of tools: over the counter wearable devices.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Mike%20Snyder%202017%20Show.mp3" length="32573462" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/deep-omics-profiler-mike-snyder-now-turns-wearables/</guid>
 <pubDate>Thu, 18 May 2017 09:39:07 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/MikeSnyder2.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Over $1 Billion Invested this Past Year: Synthetic Biology in 2017 with John Cumbers  </title>
 <link>https://mendelspod.com/podcasts/over-1-billion-invested-past-year-synthetic-biology-2017-john-cumbers/</link>
 <description>What does it take to make it in synthetic biology in 2017?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/John%20Cumbers%202017%20Show-auphonic.mp3" length="29583148" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/over-1-billion-invested-past-year-synthetic-biology-2017-john-cumbers/</guid>
 <pubDate>Thu, 11 May 2017 09:11:19 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/John_Cumbers.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Green Light for DTC, Blood Mammograms, and Ancient DNA:  April 2017 with Nathan and Laura</title>
 <link>https://mendelspod.com/podcasts/green-light-dtc-blood-mammograms-and-ancient-dna-april-2017-nathan-and-laura/</link>
 <description>For genomics nerds, April 2017 will be remembered as the date when the FDA adopted a more open policy towards 23andMe and direct-to-consumer (DTC) genetic testing.   What does this decision mean, and just where is the FDA drawing the line?  A genetic counselor herself, Laura found the decision “head turning.”

“There’s lots of reasons why some genetic counselors are not going to be thrilled to deal with everyone’s 23andMe results,” she says.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/April%20Review%20Show%202017.mp3" length="24183196" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/green-light-dtc-blood-mammograms-and-ancient-dna-april-2017-nathan-and-laura/</guid>
 <pubDate>Mon, 01 May 2017 09:25:27 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/23andme-blimp.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>With 50 Million Users, Is Academia.edu Speeding Up Science?  </title>
 <link>https://mendelspod.com/podcasts/50-million-users-academiaedu-speeding-science/</link>
 <description>Today we  follow up with Richard Price, the founder and CEO of the most popular social sharing site for the academic sector, Academia.edu.   When we talked to Richard almost five years ago, the site had 1.5 million users, mostly academics sharing their own papers so that their peers had access without any paywalls.  Today the site boasts over 50 million users and serves as a laboratory for the future of academic publishing.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Richard%20Price%202017%20Show.mp3" length="30709826" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/50-million-users-academiaedu-speeding-science/</guid>
 <pubDate>Tue, 18 Apr 2017 10:03:16 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Richard_Price.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>How to Improve Lab Tests in the Absence of FDA Regulation?</title>
 <link>https://mendelspod.com/podcasts/how-improve-lab-tests-absence-fda-regulation/</link>
 <description>Rubbing shoulders at molecular medicine conferences these days one senses a sigh of relief when you talk about laboratory developed tests (LDTs).  With the FDA’s decision to put regulation on hold coupled with the expected confirmation of Scott Gottlieb as FDA commissioner, those in the lab testing business seem to be confidently settling back to the status quo.  And those who were arguing that all we need is a “beefed up” CLIA to hold labs to better testing standards don’t appear to be motivated to do so anymore.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Russell%20Garlick%202017%20Show.mp3" length="23071619" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/how-improve-lab-tests-absence-fda-regulation/</guid>
 <pubDate>Thu, 13 Apr 2017 10:58:30 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/russell_garlick.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> Known for Medical Devices, 116 Yr Old BD Makes a Bold Move in Genomics</title>
 <link>https://mendelspod.com/podcasts/known-medical-devices-116-yr-old-bd-makes-bold-move-genomics/</link>
 <description>Talk to someone who attended this year’s AGBT, and you’ll know the big buzz was about single cell genomics.  One of the exciting new platforms came from a new player in the genomics space and yet from a very old company.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Stephen%20Gunstream%202017%20Show.mp3" length="20338371" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/known-medical-devices-116-yr-old-bd-makes-bold-move-genomics/</guid>
 <pubDate>Wed, 05 Apr 2017 10:46:34 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Stephen%20Gunstream.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Proposed NIH Cuts, Undermining GINA, and Game Changing Drugs: March 2017 with Nathan and Laura</title>
 <link>https://mendelspod.com/podcasts/proposed-nih-cuts-undermining-gina-and-game-changing-drugs-march-2017-nathan-and-laura/</link>
 <description>The largest cut to NIH budget ever, rolling back genetic non-discriminatory law—the bad news continues to roll from Washington.  But there was great news this month as well.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/March%20Review%20Show%202017.mp3" length="22339818" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/proposed-nih-cuts-undermining-gina-and-game-changing-drugs-march-2017-nathan-and-laura/</guid>
 <pubDate>Fri, 31 Mar 2017 09:15:33 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/geneticdis.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Art in the Lab (Falling in Love with Bacteria)</title>
 <link>https://mendelspod.com/podcasts/art-lab-falling-love-bacteria/</link>
 <description>Today’s guest makes time to create beauty in the lab. Memo Berkmen is a bacterial artist along with being a staff scientist at New England Bio Labs. He and his colleague, Maria Penil, were the winners of the American Society for Microbiology’s agar art contest in 2015. Their felicitous relationship with the unseen, often unnoticed, world of ancient organisms fills us with wonder and inspiration.

-----

</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Memo%20Berkmen%202017%20Show.mp3" length="20940573" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/art-lab-falling-love-bacteria/</guid>
 <pubDate>Tue, 28 Mar 2017 10:04:10 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/MemoBerkmen.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Flint Whistleblower Says Today&#039;s Science Is to Blame for Its Own Lack of Public Trust</title>
 <link>https://mendelspod.com/podcasts/flint-whistleblower-says-todays-science-blame-its-own-lack-public-trust/</link>
 <description>Marc Edwards is telling a different story than the one most of us have been reading and hearing lately.  But then he’s used to it.

Marc was the engineer from Virginia Tech who was called one day in September, 2015, by a resident of Flint, Michigan.  A Ms Lee Ann Walters wanted Marc to check out her water.  When Marc and his team got to Flint they uncovered super high levels of lead in the potable water, with over 100,000 people exposed to high lead levels and 12,000 people with lead poisoning.  You know the rest.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Marc%20Edwards%202017%20Show.mp3" length="29683834" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/flint-whistleblower-says-todays-science-blame-its-own-lack-public-trust/</guid>
 <pubDate>Thu, 16 Mar 2017 10:35:39 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Marc%20Edwards.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>The Story of Geisinger and Doing Genomic Medicine at the Right Pace  </title>
 <link>https://mendelspod.com/podcasts/story-geisinger-and-doing-genomic-medicine-right-pace/</link>
 <description>Mike Murray and the crew over at Geisinger are making the implementation of genomic medicine look down right easy.

In today’s interview, Mike explains GenomeFIRST Medicine, a program at the Geisinger Health System in Pennsylvania to offer care “that is based on an individual’s DNA sequence.”  The healthcare provider boasts its own biobank and has partnered up with Regeneron’s Genome Center to offer exome screening to self selected patients.  As of DNA Day last year, April 25th 2016, 100,000 recruits had signed up.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Mike%20Murray%202017%20Show.mp3" length="26141846" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/story-geisinger-and-doing-genomic-medicine-right-pace/</guid>
 <pubDate>Wed, 08 Mar 2017 10:14:57 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Mike%20Murray.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>In-Situ Sequencing, CRISPR Patents, and Racist Milk Drinkers: February 2017 with Nathan and Laura</title>
 <link>https://mendelspod.com/podcasts/situ-sequencing-crispr-patents-and-racist-milk-drinkers-february-2017-nathan-and-laura/</link>
 <description>Commentators Nathan Pearson and Laura Hercher join us to look back on February’s genomics headlines.

Beginning this time with science, Nathan says we should be expecting great things from new in-situ sequencing.  Laura found it encouraging that the National Academy of Sciences shifted to be more in support of genome editing.  Theral asks what life forms are left to sequence for the Earth BioGenome Project?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/February%202017%20Review%20Show%20with%20Nathan%20and%20Laura-auphonic.mp3" length="25439407" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/situ-sequencing-crispr-patents-and-racist-milk-drinkers-february-2017-nathan-and-laura/</guid>
 <pubDate>Tue, 28 Feb 2017 21:53:02 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/in%20situ%20sequencing.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> New Pocket Size Nanopore Device Could Revolutionize Diagnostic and Other Testing</title>
 <link>https://mendelspod.com/podcasts/new-pocket-size-nanopore-device-could-revolutionize-diagnostic-and-other-testing/</link>
 <description>First of all, watch the video below.

A Santa Cruz company is now previewing a nanopore device that could be a major disruptor in molecular testing.  The device is the size of a glucometer and could take all kinds of testing—perhaps someday even cancer-tracking liquid biopsies—into the home with its ease of use and ability to work with thousands of different assays.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Dan%20Heller%202017%20Show.mp3" length="20385495" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/new-pocket-size-nanopore-device-could-revolutionize-diagnostic-and-other-testing/</guid>
 <pubDate>Sun, 19 Feb 2017 20:01:59 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Dan%20Heller.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>By Changing a Basic Lab Step, Acoustic Liquid Transfer Having a Broad Impact</title>
 <link>https://mendelspod.com/podcasts/changing-basic-lab-step-acoustic-liquid-transfer-having-broad-impact/</link>
 <description>Freeman Dyson famously said, “the great advances in science usually result from new tools rather than from new doctrine.”

Today we talk with Mark Fischer-Colbrie, CEO of Labcyte, a company which has made some waves--literally-- in the life sciences by changing a very fundamental laboratory procedure: liquid transfer.  For some years now, Labcyte has been selling machines that move liquid around with sound.  By eliminating the need for pipette tips and other “solid” surfaces, the machines guarantee much more precision.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Mark%20Fischer-Colbrie%202017%20Show.mp3" length="23330796" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/changing-basic-lab-step-acoustic-liquid-transfer-having-broad-impact/</guid>
 <pubDate>Mon, 13 Feb 2017 17:12:12 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/echo-acoustic-dispensing-200x150.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Many Biologists Today Don’t Have Enough Computer Science to Use the Databases</title>
 <link>https://mendelspod.com/podcasts/many-biologists-today-dont-have-enough-computer-science-use-databases/</link>
 <description>Moray Campbell was for all intents and purposes an accomplished and successful cancer biologist at the renowned Roswell Park Cancer Center.  Then one day he woke up and realized he was becoming irrelevant.  He was a traditionally trained wet lab biologist who was getting left behind by computer science.   Any scientist must keep up with their field, but this was different.  A few conferences and journals--reading the news everyday was not going to be enough.  Facing reality, Moray enrolled in a bioinformatics masters program at Johns Hopkins.

That was in 2013.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Moray%20Campbell%20Show%202017.mp3" length="27729343" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/many-biologists-today-dont-have-enough-computer-science-use-databases/</guid>
 <pubDate>Wed, 08 Feb 2017 21:16:54 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Moray%20Campbell%202.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Cardiologists Love Genomics:  Euan Ashley, Stanford</title>
 <link>https://mendelspod.com/podcasts/cardiologists-love-genomics-euan-ashley-stanford/</link>
 <description>Euan Ashley is one of the big names in genomic medicine that has been missing from our guest list.  We’re happy to correct that today.

In 2010, he led the team who did the first clinical interpretation of a human genome--that of his Stanford colleague, Steve Quake.  Since then Euan, an MD PhD, has been driving to make the use of new genomic tools and discoveries a routine part of medicine at Stanford, particularly in his own discipline of cardiology.

A regular speaker on the conference circuit, Euan titles his talks, &quot;Genomic Medicine Is Here.&quot;</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Euan%20Ashley%202017%20Show.mp3" length="27869423" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/cardiologists-love-genomics-euan-ashley-stanford/</guid>
 <pubDate>Mon, 06 Feb 2017 19:53:32 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Euan%20Ashley.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Scientists vs Trump: January 2017 with Nathan and Laura</title>
 <link>https://mendelspod.com/podcasts/scientists-vs-trump-january-2017-nathan-and-laura/</link>
 <description>As we look back at January’s headlines with our two regular commentators, Nathan and Laura, the question becomes:  How much should we ignore the fire raging across America to focus on the science?

Speaking of Trump&#039;s new immigration order and the very real threat of a &quot;brain drain,&quot; Nathan tells of his own personal time doing research in Iran, commending scientists there and the many Iranian scientists here.  But he says Iran has already announced they&#039;re going to retaliate.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/January%202017%20Review%20with%20Nathan%20and%20Laura.mp3" length="21672813" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/scientists-vs-trump-january-2017-nathan-and-laura/</guid>
 <pubDate>Thu, 02 Feb 2017 09:56:18 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/science%20v%20trump.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Want to Stop Smoking? Start with Epigenetic Biomarker that Tells Doc the Truth</title>
 <link>https://mendelspod.com/podcasts/want-stop-smoking-start-epigenetic-biomarker-tells-doc-truth/</link>
 <description>Why are there no viable psychiatric genetic tests, we ask today’s guest.

Rob Philibert is a geneticist and psychiatrist working at the University of Iowa.  He admits at the outset of today’s interview that the field of psychiatric genetics is in a “quandary.”

“The results are not matching the hype,” he says.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Rob%20Philibert%202017%20Show.mp3" length="22846980" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/want-stop-smoking-start-epigenetic-biomarker-tells-doc-truth/</guid>
 <pubDate>Tue, 31 Jan 2017 09:45:37 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/PhilibertRobert.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>When an Exome Test Is Part of the Therapy and Not a Diagnostic: John West on Personalis and Personalized Cancer Vaccines</title>
 <link>https://mendelspod.com/podcasts/when-exome-test-part-therapy-and-not-diagnostic-john-west-personalis-and-personalized/</link>
 <description>Podcast brought to you by: &lt;a href=&quot;http://www.slonepartners.com&quot; target=&quot;_blank&quot;&gt;Slone Partners&lt;/a&gt; -  Providing the leaders that shape the clinical trials space. 

About six years ago there was a wave of genome interpretation startups getting their first rounds of funding.  One of them was Personalis, a company founded by a well known group of Stanford geneticists and bioinformaticians.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/John%20West%202017%20Show.mp3" length="22075425" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/when-exome-test-part-therapy-and-not-diagnostic-john-west-personalis-and-personalized/</guid>
 <pubDate>Tue, 24 Jan 2017 13:07:23 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/John%20West.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>People Told Us It Was Impossible: UCSC’s Mark Akeson on Nanopore Sequencing</title>
 <link>https://mendelspod.com/podcasts/people-told-us-it-was-impossible-ucscs-mark-akeson-nanopore-sequencing/</link>
 <description>Mark Akeson has been working on nanopore sequencing at UC Santa Cruz’s biophysics lab for twenty years. Up until the past few years with the launch of Oxford Nanopore’s sequencers, that work was mostly the methodical toil of the quiet inventor.
Today it is quite ordinary to see a sequencer the size of your wallet being taken out into the field for DNA work. But for years, the naysayers dominated.
“Back in the day, the skeptics outnumbered the proponents 99 to 1,” Mark says in today’s show.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Mark%20Akeson%20Show%202017.mp3" length="26118104" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/people-told-us-it-was-impossible-ucscs-mark-akeson-nanopore-sequencing/</guid>
 <pubDate>Wed, 18 Jan 2017 10:53:35 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/MarkAkeson.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>When Long Reads are Double the Price of Short Reads, Short Reads Are Dead, Says Evan Eichler</title>
 <link>https://mendelspod.com/podcasts/when-long-reads-are-double-price-short-reads-short-reads-are-dead-says-evan-eichler/</link>
 <description>Each year at this time, sequencing tools leader, Illumina, generates another round of sequencing buzz in the industry, this year by announcing the $100 genome is around the corner with their latest boxes.  But more and more, people are asking just what they will get with that $100.  Indeed, what do they get today with a $1,500 genome?

Illumina sells short read sequencing technology which is unable to characterize much of the human genome, particularly complex regions which are responsible for many of the known and unknown diseases.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Evan%20Eichler%202017%20Show.mp3" length="30667930" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/when-long-reads-are-double-price-short-reads-short-reads-are-dead-says-evan-eichler/</guid>
 <pubDate>Thu, 12 Jan 2017 09:52:21 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/evan%20eichler.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Genomics in 2016: Nathan and Laura Name Their Top Stories</title>
 <link>https://mendelspod.com/podcasts/genomics-2016-nathan-and-laura-name-their-top-stories/</link>
 <description>From new CRISPR trials in humans to mitochondrial transfer therapy, from the spinout by Illumina of two new genomics health companies to the complete and utter failure of Theranos, from the approval by the FDA of GM mosquitos to the FDA giving up on LDT regulation as a result of the election, the genomics headlines of 2016 didn’t fail to dazzle, deliver, and disappoint.

Hear which stories our regular commentators, Laura Hercher and Nathan Pearson, chose as their top and also most underreported of the year in today’s look back on 2016.
</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/2016%20Review%20with%20Nathan%20and%20Laura.mp3" length="27323385" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/genomics-2016-nathan-and-laura-name-their-top-stories/</guid>
 <pubDate>Wed, 28 Dec 2016 17:03:18 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Genomics2016b.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Hank Greely on “The End of Sex&quot; and Other Stuff</title>
 <link>https://mendelspod.com/podcasts/hank-greely-end-sex/</link>
 <description>Each year at this time we bring on a guest who is somewhat out of the way of our normal lineup, for example, a science fiction writer or a philosopher.  Today Theral interviews a law professor who loves to philosophize and write about the impact of biotechnology on our lives now and in the near future.    His newest book out this year,  “The End of Sex and the Future of Human Reproduction,”  is another comprehensive and provocative example of what has made Stanford’s Hank Greely such an in-demand speaker both to scientist and non-scientist audiences alike.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Hank%20Greely%202016%20Show.mp3" length="34557645" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/hank-greely-end-sex/</guid>
 <pubDate>Thu, 22 Dec 2016 12:09:16 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Hank%20Greely%20standing_0.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>How to Scale Cancer Genomics, with Marco Marra, UBC</title>
 <link>https://mendelspod.com/podcasts/how-scale-cancer-genomics-marco-marra-ubc/</link>
 <description>Back in 2009 at the annual AGBT meeting for sequencing, Marco Marra presented one of the first cases of cancer treatment using whole genome sequencing.

We caught up with Marco at his office at the University of British Columbia where he heads the Department of Medical Genetics.  Marco also directs the Genome Sciences Center which is part of a very special organization called the BC Cancer Agency.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Marco%20Marra%202016%20Show.mp3" length="25135709" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/how-scale-cancer-genomics-marco-marra-ubc/</guid>
 <pubDate>Tue, 06 Dec 2016 10:20:11 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/marco-marra-slider.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>What Does the Election Mean for Genomics? November 2016 with Nathan and Laura</title>
 <link>https://mendelspod.com/podcasts/what-does-election-mean-genomics-november-2016-nathan-and-laura/</link>
 <description>While everyone is asking what will become of Obamacare, we ask our regular commentators, Nathan Pearson and Laura Hercher, specifically about genomics and medicine.

Nathan begins by saying that data scientists everywhere should be humbled.  Does the failure to predict the election send out warnings about big data predictions in genomics?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/November%202016%20Review%20with%20Nathan%20and%20Laura.mp3" length="25287798" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/what-does-election-mean-genomics-november-2016-nathan-and-laura/</guid>
 <pubDate>Thu, 01 Dec 2016 09:38:05 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/election2016.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>The Saga Continues:  Ethan Perlstein, Indie Scientist, Part 3</title>
 <link>https://mendelspod.com/podcasts/saga-continues-ethan-perlstein-indie-scientist-part-3/</link>
 <description>Today Ethan Perlstein joins us on the program for a third time.  His path as a ‘rogue scientist’ has become a bit of a case study here at Mendelspod as we look into alternate paths for scientists and for drug development.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Ethan%20Perlstein%202016%20Show.mp3" length="26524175" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/saga-continues-ethan-perlstein-indie-scientist-part-3/</guid>
 <pubDate>Tue, 29 Nov 2016 10:47:18 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Ethan%20Perlstein%202016.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Biomarker Panel to Predict Type 1 Diabetes</title>
 <link>https://mendelspod.com/podcasts/biomarker-panel-predict-type-1-diabetes/</link>
 <description>When we talk precision medicine on Mendelspod, we’re usually talking about oncology.  But today we shift our focus to diabetes.

Raghu Mirmira is an MD PhD at Indiana University who is working on a panel of biomarkers that would predict Type 1 diabetes.  That’s right.  Predict.

Having already found a DNA biomarker candidate which detects dying beta cells using the new technology of digital PCR, Raghu is now working to improve the panel with other metabolites.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Raghu%20Mirmira%202016%20Show.mp3" length="17564070" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/biomarker-panel-predict-type-1-diabetes/</guid>
 <pubDate>Thu, 17 Nov 2016 12:17:41 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Raghu-Mirmira.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Can You Name the World’s Largest Single Disease Research Charity?</title>
 <link>https://mendelspod.com/podcasts/can-you-guess-worlds-largest-single-disease-charity/</link>
 <description>Let’s take a break from the US and head over to the UK, home of the world’s largest single disease medical research charity.
Cancer Research UK (CRUK) raises five hundred million pounds a year for research and drug discovery into any and all of the two hundred plus types of cancer. The charity is extremely well integrated into U.K. culture, and uniquely English in that the donations are mostly small and come from all corners of society. A third of CRUK’s funding comes from donations averaging £10 or less.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Allan%20Jordan%202016%20Show.mp3" length="25684781" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/can-you-guess-worlds-largest-single-disease-charity/</guid>
 <pubDate>Mon, 14 Nov 2016 18:53:21 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/allan-jordan.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Why Diversity Is the Only Path Forward: Sarah Tishkoff on African Genomics</title>
 <link>https://mendelspod.com/podcasts/why-diversity-only-path-forward-sarah-tishkoff-african-genomics/</link>
 <description>Are you lactose tolerant?  If you’re of Northern European ancestry this is because of a stretch of DNA in a gene enhancer that developed some 9,000 years ago.  That&#039;s the same time Northern Europeans began domesticating cattle for milk.  If you’re of African ancestry, you may have one of three mutations which appeared independently of the European mutation--and of each other--about 6,000 years ago, again when dairying began.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Sarah%20Tishkoff%202016%20Show.mp3" length="31846848" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/why-diversity-only-path-forward-sarah-tishkoff-african-genomics/</guid>
 <pubDate>Thu, 03 Nov 2016 09:46:22 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Sarah%20Tishkoff.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>October 2016 with Nathan and Laura</title>
 <link>https://mendelspod.com/podcasts/october-2016-nathan-and-laura/</link>
 <description>Today’s show was recorded on Halloween, which now feels so yesterday.  Forgive us for some spookiness.

What doesn’t feel so yesterday is the launch this past month of Helix, a company spun out of Illumina that aims to add exomes to the lineup of direct-to-consumer testing.  Nathan points out their model for delivering data incrementally through various apps.  Laura questions how Helix will vet the apps.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/October%202016%20Review%20with%20Nathan%20and%20Laura.mp3" length="21937621" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/october-2016-nathan-and-laura/</guid>
 <pubDate>Mon, 31 Oct 2016 19:54:59 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/spider-web.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>We’re Over Halfway There: Baylor&#039;s Richard Gibbs on Clinical Genetics</title>
 <link>https://mendelspod.com/podcasts/were-over-halfway-there-baylors-richard-gibbs-clinical-genetics/</link>
 <description>There’s a basic assumption in our field today that has been around for some time.   We think of medicine as on a direct and even continuum with science.  That discoveries in genomics, for example, will lead directly to breakthroughs in medicine.  But the breakthroughs on the medical side have been much more rare to date than those coming from the study of biology and genomics.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Richard%20Gibbs%202016%20Show.mp3" length="29180969" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/were-over-halfway-there-baylors-richard-gibbs-clinical-genetics/</guid>
 <pubDate>Tue, 25 Oct 2016 13:46:52 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Richard%20Gibbs.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>With FDA Guidance on LDTs Still Not Out, What Are Labs Doing?</title>
 <link>https://mendelspod.com/podcasts/fda-guidance-ldts-still-not-out-what-are-labs-doing/</link>
 <description>As we get closer to the election and the end of 2016, the debate over LDT regulation has gone quiet.  At this time last year, there was one hearing after another, first in the Senate, then in the House.  The FDA’s Jeffrey Shuren was called before congress and drilled over the nuances of the guidance as well as asked when it would be released.  He said, in the first half of 2016.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/John%20Longshore%202016%20Show.mp3" length="23494989" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/fda-guidance-ldts-still-not-out-what-are-labs-doing/</guid>
 <pubDate>Wed, 19 Oct 2016 10:08:49 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/John%20Longshore.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Reference Genome Making Major Strides in Ethnic Diversity, Says Valerie Schneider, NCBI</title>
 <link>https://mendelspod.com/podcasts/reference-genome-making-major-strides-ethnic-diversity-says-valerie-schneider-ncbi/</link>
 <description>A couple months back, we &lt;a href=&quot;http://mendelspod.com/podcasts/august-2016-nathan-and-laura/&quot;&gt;reported&lt;/a&gt; on a study showing that genetic tests for an inherited heart disorder were more likely to come back with false positive results for black Americans than for whites. The study provoked many in our industry to urge scientists to incorporate more ethnic diversity in their studies.  So far, biology has been too Eurocentric—the databases are implicitly racist, they argue.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Valerie%20Schneider%202016%20Show.mp3" length="26746218" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/reference-genome-making-major-strides-ethnic-diversity-says-valerie-schneider-ncbi/</guid>
 <pubDate>Tue, 11 Oct 2016 10:36:06 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Vallerie_Schneider%202016.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>September 2016 with Nathan and Laura</title>
 <link>https://mendelspod.com/podcasts/september-2016-nathan-and-laura/</link>
 <description>There were many headlines this past week heralding the first three parent baby to be born.  But in fact, as our commentators point out in today’s look back on last month’s genomics news, three parent babies have been around for some time.  So why are couples going to Mexico for mitochondrial transfer today?  Why is it not legal in the U.S.?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/September%202016%20Review%20with%20Nathan%20and%20Laura.mp3" length="24067820" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/september-2016-nathan-and-laura/</guid>
 <pubDate>Tue, 04 Oct 2016 09:56:04 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/newborn.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Luke Timmerman on His New Biography of Lee Hood</title>
 <link>https://mendelspod.com/podcasts/luke-timmerman-his-new-biography-lee-hood/</link>
 <description>There is tons of life science journalism.  Our coffee tables and inboxes fill up each week with that quarterly or that daily.  We sift through headlines and product advertisements to assess what’s going on in our industry.   It’s our job to know.   In this age of several-times-per-day newsletters and 24 hrs a day Twitter, we catch what we can.

And occasionally, we come across a carefully written piece or a well done interview, and we take a moment to realize with some awe the history that is being made in our industry.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Luke%20Timmerman%202016%20Show.mp3" length="26114617" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/luke-timmerman-his-new-biography-lee-hood/</guid>
 <pubDate>Tue, 27 Sep 2016 11:14:38 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/LukeTimmerman11012014.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>How Personalized is Personalized Medicine?  Krister Wennerberg on FIMM’s Individualized Systems Medicine</title>
 <link>https://mendelspod.com/podcasts/how-personalized-personalized-medicine-krister-wennerberg-fimms-individualized-systems/</link>
 <description>Most of the time, when we talk about personalized medicine, it’s not that personalized.  What we’re really talking about is population-based medicine.  However, there is a growing number of clinical/research groups around the world, including the folks at the Finnish Institute for Molecular Medicine (FIMM) who are combining an older method of functional profiling with new molecular profiling to come up with what the Fins call &#039;Individualized Systems Medicine.&#039;</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Krister%20Wennerberg%20Show.mp3" length="20788494" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/how-personalized-personalized-medicine-krister-wennerberg-fimms-individualized-systems/</guid>
 <pubDate>Thu, 22 Sep 2016 13:40:42 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/krister-wennerberg.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Digital PCR Opens Up New Liquid Biopsy Opportunity in Melanoma Treatment: David Polsky, NYU</title>
 <link>https://mendelspod.com/podcasts/digital-pcr-opens-new-liquid-biopsy-opportunity-melanoma-treatment-david-polsky-nyu/</link>
 <description>The history of science is also a history of toolmaking.  And nowhere is this more true than in modern biology.  New instruments in the lab allow biologists additional modes of discovery, new levels of quantification, and the opportunity to pursue new and old questions with more data.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/David%20Polsky%20Show%202016.mp3" length="20411775" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/digital-pcr-opens-new-liquid-biopsy-opportunity-melanoma-treatment-david-polsky-nyu/</guid>
 <pubDate>Tue, 20 Sep 2016 10:07:56 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/David%20Polsky.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> Erica Ramos on Her Pioneering Role as Genetic Counselor for Industry</title>
 <link>https://mendelspod.com/podcasts/erica-ramos-her-pioneering-role-genetic-counselor-industry/</link>
 <description>For the next installment of our series on genetic counseling, we’re joined by Erica Ramos.  She’s the president-elect of the National Society of Genetic Counselors and was the second genetic counselor hired at Illumina where she’s been for four years.  Illumina now has 15 genetic counselors.

Erica has been a trail blazer throughout her career.  Before joining Illumina, she was the first ‘cancer counselor’ in the city of Las Vegas, Nevada.  Her time at Illumina has been a prime example of the evolving role of the industry counselor.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Erica%20Ramos%20Show%202106.mp3" length="25683489" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/erica-ramos-her-pioneering-role-genetic-counselor-industry/</guid>
 <pubDate>Tue, 13 Sep 2016 21:54:15 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Erica%20Ramos.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>August 2016 with Nathan and Laura</title>
 <link>https://mendelspod.com/podcasts/august-2016-nathan-and-laura/</link>
 <description>It’s the end of summer and end of another month.  Joining us to discuss the genomics headlines of August are Laura Hercher and Nathan Pearson.

A recent study demonstrating that breast cancer patients with low genomic risk may not need chemotherapy is just what precision medicine is all about, isn’t it?  Theral and Laura think the study is a big deal.  Nathan’s not so sure.

Nathan is convinced though that Eurocentric studies have implicit racism.  Laura agrees, saying the lack of racial diversity in biological databases is a major weakness that we must face head on.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/August%202016%20Review%20with%20Nathan%20and%20Laura.mp3" length="19000889" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/august-2016-nathan-and-laura/</guid>
 <pubDate>Wed, 31 Aug 2016 21:16:10 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/RACISM.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>A Maniacal Commitment to Science:  Peering into Regeneron’s Genetics Center with Jeff Reid</title>
 <link>https://mendelspod.com/podcasts/maniacal-commitment-science-peering-regenerons-genetics-center-jeff-reid/</link>
 <description>Today we feature a pharma company that has been around for some time but recently getting more media coverage for the impressive scale of their new genetic center.  Regeneron Pharmaceuticals, insiders joke, has been an overnight success that took 25 years.

One might think every big pharma company has their own genetic center for internal R &amp; D.  But today’s guest, Jeff Reid, Executive Director of Genome Informatics at the Regeneron Genetic Center (RGC), says that actually deep genetic research is often outsourced.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Jeff%20Reid%20Show%202016.mp3" length="26524578" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/maniacal-commitment-science-peering-regenerons-genetics-center-jeff-reid/</guid>
 <pubDate>Wed, 17 Aug 2016 20:55:14 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Jeff%20Reid.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>The Days of Miracle and Wonder:  Laura Hercher on Genetic Counseling, Part 2</title>
 <link>https://mendelspod.com/podcasts/days-miracle-and-wonder-laura-hercher-genetic-counseling-part-2/</link>
 <description>We often hear at conferences that there are too few genetic counselors.  And that this bottleneck is constraining the delivery and promise of genomic medicine.   Is this true?

It is 100% true, says Laura Hercher of Sarah Lawrence College in the second part of our interview on genetic counseling.

“We graduate just under 300 genetic counselors a year.  And last year at our annual meeting [National Society of Genetic Counselors], there were posted over 600 jobs.  We’re producing jobs at a much greater rate than we’re producing counselors.”</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Laura%20Hercher%20Show%202016%20Part%202.mp3" length="18513150" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/days-miracle-and-wonder-laura-hercher-genetic-counseling-part-2/</guid>
 <pubDate>Sat, 30 Jul 2016 17:39:52 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Miracle%20and%20Wonder.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>The Days of Miracle and Wonder:  Laura Hercher on Genetic Counseling, Part 1</title>
 <link>https://mendelspod.com/podcasts/days-miracle-and-wonder-laura-hercher-genetic-counseling-part-1/</link>
 <description>They’ve been called the “unsung heroes” of our age.  They are primarily women.  And when the trend for most of us is to become specialists, they have been generalists.

Today we begin a special series on genetic counselors.  Our first guest, a genetic counselor herself, is a name familiar to our audience.  Laura Hercher is one of our regular month-in-reviewers, and today it’s all about her.  She is on the faculty at Sarah Lawrence College where the first genetic counseling program was begun in 1969 and where half of the nation’s genetic counselors have been trained.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Laura%20Hercher%20Show%202016%20Part%201.mp3" length="23302747" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/days-miracle-and-wonder-laura-hercher-genetic-counseling-part-1/</guid>
 <pubDate>Sat, 30 Jul 2016 17:27:03 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/laura%20hercher.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>A Precision Medicine Platform Comes of Age: Jonathan Hirsch, Syapse</title>
 <link>https://mendelspod.com/podcasts/precision-medicine-platform-comes-age-jonathan-hirsch-syapse/</link>
 <description>Today’s show with Jonathan Hirsch, the President and co-founder of Syapse begins a couple years ago. We first featured him on the program in January of 2014 with the headline, &lt;a href=&quot;http://mendelspod.com/podcast/omics-clinic-site-weve-all-been-waiting/&quot;&gt;Is this the Omics-to-Clinic Site We’ve All Been Waiting For?&lt;/a&gt;</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Jonathan%20Hirsch%20Show%202016.mp3" length="22664663" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/precision-medicine-platform-comes-age-jonathan-hirsch-syapse/</guid>
 <pubDate>Thu, 21 Jul 2016 10:29:10 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/JonHirsch.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>FDA’s Liz Mansfield on New NGS Guidances</title>
 <link>https://mendelspod.com/podcasts/fdas-liz-mansfield-new-ngs-guidances/</link>
 <description>On July 6th, as part of the President’s Precision Medicine Initiative, the FDA issued two new draft guidances for the oversight of next gen sequencing (NGS) tests.  The first guidance is for using NGS testing to diagnose germline diseases.  In the second, the FDA lists guidelines for building and using genetic variant databases.

To help us understand just what the guidance is and what led to its release, we’re joined by Liz Mansfield, the Deputy Office Director for Personalized Medicine at the FDA.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Liz%20Mansfield%20Show%202016.mp3" length="16924249" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/fdas-liz-mansfield-new-ngs-guidances/</guid>
 <pubDate>Tue, 19 Jul 2016 09:18:39 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/LizMansfieldSquare_0.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>How Is the Brexit Impacting Genomics? with Clare Turnbull and Hadyn Parry</title>
 <link>https://mendelspod.com/podcasts/how-brexit-impacting-genomics-clare-turnbull-and-hadyn-parry/</link>
 <description>Today&#039;s guests have been separately on the program recently.  And we&#039;ve asked them, both Brits, to come back on for a discussion of the Brexit.  Clare Turnbull is Clinical Lead for the 100K Genomes Project Cancer Program at Genomics England.  Hadyn Parry is the CEO at Oxitec, a company based in Oxford which is already selling their genetically engineered mosquitos into Brazil to deal with viral diseases like Zika and Dengue Fever.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Brexit%20Show%20with%20Clare%20Turnbull%20and%20Hadyn%20Parry%202016.mp3" length="21746694" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/how-brexit-impacting-genomics-clare-turnbull-and-hadyn-parry/</guid>
 <pubDate>Mon, 11 Jul 2016 19:53:43 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/brexit.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>It’s Not Really Bulls and Bears:  John Carroll on His New Gig, the Brexit, and a New Metaphor for the Market</title>
 <link>https://mendelspod.com/podcasts/its-not-really-bulls-and-bears-john-carroll-his-new-gig-brexit-and-new-metaphor-market/</link>
 <description>John Carroll has been the editor-in-chief at Fierce Biotech for thirteen years.  Now he&#039;s moved to a new gig.   Two weeks ago, he and a former colleague launched a new and independent life science media site, Endpoints.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/John%20Carroll%202016%20Show.mp3" length="21461549" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/its-not-really-bulls-and-bears-john-carroll-his-new-gig-brexit-and-new-metaphor-market/</guid>
 <pubDate>Thu, 07 Jul 2016 11:03:17 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/john-carroll.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>June 2016 with Nathan and Laura: GMO Labeling, Misspelling CRISPR, Sequenom Patent Loss, SmidgIon</title>
 <link>https://mendelspod.com/podcasts/june-2016-nathan-and-laura-gmo-labeling-misspelling-crispr-sequenom-patent-loss-smidgion/</link>
 <description>Today&#039;s show was recorded July 1st, the first day that Vermont’s GMO labeling law went into effect.  Just how big a win was this for the anti-GMO crowd, we ask our two commentators, Nathan Pearson and Laura Hercher.  They have a surprisingly optimistic take, suggesting that the GMO labeling could become a positive marketing tool.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/June%202016%20with%20Nathan%20and%20Laura.mp3" length="25601392" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/june-2016-nathan-and-laura-gmo-labeling-misspelling-crispr-sequenom-patent-loss-smidgion/</guid>
 <pubDate>Tue, 05 Jul 2016 11:26:26 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Vermont-GMO-Labeling-Required.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Know Then Thyself:  Kari Stefansson, deCODE genetics</title>
 <link>https://mendelspod.com/podcasts/know-then-thyself-kari-stefansson-decode-genetics/</link>
 <description>Kari Stefansson is a name well known in the field of human genetics.   His founding of deCODE genetics in his native Iceland in 1996 took our field into a new frontier with the unique opportunity to work with not only a homogenous population but also to integrate with a large centralized healthcare database.  It also surfaced a huge ethical debate about genomic privacy.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Kari%20Stefansson%20Show%202016.mp3" length="38367875" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/know-then-thyself-kari-stefansson-decode-genetics/</guid>
 <pubDate>Thu, 30 Jun 2016 12:04:41 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/karistefansson.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Sequenom Patent Loss a Threat to Personalized Medicine, Says Kevin Noonan</title>
 <link>https://mendelspod.com/podcasts/sequenom-patent-loss-threat-personalized-medicine-says-kevin-noonan/</link>
 <description>It’s a non-decision with big implications.  On Monday, the Supreme Court turned down an appeal by Sequenom in their patent case with Ariosa.  The rebuff by the highest court kills Sequenom’s prenatal screening test patent for good.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Kevin%20Noonan%20Show%202016.mp3" length="20744871" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/sequenom-patent-loss-threat-personalized-medicine-says-kevin-noonan/</guid>
 <pubDate>Wed, 29 Jun 2016 11:45:24 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Kevin%20Noonan_0.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Bringing Home Some Diagnostics Gold:  Brad Gray, NanoString Show How It’s Done</title>
 <link>https://mendelspod.com/podcasts/bringing-home-some-diagnostics-gold-brad-gray-nanostring-show-how-its-done/</link>
 <description>You hear it everywhere.  And it’s getting old.  That  &quot;diagnostics is a tough slog.”  That it’s the “redheaded stepchild of healthcare.”

And today’s guest doesn’t disappoint, repeating both these phrases.  But Brad Gray and NanoString can claim some big “slogging&quot; success.  They’re coming out on top in diagnostics through some clever business strategy built on a solid platform.    Made CEO at just 33 years of age, Brad has taken NanoString public and overseen a successful expansion from the research to the clinical market.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Brad%20Gray%20Show%202016-auphonic.mp3" length="20366938" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/bringing-home-some-diagnostics-gold-brad-gray-nanostring-show-how-its-done/</guid>
 <pubDate>Fri, 24 Jun 2016 10:27:24 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/BradGray.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Mukherjee Mess-up, the Secret Harvard Meeting, and Success in Gene Therapy: May 2016 with Nathan and Laura</title>
 <link>https://mendelspod.com/podcasts/mukherjee-mess-secret-harvard-meeting-and-success-gene-therapy-may-2016-nathan-and-laura/</link>
 <description>Today we look back on the genomics headlines over the past month (and a few days).  To do this we’re joined by our regular commentators, Nathan Pearson and Laura Hercher.

First we take on the science journalism kerfuffle of the year.  When Pulitzer Prize winning author, Siddhartha Mukerjee, got epigenetics wrong in his New Yorker piece, scientists came out en masse to denounce it.  Nathan reassures us that scientists aren’t afraid of writers.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/May%202016%20with%20Nathan%20and%20Laura_0.mp3" length="23696733" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/mukherjee-mess-secret-harvard-meeting-and-success-gene-therapy-may-2016-nathan-and-laura/</guid>
 <pubDate>Mon, 06 Jun 2016 10:13:11 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Secret%20Meeting.jpeg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> When Do We Move to Population Based Cancer Screening for Those with High Genetic Risk? Josh Schiffman, U of U</title>
 <link>https://mendelspod.com/podcasts/when-do-we-move-population-based-cancer-screening-those-high-genetic-risk-josh-schiffman-u/</link>
 <description>Last year when we were promised a soon-to-be-on-the-market, pan cancer, genetic based screening test, many of us were taken aback at the hubris.  Not only does the science have a ways to go, there are deep ethical conflicts to work through.  However, cancer screening based on a patient’s genetics is already being done in certain niche areas.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Joshua%20Schiffman%20Show%202016.mp3" length="25463707" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/when-do-we-move-population-based-cancer-screening-those-high-genetic-risk-josh-schiffman-u/</guid>
 <pubDate>Mon, 23 May 2016 22:46:01 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Josh%20Schiffman.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>The Solid Future of Liquid Biopsies with Michael Nall, Biocept</title>
 <link>https://mendelspod.com/podcasts/solid-future-liquid-biopsies-michael-nall-biocept/</link>
 <description>There’s been lots in the news this past year about liquid biopsies—those non-invasive tests which locate biomarkers in a vial of blood.  Much of that press (perhaps too much) has been about using these blood tests for cancer screening:  predictive tests that could be available to consumers some time in the future.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Michael%20Nall%20Show%202016.mp3" length="27526074" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/solid-future-liquid-biopsies-michael-nall-biocept/</guid>
 <pubDate>Wed, 18 May 2016 22:10:11 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Michael%20Nall.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Genomics Is Oversubscribed, Says Creator of BLAST</title>
 <link>https://mendelspod.com/podcasts/genomics-oversubscribed-says-creator-blast/</link>
 <description>One of the original Celera team that worked on the Human Genome Project, Gene Myers is now setting up the new Center for Systems Biology at the Max Planck Institute of Molecular Cell Biology and Genetics.

However, unlike many others such centers, the main focus of this institute will not be genomics.  Rather Myers is going for microscopy.

“Genomics is only about 20% of it,” he says in today’s interview from his office in Dresden, Germany</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Gene%20Myers%20Show%202016.mp3" length="27085773" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/genomics-oversubscribed-says-creator-blast/</guid>
 <pubDate>Thu, 12 May 2016 10:48:49 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/MYERS.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>With 10K Genomes Sequenced, Genomics England in High Gear:  Clare Turnbull, Clinical Lead</title>
 <link>https://mendelspod.com/podcasts/10k-genomes-sequenced-genomics-england-high-gear-clare-turnbull-clinical-lead/</link>
 <description>We’ve heard on the program over the past few years that genomic medicine will probably take off first in a country with a centralized health service.   And when the U.K. announced their 100K Genomes Project at the end of 2012 with the creation of Genomics England in 2013, it was certainly a bold visionary move to do just that—to put the entire country on a progressive path toward precision medicine for all.

So with 10K genomes sequenced, how is the project going?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Clare%20Turnbull%202016%20Show-auphonic.mp3" length="30813120" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/10k-genomes-sequenced-genomics-england-high-gear-clare-turnbull-clinical-lead/</guid>
 <pubDate>Thu, 05 May 2016 11:54:47 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Clare%20Turnbull.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> April 2016 with Nathan and Laura: Big Money, More CRISPR Studies, Genomic Superheroes, and a Pot Chaser</title>
 <link>https://mendelspod.com/podcasts/april-2016-nathan-and-laura-big-money-more-crispr-studies-genomic-superheroes-and-pot/</link>
 <description>This month we saw Big Money being infused into genomics and other life science research projects.  There’s no question that science is big business, but do we see improved healthcare as a result?

Was the NIH too hasty in it’s ban on gene editing of human embryos?

Superheroes are lurking among us everywhere . . . or so the mainstream media would have us believe in their take on a new study from the Icahn School of Medicine.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/April%202016%20with%20Nathan%20and%20Laura.mp3" length="23914038" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/april-2016-nathan-and-laura-big-money-more-crispr-studies-genomic-superheroes-and-pot/</guid>
 <pubDate>Mon, 02 May 2016 11:22:32 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/superhero.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>A Sneak Peek into the Future of Clinical Genomics with Ben Solomon, Inova </title>
 <link>https://mendelspod.com/podcasts/sneak-peek-future-clinical-genomics-ben-solomon-inova/</link>
 <description>We hear from some that soon each baby&#039;s genome will be sequenced at birth.  This vast amount of genomic information will be stored in a person&#039;s medical record for life and be referenced for personalized healthcare, be it for a diagnostic, a prognostic, or a prediction.  But others say that it is still way too early to be generating so much information on each person when we know so little about the genome.  This camp  argues that we should deal with patients on a case by case basis using a more targeted approach.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Ben%20Solomon%202016%20Show.mp3" length="35724113" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/sneak-peek-future-clinical-genomics-ben-solomon-inova/</guid>
 <pubDate>Wed, 27 Apr 2016 20:31:59 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Ben%20Solomon.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Preprints and the Future of Science Publishing with Jason Hoyt, PeerJ</title>
 <link>https://mendelspod.com/podcasts/preprints-and-future-science-publishing-jason-hoyt-peerj/</link>
 <description>A renewed effort has been underway by leading biologists this year to persuade their colleagues to preprint.  This is the posting of a paper to an open access server before peer review and publication.  The proponents argue that preprinting will be good for science because discoveries will be made available sooner.   The peer review process can take several months, and by preprinting, a biologist doesn’t have to wait to get their work out there and begin interacting with the community.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Jason%20Hoyt%202016%20Show.mp3" length="27943790" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/preprints-and-future-science-publishing-jason-hoyt-peerj/</guid>
 <pubDate>Mon, 11 Apr 2016 15:59:57 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Jason%20Hoyt.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Flipping Drug Development Upside Down:  Niven Narain, BERG Health</title>
 <link>https://mendelspod.com/podcasts/flipping-drug-development-upside-down-niven-narain-berg-health/</link>
 <description>The promise of rational drug design has driven pharma companies for years.  The history of the industry has been one of trial and error, or “guess and check”, as scientists often say.  Companies have screened thousands and thousands of compounds looking for one that might work—the proverbial needle in the haystack.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Niven%20Narain%20Show.mp3" length="29533109" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/flipping-drug-development-upside-down-niven-narain-berg-health/</guid>
 <pubDate>Wed, 06 Apr 2016 11:53:03 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Niven%20Narain.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> March 2016 with Nathan and Laura:  Genomic Jenga and the Creator, the Anti-Abortion Lobby and Genetic Testing, and Theranos, Again</title>
 <link>https://mendelspod.com/podcasts/march-2016-nathan-and-laura-genomic-jenga-and-creator-anti-abortion-lobby-and-genetic/</link>
 <description>Which company offers the gold standard of sequencing?  Nathan starts us out with a metaphor to compare linked reads with real long reads.  Then it’s on to this month’s “knockout paper” that moves us yet further from a deterministic view of genetics.  Or is this genomic Jenga part of the “proper design of the Creator”?  Laura links a new Indiana law banning abortion due to chromosomal abnormalities such as Down Syndrome to a larger effort by the anti-abortion lobby to go after all genetic testing.  Theranos plays the Donald Trump of our industry.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/March%202016%20in%20Review%20with%20Nathan%20and%20Laura.mp3" length="23246212" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/march-2016-nathan-and-laura-genomic-jenga-and-creator-anti-abortion-lobby-and-genetic/</guid>
 <pubDate>Fri, 01 Apr 2016 11:03:47 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Jenga.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Medicine and the Limits of Science with Michel Accad, MD</title>
 <link>https://mendelspod.com/podcasts/medicine-and-limits-science-michel-accad-md/</link>
 <description>Are drug prices really too high?  If so, how do we bring them down?  Is precision medicine and the use of molecular profiles really making a difference in healthcare today?

These are questions that regularly haunt our industry and the journalists who cover it.  But there will be no answers until we face the grand question of all, what today&#039;s guest calls the most nagging question in medicine:  What is health?

Today we begin a new series focused on just this question.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Michel%20Accad%20Show.mp3" length="32407202" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/medicine-and-limits-science-michel-accad-md/</guid>
 <pubDate>Wed, 30 Mar 2016 09:58:21 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Michel%20Accad.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>How Good are Linked Reads? Serge Saxonov, 10X Genomics</title>
 <link>https://mendelspod.com/podcasts/how-good-are-linked-reads-serge-saxonov-10x-genomics/</link>
 <description>When 10X Genomics launched their GemCode sequencing instrument at last year’s AGBT conference, what they offered seemed too good to be true.  10X was promising researchers a machine that could generate long reads using Illumina’s short read technology at a price lower than what PacBio could offer with their “real” long read instruments.  A year earlier, Illumina had announced they were buying Moleculo, a company that promised to offer long read data out of the short reads.  But good data with the Moleculo platform failed to materialize.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Serge%20Saxanov%20Show%202016.mp3" length="39079856" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/how-good-are-linked-reads-serge-saxonov-10x-genomics/</guid>
 <pubDate>Tue, 15 Mar 2016 12:12:45 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/serge-saxonov.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>A Home Run on the First Hit: PacBio’s Jonas Korlach</title>
 <link>https://mendelspod.com/podcasts/home-run-first-hit-pacbio-jonas-korlach/</link>
 <description>Jonas Korlach is a natural storyteller—a rare trait in a scientist who is more comfortable presenting data than talking of himself.   Jonas is the co-inventor of PacBio’s SMRT (single molecule, real time) sequencing, and we wanted to hear from him directly how it all got started, and also when the team realized that they had something big with long reads and close to 100X coverage.  How many of us can boast of hitting it out of the park on our first try?
</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Jonas%20Korlach%20Show%202016.mp3" length="28875144" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/home-run-first-hit-pacbio-jonas-korlach/</guid>
 <pubDate>Tue, 08 Mar 2016 11:10:25 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/JonasKorlach.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> Digital Pathology at Scale: Epic Sciences Takes CTC Technology to the Next Level </title>
 <link>https://mendelspod.com/podcasts/digital-pathology-scale-epic-sciences-takes-ctc-technology-next-level/</link>
 <description>It’s the beginning of the age of liquid biopsies, when less invasive, regular blood draws will provide more information than the occasional solid tissue biopsy.  Companies that offer tests based on circulating tumor cells or cell free DNA in the blood are popping up like genome interpretation companies were a few years ago.  As our understanding of biology at the molecular level advances--particularly in the field of cancer research--the more this practical and focused approach for teasing out the information in the cell, in the body gains steady adoption.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Murali%20Prahalad%202016%20Show.mp3" length="33168800" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/digital-pathology-scale-epic-sciences-takes-ctc-technology-next-level/</guid>
 <pubDate>Thu, 03 Mar 2016 10:49:19 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/MuraliPrahalad.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> February 2016: Mosquitos, Preprints, and that Rocking White House Summit</title>
 <link>https://mendelspod.com/podcasts/february-2016-mosquitos-preprints-and-rocking-white-house-summit/</link>
 <description>It’s time again to look back on another month with Nathan and Laura.
</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/February%202016%20with%20Nathan%20and%20Laura.mp3" length="28480337" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/february-2016-mosquitos-preprints-and-rocking-white-house-summit/</guid>
 <pubDate>Tue, 01 Mar 2016 09:49:33 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Aedes-Aegyti-mosquito.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>  BioNano Genomics Stakes Out Sequencing Territory as They Discover Lots of De Novo Variants in Reference Genome Projects</title>
 <link>https://mendelspod.com/podcasts/bionano-genomics-stakes-out-sequencing-territory-they-discover-lots-de-novo-variants/</link>
 <description>If you attended or followed the recent AGBT conference about all things sequencing, you probably saw a few BioNano Genomics t-shirts with the slogan, “Back to the Map.”  They’re referring of course, to a genome map.  Just like Google Maps, a genome map consists of landmarks that tell scientists where on the genome they are.  But unlike Google Maps and more like the maps North America that were made by European explorers in the 17th century, the map of the human genome is quite incomplete, the map of a frontier.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Erik%20Holmlin%20Show%202016.mp3" length="35008332" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/bionano-genomics-stakes-out-sequencing-territory-they-discover-lots-de-novo-variants/</guid>
 <pubDate>Thu, 25 Feb 2016 11:06:52 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/ErikHolmlin2016.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Is Oxitec Ready to Scale as Governments Seek Options to Control the Zika Virus?</title>
 <link>https://mendelspod.com/podcasts/oxitec-ready-scale-governments-seek-options-control-zika-virus/</link>
 <description>With constant news topping the headlines about the Zika virus, a synthetic biology company out of Oxford England, Oxitec, has been getting some good press. For over ten years now, Oxitec has been developing their genetically engineered mosquitos as a way to lower virus spreading mosquito populations.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Hadyn%20Parry%20Show.mp3" length="27748487" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/oxitec-ready-scale-governments-seek-options-control-zika-virus/</guid>
 <pubDate>Mon, 22 Feb 2016 20:15:15 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Hadyn%20Parry%20Thumb.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Human Genome Turns 15: Mike Hunkapiller</title>
 <link>https://mendelspod.com/podcasts/human-genome-turns-15-mike-hunkapiller/</link>
 <description>We’re all familiar with the announcement in the year 2000 by US President, Bill Clinton, and the UK’s Prime Minister, Tony Blair, that scientists had completed the first draft of the human genome.  It was a big deal.  But the actual publications didn’t happen until the next year, February of 2001.  Which means that this February is the fifteenth anniversary of the publication of the first human genome.  For our commemorative show we’re joined by Mike Hunkapiller, the CEO of Pacific Biosciences.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Mike%20Hunkapiller%20Show%202016.mp3" length="29349465" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/human-genome-turns-15-mike-hunkapiller/</guid>
 <pubDate>Thu, 04 Feb 2016 09:36:59 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/mikeh2.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>January 2016: Landergate, Grail, and Cancer Moonshot</title>
 <link>https://mendelspod.com/podcasts/january-2016-landergate-grail-and-cancer-moonshot/</link>
 <description>“It being the month of Hypeuary, go hither through break in yonder wall called LanderGate, and thou wilt be on route to reach the Grail.  Drink from this to find your Cure, and Death shall haunt you even more.”  -Pithy Monton</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/January%202016%20Show.mp3" length="21858588" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/january-2016-landergate-grail-and-cancer-moonshot/</guid>
 <pubDate>Mon, 01 Feb 2016 09:35:20 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Grail.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Frontiers of Sequencing: Putting Long Reads and Graph Assemblies to Work</title>
 <link>https://mendelspod.com/podcasts/frontiers-sequencing-putting-long-reads-and-graph-assemblies-work/</link>
 <description>OK, so we get it. Long read sequencing technology is cool. But how cool? Is it another great player on the field, or does it change the game altogether? </description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Mike%20and%20Maria%20Show.mp3" length="34578171" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/frontiers-sequencing-putting-long-reads-and-graph-assemblies-work/</guid>
 <pubDate>Thu, 28 Jan 2016 09:11:23 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/karyotype.gif" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Why Drugs Are Priced So High and Diagnostics So Low</title>
 <link>https://mendelspod.com/podcasts/why-drugs-are-priced-so-high-and-diagnostics-so-low/</link>
 <description>Pharma companies face escalated flack over high drug prices.  Meanwhile the diagnostics industry toils away at comparative pennies to the dollar.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Saurabh%20Jha%20Show.mp3" length="29069307" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/why-drugs-are-priced-so-high-and-diagnostics-so-low/</guid>
 <pubDate>Thu, 21 Jan 2016 09:13:01 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Saurabh-Jha.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Who Is John Ioannidis?</title>
 <link>https://mendelspod.com/podcasts/who-john-ioannidis-0/</link>
 <description>It’s now been over ten years since John Ioannidis published his now famous paper, &lt;a href=&quot;http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0020124&quot;&gt;Why Most Published Research Findings Are False&lt;/a&gt;.   What response has John seen from the scientific community? How has the paper changed his career and role in the scientific community? Join us for a look at science itself.
</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/John%20Ioannidis%20Show.mp3" length="33816555" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/who-john-ioannidis-0/</guid>
 <pubDate>Thu, 14 Jan 2016 10:05:15 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/John%20Ioannidis.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Cancer: Year in Review 2015 with Anna Barker</title>
 <link>https://mendelspod.com/podcasts/cancer-year-review-2015-anna-barker/</link>
 <description>As we begin the countdown to the new year, we take a look back at 2015 in cancer research, treatment and prevention.  Mendelspod is increasingly becoming known for the coverage of genomics and precision medicine, and cancer as a disease area offers a specific window whereby we can look at practical outcomes.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Anna%20Barker%202015%20Show.mp3" length="38288619" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/cancer-year-review-2015-anna-barker/</guid>
 <pubDate>Wed, 30 Dec 2015 12:02:22 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Anna%20Barker_0.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Sci-Fi Author Kim Stanley Robinson Talks Life Science 2015</title>
 <link>https://mendelspod.com/podcasts/sci-fi-author-kim-stanley-robinson-talks-life-science-2015/</link>
 <description>At the end of the year our goal is to bring the audience some unusual programming, some new outside perspectives on the topics we cover. As with last year, we talk today with science fiction writer, Kim Stanley Robinson, author of the Mars Trilogy, 2312, and Shaman. </description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/KSR%202015%20Show.mp3" length="39646827" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/sci-fi-author-kim-stanley-robinson-talks-life-science-2015/</guid>
 <pubDate>Tue, 22 Dec 2015 12:00:09 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Aurora.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> Yes to FDA Regulation of LDTs, But We Need a New Framework, Says David Spetzler</title>
 <link>https://mendelspod.com/podcasts/yes-fda-regulation-ldts-we-need-new-framework-says-david-spetzler/</link>
 <description>We set up an interview with David Spetzler, the CSO of Caris Life Sciences, to hear about some promising new liquid biopsy tests they are developing.  And we do that in today’s show.  But first, the interview takes a turn toward the regulation of molecular tests.  Spetzler says that Caris is already doing as many quality certifications as possible short of FDA oversight.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/David%20Spetzler%20Show.mp3" length="31103163" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/yes-fda-regulation-ldts-we-need-new-framework-says-david-spetzler/</guid>
 <pubDate>Thu, 03 Dec 2015 09:05:30 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/David-Spetzler.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Genomics and the Cloud Going Through “a Second Puberty,” says AWS’ Angel Pizarro</title>
 <link>https://mendelspod.com/podcasts/genomics-and-cloud-going-through-second-puberty-says-aws-angel-pizarro/</link>
 <description>Angel Pizarro has watched as genomics and cloud computing have grown up together.   Formerly a bioinformatics director at University of Pennsylvania, Angel is now the Technical Business Development Manager at Amazon Web Services.

At U Penn, Angel was part of the shift from setting up one’s own facility with expensive computer equipment for handling the rapid growth of omics data to using a third party service, such as AWS.  He says that genomics and the cloud are both going through a &quot;second puberty.” In today&#039;s show, Angel explains growing pains involved.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Angel%20Pizarro%20Show.mp3" length="30473307" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/genomics-and-cloud-going-through-second-puberty-says-aws-angel-pizarro/</guid>
 <pubDate>Tue, 24 Nov 2015 09:27:22 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Angel%20Pizarro.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Hot Biotech Market Neglects Stem Cell Therapies, Says CIRM&#039;s Neil Littman</title>
 <link>https://mendelspod.com/podcasts/hot-biotech-market-neglects-stem-cell-therapies-says-cirms-neil-littman/</link>
 <description>In 2004, California voters approved Prop 71 to fund the field of stem cell research by setting up the California Institute of Regenerative Medicine, or CIRM, with $3 billion.  George W. Bush was in the White House at the time, and since 2001, his administration had been limiting research that used embryonic stem cells.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Neil%20Littman%20Show.mp3" length="25132059" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/hot-biotech-market-neglects-stem-cell-therapies-says-cirms-neil-littman/</guid>
 <pubDate>Wed, 18 Nov 2015 09:57:17 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Neil%20Littman.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>The Future of Diagnostics Reimbursement with Bruce Quinn</title>
 <link>https://mendelspod.com/podcasts/future-diagnostics-reimbursement-bruce-quinn/</link>
 <description>We toss the term &quot;precision medicine&quot; around with ease today, and yet payers continue to refuse to pay for diagnostic tests.
These are tests that might indicate which treatment will work for a specific patient, thereby saving perhaps hundreds of thousands of dollars, not to mention protecting the patient from unnecessary harm. These are tests which prevent invasive procedures such as unnecessary biopsies.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Bruce%20Quinn%20Show.mp3" length="25120827" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/future-diagnostics-reimbursement-bruce-quinn/</guid>
 <pubDate>Thu, 12 Nov 2015 08:45:00 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Bruce%20Quinn.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Framingham for the Modern Era:  Josie Briggs on the Precision Medicine Initiative</title>
 <link>https://mendelspod.com/podcasts/framingham-modern-era-josie-briggs-precision-medicine-initiative/</link>
 <description>Josie Briggs is Director of the National Center for Complementary and Integrative Health (NCCIH) at the NIH.  She is also currently serving as interim director of the president’s new Precision Medicine Initiative (PMI).

What has happened since the president announced the initiative, what is the proposed timeline going forward, and how much money will there be for the project ongoing?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Josie%20Briggs%20Show.mp3" length="20941227" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/framingham-modern-era-josie-briggs-precision-medicine-initiative/</guid>
 <pubDate>Wed, 04 Nov 2015 09:54:30 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/JosieBriggs.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> Do Alternate Proposals to Regulate LDTs Stand a Chance?</title>
 <link>https://mendelspod.com/podcasts/do-alternate-proposals-regulate-ldts-stand-chance/</link>
 <description>As the FDA works away on final guidance for regulating LDTs, various professional groups unhappy with the course of the FDA have put together and hurried their own proposals up to Captiol Hill. The Diagnostic Testing Working Group (DTWG) has had their proposal drafted into legislation which has already been revised once in the House Energy and Commerce Committeee, while proposals from the College of American Pathologists (CAP) and the Association of Molecular Pathology (AMP) have been presented to both the Senate and the House.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Scott%20McGoohan%20Show.mp3" length="26017227" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/do-alternate-proposals-regulate-ldts-stand-chance/</guid>
 <pubDate>Wed, 28 Oct 2015 22:05:20 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Scott%20McGoohan.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Does the Reproducibility Project in Cancer Biology Offer a Model for a New Kind of Science Auditing?</title>
 <link>https://mendelspod.com/podcasts/does-reproducibility-project-cancer-biology-offer-model-new-kind-science-auditing/</link>
 <description>Here on the show, we’ve talked about the lack of reproducibility for much of biological research.  We’ve bandied around various percentages--is it 50% or up to 90% that can&#039;t be replicated?  And we’ve poked around various issues that may be causing such poor science.

Nicole Perfito is the manager of the Reproducibility Project: Cancer Biology, an effort between Science Exchange and the Center for Open Science.  The goal of this project is to take nearly forty “high impact” papers in the field of cancer and try to replicate them.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Nicole%20Perfito%20Show.mp3" length="25683723" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/does-reproducibility-project-cancer-biology-offer-model-new-kind-science-auditing/</guid>
 <pubDate>Tue, 27 Oct 2015 09:26:01 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Nicole%20Perfito.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>After CMS Announcement, Peter Maag and CareDx Fight for Life</title>
 <link>https://mendelspod.com/podcasts/after-cms-announcement-peter-maag-and-caredx-fight-life/</link>
 <description>By listening to him, you wouldn’t know that Peter Maag, the CEO of CareDx, was fighting to keep his company from the brink. We booked Peter for the show after &lt;a href=&quot;http://www.bizjournals.com/sanfrancisco/blog/biotech/2015/10/caredx-cdna-heart-transplant-allomap-cms-medicare.html&quot;&gt;news came out&lt;/a&gt; that CMS was once again threatening to lower reimbursement rates of established diagnostic tests.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Peter%20Maag%20Show.mp3" length="20872971" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/after-cms-announcement-peter-maag-and-caredx-fight-life/</guid>
 <pubDate>Thu, 22 Oct 2015 09:01:28 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/PeterMaag.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> The Goal Is De Novo Assembly in the Clinic, Says Jim Lupski, Baylor</title>
 <link>https://mendelspod.com/podcasts/goal-de-novo-assembly-clinic-says-jim-lupski-baylor/</link>
 <description>Today’s story is one of a personal quest, of groundbreaking science, and the creation of a new movement in human genomics.

Jim Lupski is a professor at Baylor College of Medicine where he’s on the frontline of incorporating genomic research into everyday clinical practice.  The story begins with Jim’s own genome, which is perhaps the most sequenced genome ever.  Jim&#039;s life as a leading genomic researcher has been driven in part for a strong personal reason.   He has a rare genetic disease named after three researchers who first defined it, Charcot Marie Tooth Neuropathy.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/James%20Lupski%20Show.mp3" length="24855579" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/goal-de-novo-assembly-clinic-says-jim-lupski-baylor/</guid>
 <pubDate>Tue, 20 Oct 2015 08:51:55 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/James%20Lupski.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Cliff Reid Says New Supersequencer Leads the Pack for High Throughput Clinical Sequencing</title>
 <link>https://mendelspod.com/podcasts/cliff-reid-says-new-supersequencer-leads-pack-high-throughput-clinical-sequencing/</link>
 <description>Cliff Reid, CEO of Complete Genomics, is back on the conference circuit, touting a new product.  After years of building his company to do sequencing as a service, Cliff presented data at last week&#039;s ASHG meeting on Complete&#039;s first sequencer as a product, or what they are calling the Revolocity supersequencer.

Cliff was a pioneer in developing the service model, offering only whole human genome sequencing.  But after being bought out by BGI, who already had a service business in China, he was compelled to shift his business model to that of selling sequencers.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Cliff%20Reid%20Show%20Oct%202015.mp3" length="30915675" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/cliff-reid-says-new-supersequencer-leads-pack-high-throughput-clinical-sequencing/</guid>
 <pubDate>Fri, 16 Oct 2015 09:38:02 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Cliff%20Reid%202015.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> Defending the Value of Biotech Innovation in California: Sara Radcliffe, CLSA</title>
 <link>https://mendelspod.com/podcasts/defending-value-biotech-innovation-california-sara-radcliffe-clsa/</link>
 <description>Earlier this year, the California Life Sciences Association (CLSA) launched, becoming the first statewide policy and advocacy group for biotech. The new nonprofit, a merger between BayBio and the California Healthcare Institute, is led by CEO Sara Radcliffe, former Executive VP of Health at the international Biotechnology Industry Organization (BIO) in Washington.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Sara%20Radcliffe%202015.mp3" length="22868406" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/defending-value-biotech-innovation-california-sara-radcliffe-clsa/</guid>
 <pubDate>Thu, 08 Oct 2015 20:03:54 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/SaraRadcliffe.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Long Read Sequencing  Dramatically Improves Blood Matching: Steven Marsh, Anthony Nolan Institute</title>
 <link>https://mendelspod.com/podcasts/long-read-sequencing-dramatically-improves-blood-matching-steven-marsh-anthony-nolan/</link>
 <description>One of the popular questions on the program this past year is how those doing sequencing decide between the quality of Pacific Bioscience&#039;s long reads and the cheaper short read technology, such as that of Illumina or Thermo Fisher.  Today’s guest provides the most clear and dramatic answer yet: use the PacBio system exclusively.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Steve%20Marsh%20Show.mp3" length="25378731" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/long-read-sequencing-dramatically-improves-blood-matching-steven-marsh-anthony-nolan/</guid>
 <pubDate>Tue, 06 Oct 2015 09:10:54 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Steven%20Marsh.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>The World of DIY Genomics with K T Pickard</title>
 <link>https://mendelspod.com/podcasts/world-diy-genomics-k-t-pickard/</link>
 <description>K Thomas Pickard is not at all into sports cars.   So when he hit midlife crisis, it wasn’t a Porsche or a golf club membership that would reenergize his quiet moments.  Nope.  K T got his genome sequenced.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/KT%20Pickard%20Show.mp3" length="30539835" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/world-diy-genomics-k-t-pickard/</guid>
 <pubDate>Thu, 01 Oct 2015 13:07:16 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/KTPickard.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Sequencing in Space:  Chris Mason, Cornell</title>
 <link>https://mendelspod.com/podcasts/sequencing-space-chris-mason-cornell/</link>
 <description>The last time we talked with Chris Mason of Weill Cornell Medical College the Supreme Court had just decided the controversial Myriad gene patent case.  How forever ago two years can seem.  Since then Chris has swabbed and sequenced the microbiome of New York City and began the project of sequencing in space.

His favorite research this year has been to longitudinally profile the genome, epigenome, transcriptome, metabolome and microbiome of identical twins, one in space and one on earth.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Chris%20Mason%20Show.mp3" length="32425947" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/sequencing-space-chris-mason-cornell/</guid>
 <pubDate>Thu, 24 Sep 2015 09:08:31 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Chris%20Mason_0.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Is the Future of Biology a Return to Chemistry?  Carolyn Bertozzi, Stanford</title>
 <link>https://mendelspod.com/podcasts/future-biology-return-chemistry-carolyn-bertozzi-stanford/</link>
 <description>Classes for the school year begin this week at Stanford University.    New to the faculty is Carolyn Bertozzi, an American chemist who made her name across the bay at Berkeley and was wooed to Stanford by a chance to do research and teach chemistry in a new interdisciplinary institute known as ChEM-H.  The institute will bring chemists, engineers, biologists and medical doctors together to understand life at a chemical level.  We’ve often heard of biology and engineering institutes, or bringing bio and IT.  This institute ups the ante and includes chemistry and medicine.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Carolyn%20Bertozzi%20Show.mp3" length="28425195" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/future-biology-return-chemistry-carolyn-bertozzi-stanford/</guid>
 <pubDate>Mon, 21 Sep 2015 21:38:34 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/CarolynBertozzi.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Going Beyond the $1,000 Genome with Mark Gerstein</title>
 <link>https://mendelspod.com/podcasts/going-beyond-1000-genome-mark-gerstein/</link>
 <description>Though recent guests at Mendelspod say we&#039;re not quite to the $1,000 genome, we&#039;re close enough to use that benchmark in genomics discussions.  But what are we getting for that almost $1,000?

Mark Gerstein is the co-director of the Yale Computational Biology and Bioinformatics program where he focuses on better annotation of the human genome and better ways to mine big genomics data.  He has played a big role in some of the large genomics initiatives since the first human genome project, including ENCODE and the 1,000 Genomes Project.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Mark%20Gerstein%20Show.mp3" length="31253931" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/going-beyond-1000-genome-mark-gerstein/</guid>
 <pubDate>Thu, 17 Sep 2015 09:00:03 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Mark_Gerstein.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Creating the Foundation of Genomics: Marc Salit, NIST</title>
 <link>https://mendelspod.com/podcasts/creating-foundation-genomics-marc-salit-nist/</link>
 <description>What is a human genome?  Well it’s the three billion letters of our DNA.  But how is it measured?  How do we know when we have it accurately represented?

These are questions that will have to be answered as precision medicine takes hold; for we must have defined standards that will be the basis for regulatory policy, commerce, and better research.  These are also the questions that are foremost on the mind of today’s guest.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Marc%20Salit%20Show.mp3" length="32725755" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/creating-foundation-genomics-marc-salit-nist/</guid>
 <pubDate>Thu, 10 Sep 2015 10:15:46 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/MarcSalit.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Still Unhappy with FDA’s Plan to Regulate LDTs, Professional Lab Groups Go Direct to the Senate </title>
 <link>https://mendelspod.com/podcasts/still-unhappy-fdas-plan-regulate-ldts-professional-groups-go-direct-senate/</link>
 <description>It&#039;s no secret that America&#039;s molecular testing laboratories by and large are worried that the FDA&#039;s plan to regulate laboratory developed tests, or LDTs, will severely harm patients. Now they have a new proposal which they are taking directly to Capitol Hill.
Roger Klein is the Medical Director of Molecular Oncology at the Cleveland Clinic. He’s also serving as the spokesperson for the Association for Molecular Pathology (AMP) on the controversial topic of regulating LDTs.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Roger%20Klein%20Show.mp3" length="26275995" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/still-unhappy-fdas-plan-regulate-ldts-professional-groups-go-direct-senate/</guid>
 <pubDate>Tue, 08 Sep 2015 11:12:14 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/RogerKlein.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>A Diagnostic Success Story with Alka Chaubey, Greenwood Genetic Center</title>
 <link>https://mendelspod.com/podcasts/diagnostic-success-story-alka-chaubey-greenwood-genetic-center/</link>
 <description>Diagnostics can be a tough business.  The FDA is making a strong push to bring more oversight.  Obtaining reimbursement can be outright Sisyphean.  And clinicians are slow on the uptake.  All of which makes today’s story so good.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Alka%20Chaubey%20Complete%20Show.mp3" length="27244080" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/diagnostic-success-story-alka-chaubey-greenwood-genetic-center/</guid>
 <pubDate>Thu, 03 Sep 2015 10:24:40 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/AlkaChaubey.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>With Two New Easy-to-Use Sequencing Instruments, Thermo Readies for Primetime in the Clinic</title>
 <link>https://mendelspod.com/podcasts/two-new-easy-use-sequencing-instruments-thermo-readies-primetime-clinic/</link>
 <description>The race to the $1,000 genome has been full of breathtaking advances, one after the other. But is next gen sequencing reaching maturity? Will there be that many more significant innovations?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Thermo%20S5%20Show.mp3" length="22876155" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/two-new-easy-use-sequencing-instruments-thermo-readies-primetime-clinic/</guid>
 <pubDate>Tue, 01 Sep 2015 09:02:03 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Screen%20Shot%202015-09-01%20at%207.31.02%20AM.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Here&#039;s Looking at Euclid</title>
 <link>https://mendelspod.com/podcasts/heres-looking-euclid/</link>
 <description>A slow week in life science left us scratching our heads about the purpose of some new studies.

The first, a major project to study the microbes in about 1,200 homes appeared under headlines such as this from Tech Times, &quot;Household Bacteria Can Reveal Volumes about Home Residents.&quot;  Volumes?  Really?

A second study claimed that we are less successful at biomedical research today because life expectancy is not going up at the same rate as the growth in funding or the increasing number of scientists.  That&#039;s a high bar to set.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/G%26TShowAug28.mp3" length="4823307" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/heres-looking-euclid/</guid>
 <pubDate>Fri, 28 Aug 2015 12:36:46 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/casablanca.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> Is This the Future of Clinical Trials for Cancer?  Stanley Hamilton on the NCI’s New MATCH Trial</title>
 <link>https://mendelspod.com/podcasts/future-clinical-trials-cancer-stanley-hamilton-ncis-new-match-trial/</link>
 <description>It’s taken some time, but the NCI is finally sponsoring a big time clinical trial for cancer where the patients are organized by the genomic pathway that defines their cancer rather than the organ type.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Stanley%20Hamilton%20Show.mp3" length="26892459" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/future-clinical-trials-cancer-stanley-hamilton-ncis-new-match-trial/</guid>
 <pubDate>Wed, 26 Aug 2015 19:56:47 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Stanley%20Hamilton.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Brian Kennedy and Aubrey de Grey on their Converging Approaches to Aging Research</title>
 <link>https://mendelspod.com/podcasts/brian-kennedy-and-aubrey-de-grey-their-converging-approaches-aging-research/</link>
 <description>Last week we attended the 2015 Rejuvenation Biotechnology Conference where we heard about the latest developments in aging research.

We were fortunate enough to sit down with two of the major figures in the field of aging research, Aubrey de Grey, CSO of the SENS Research Foundation and Brian Kennedy, CEO of the Buck Institute for Research on Aging.  Brian and Aubrey have gone about their work in different ways but say that their approaches are now converging as the momentum behind aging research increases.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Aubrey%20and%20Brian%20Show.mp3" length="22856283" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/brian-kennedy-and-aubrey-de-grey-their-converging-approaches-aging-research/</guid>
 <pubDate>Tue, 25 Aug 2015 08:56:58 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Rejbiocon.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>The Business of Aging and Three Reasons Why the FDA Drug Approval Rate Is So High</title>
 <link>https://mendelspod.com/podcasts/business-aging-and-three-reasons-why-fda-drug-approval-rate-so-high/</link>
 <description>We&#039;re back in the office after a fabulous vacation, and ready to have some fun.  It&#039;s Friday, and time for Gene and Tonic.

Yes, we celebrate the news this week that women have their own sex pill.  And we make our best guesses as to why the FDA&#039;s drug approval rate is up in the stratosphere.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/G%26TShowAug21.mp3" length="5576283" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/business-aging-and-three-reasons-why-fda-drug-approval-rate-so-high/</guid>
 <pubDate>Fri, 21 Aug 2015 13:48:58 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/FDA%20approved.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>New York Genome Center’s Nathan Pearson on Public Outreach for Genomics</title>
 <link>https://mendelspod.com/podcasts/new-york-genome-center%E2%80%99s-nathan-pearson-public-outreach-genomics/</link>
 <description>Nathan Pearson, formerly a genome scientist at Ingenuity and Knome, has been doing public outreach for genomics at the New York Genome Center for about a year now.   In today’s interview, Nathan says he always wanted to be able to speak directly to the larger public about the great science he’s been involved in.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Nathan%20Pearson%20Aug%202015%20Show.mp3" length="35443467" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/new-york-genome-center%E2%80%99s-nathan-pearson-public-outreach-genomics/</guid>
 <pubDate>Tue, 18 Aug 2015 19:39:59 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/NathanPearson2.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Tim Triche on Using Arrays for Cancer Research</title>
 <link>https://mendelspod.com/podcasts/tim-triche-using-arrays-cancer-research/</link>
 <description>We recently interviewed cancer researcher Tim Triche from Children&#039;s Hospital Los Angeles. Tim had two main points: First, microarrays are still a very valuable tool for research and for the clinic. Second, there are perhaps more answers for cancer research to be found in the non-coding portion of the genome than in the genes.
Here, we&#039;ve compiled Tim&#039;s comments on the staying power of arrays.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Tim%20Triche%20on%20Using%20Arrays%20in%20Cancer%20Research_0.mp3" length="8096139" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/tim-triche-using-arrays-cancer-research/</guid>
 <pubDate>Fri, 31 Jul 2015 15:18:42 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Timothy-Triche_0.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> Thermo’s Chris Linthwaite on Sequencing the Ebola Virus and the Future of Public Health</title>
 <link>https://mendelspod.com/podcasts/thermos-chris-linthwaite-sequencing-ebola-virus-and-future-public-health/</link>
 <description>Major outbreaks of deadly viruses, such as the recent spread of Ebola in Northern Africa, are nothing new on planet earth.  What is new is the technology that we are using to identify, track, and contain such plagues.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Chris%20Linthwaite%20Show.mp3" length="25320411" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/thermos-chris-linthwaite-sequencing-ebola-virus-and-future-public-health/</guid>
 <pubDate>Mon, 27 Jul 2015 21:22:15 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/ChrisLinthwaite.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>A Tool to Strengthen the Voice of Science in Online Journalism</title>
 <link>https://mendelspod.com/podcasts/tool-strengthen-voice-science-online-journalism/</link>
 <description>Emmanuel Vincent is the founder of &lt;a href=&quot;http://www.climatefeedback.org&quot;&gt;Cl&lt;/a&gt;&lt;a href=&quot;http://www.climatefeedback.org&quot; target=&quot;_blank&quot;&gt;i&lt;/a&gt;&lt;a href=&quot;http://www.climatefeedback.org&quot;&gt;mate Feedback&lt;/a&gt;, a project which includes a new tool for scientists to comment directly on climate science news. The tool is a plugin which can be downloaded for free and gives a viewer real time access to the feedback of scientists on a particular online article.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Emmanuel%20Vincent%20Show.mp3" length="24251211" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/tool-strengthen-voice-science-online-journalism/</guid>
 <pubDate>Thu, 23 Jul 2015 08:57:01 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/EmmanuelVincent.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Father of Child with Rare Disease Says Science Equals Medicine</title>
 <link>https://mendelspod.com/podcasts/father-child-rare-disease-says-science-equals-medicine/</link>
 <description>Matt Might came knocking on the door of genomic medicine out of pure necessity. After a four year diagnostic odyssey that led them to Duke University, Matt and his wife, Cristina, finally found out through exome sequencing that their son, Bertrand, was suffering from a rare disease known as NGLY1 deficiency. That was three years ago.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Matt%20Might%20Show.mp3" length="24236955" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/father-child-rare-disease-says-science-equals-medicine/</guid>
 <pubDate>Tue, 21 Jul 2015 09:36:00 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/MattMight.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Bina CEO Details Secret to Success in NGS Informatics</title>
 <link>https://mendelspod.com/podcasts/bina-ceo-details-secret-success-ngs-informatics/</link>
 <description>Last year, pharma giant Roche went on a buying spree, picking up one company after another.  In December, when it was announced they had bought out Bina Technologies, many of us were playing catch up.  Who is Bina, and how do they fit in the overall bioinformatics space?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Narges%20Bani%20Asadi%20Show.mp3" length="28594107" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/bina-ceo-details-secret-success-ngs-informatics/</guid>
 <pubDate>Fri, 17 Jul 2015 11:06:30 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Narges-Bani-Asadi.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Cancer Researcher Tim Triche on the Staying Power of Microarrays</title>
 <link>https://mendelspod.com/podcasts/cancer-researcher-tim-triche-staying-power-microarrays/</link>
 <description>In the second part of our interview with Tim Triche, Director of the Personalized Medicine Center at Children’s Hospital Los Angeles, Tim says that micro arrays are still a vital technology for today’s cancer researcher. Making use of both next-gen sequencing and arrays for his research, Tim confirms that arrays still have advantages in the clinic as well, such as quicker turn around time. 
Tim also weighs in on some ongoing questions about whether poor biospecimen quality is hampering research efforts and whether genomic medicine is paying off for patients. </description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Tim%20Triche%20Show%20Part%202.mp3" length="20647899" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/cancer-researcher-tim-triche-staying-power-microarrays/</guid>
 <pubDate>Mon, 13 Jul 2015 21:25:57 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/TimTriche.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> Want Answers? Look to the Non-Coding Region of the Genome, Says Cancer Researcher, Tim Triche</title>
 <link>https://mendelspod.com/podcasts/want-answers-look-non-coding-region-genome-says-cancer-researcher-tim-triche/</link>
 <description>Listen to Tim Triche from Children&#039;s Hospital Los Angeles for very long and you’ll get excited again about cancer research. I couldn’t stop listening. Which is why his interview is being published in two parts.
Now sure, like other guests we’ve had on the show, Tim calls this the “absolute golden age of biomedical research.” But Tim has a unique story. He has been, and is still - though less so now, he says - an outlier in cancer genomics. Whereas most cancer researchers talk about genes, Tim is more interested in non-coding RNA.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Tim%20Triche%20Show%20Part%201_0.mp3" length="26724843" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/want-answers-look-non-coding-region-genome-says-cancer-researcher-tim-triche/</guid>
 <pubDate>Wed, 08 Jul 2015 19:37:16 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Timothy-Triche.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Ivan Oransky on Today&#039;s Retraction Boom</title>
 <link>https://mendelspod.com/podcasts/ivan-oransky-todays-retraction-boom/</link>
 <description>When science journalist Ivan Oransky co-founded Retraction Watch, a blog with the express purpose of making scientific retractions more public, he didn’t think he would be posting much.
“Adam Marcus, my co-founder, was quoted as saying, ‘yeah, we figured we’d post periodically, our mothers would read it, they’d be very happy, nobody would read it other than them.’ Obviously that hasn’t been the case,” says Oransky in this first of a series of podcasts on scientific integrity.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Ivan%20Oransky%20Show.mp3" length="35570043" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/ivan-oransky-todays-retraction-boom/</guid>
 <pubDate>Tue, 07 Jul 2015 10:48:47 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/ivan-oransky.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Genomics-Palooza, Diagnostics Fraud, and Biblical Prophets on the Future of Biotech</title>
 <link>https://mendelspod.com/podcasts/genomics-palooza-diagnostics-fraud-and-biblical-prophets-future-biotech/</link>
 <description>What a week for Americans . . . What a week for genomics!
The Supreme Court rulings that Americans can keep their Obamacare and can all get married - no matter what state they live in - added the final good news to a week of genomics festivities around the country.
But it&#039;s not all positive news this week. The New York Times featured a diagnostics company under review by Medicare for fraud. Allegedly, the New Orleans based Renaissance Rx has been paying doctors to sign up patients for a huge trial of genomic based tests, even when the patients didn&#039;t qualify.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/G%26TShowJune%2026.mp3" length="6045867" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/genomics-palooza-diagnostics-fraud-and-biblical-prophets-future-biotech/</guid>
 <pubDate>Fri, 26 Jun 2015 11:59:36 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/GeorgefromBehind.jpeg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> Ethical Issues around Editing Human Germline for the Future.  Today It&#039;s about Plants and Animals, Says  NYU&#039;s Art Caplan</title>
 <link>https://mendelspod.com/podcasts/ethical-issues-around-editing-human-germline-future-today-its-about-plants-and-animals-says/</link>
 <description> Art Caplan is a prodigious writer on the topic of medical ethics. How prodigious? How about thirty-two books and over 700 peer reviewed papers on ethical conundrums ranging from organ donation to end of life care.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Art%20Caplan%20Show.mp3" length="31538187" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/ethical-issues-around-editing-human-germline-future-today-its-about-plants-and-animals-says/</guid>
 <pubDate>Tue, 23 Jun 2015 21:15:54 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Art%20Caplan.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>We Got Research, PCSK9 Inhibitors, and Clinical Trials for Religion</title>
 <link>https://mendelspod.com/podcasts/we-got-research-pcsk9-inhibitors-and-clinical-trials-religion/</link>
 <description>The international BIO convention is all about seduction.  All fifty states sent representatives to Philly this week to make the case that their state was the best for biotech. Seventy countries were there touting their awesome awesomeness.  
Does all this seduction really work?
A new class of drugs for cardiovascular disease was reviewed recently at the FDA.  Will they become blockbusters like Pfizer’s Lipitor?  </description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/G%26TShowJune%2019.mp3" length="6889995" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/we-got-research-pcsk9-inhibitors-and-clinical-trials-religion/</guid>
 <pubDate>Fri, 19 Jun 2015 09:49:02 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Statins.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>The Multi-Platform Approach to Clinical Sequencing with Bobby Sebra, Icahn School</title>
 <link>https://mendelspod.com/podcasts/multi-platform-approach-clinical-sequencing-bobby-sebra-icahn-school/</link>
 <description>Before Bobby Sebra became the Director of Technology Development at the Icahn School of Medicine at Mt Sinai in New York he worked at Pacific Biosciences, helping to develop their single molecule, long read (SMRT) sequencing technology.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Bobby%20Sebra%20Show.mp3" length="29207547" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/multi-platform-approach-clinical-sequencing-bobby-sebra-icahn-school/</guid>
 <pubDate>Mon, 15 Jun 2015 12:42:21 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/BobbySebra.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>So That Happened, The Mad Genius, and Selling SynBio</title>
 <link>https://mendelspod.com/podcasts/so-happened-mad-genius-and-selling-synbio/</link>
 <description>It’s a week of finding out again what we already knew.  First that a nobel laureate can also be a total ***hole.  And second that creative people really are crazy.

It’s also been a week for going into the future.  This week Team Mendelspod attended IndieBio’s Demo Day.  Twelve, mostly very young, founder/geeks pitched their new ideas for making the world a better place to a room of investors in downtown San Francisco.  We saw some amazing technology, but the real question seems to be, how will they sell these new synthetic biology products?!?.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/G%26TShowJune%2012.mp3" length="5968539" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/so-happened-mad-genius-and-selling-synbio/</guid>
 <pubDate>Fri, 12 Jun 2015 11:59:31 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/indieBioLogoLg.png" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Summer Genomics Festival, the Other Sports Genes, and Brain Surgery for Fruit Flies</title>
 <link>https://mendelspod.com/podcasts/summer-genomics-festival-other-sports-genes-and-brain-surgery-fruit-flies/</link>
 <description>Gene and Tonic for June 5, 2015
What does genomics have to do with a hippie rock music event?  A few things.  Find out in today’s humorous preview of the Festival of Genomics, happening later this month in Boston.  
Yes, there are the sports genes everyone knows about.  But what about those less studied that might affect your career in sports?  Do you know what is written on the sports page of your genome?
And what has Ben Carson considering brain surgery?  Tune in to this week’s wrap of genomics news - it’s another Gene and Tonic from Mendelspod.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/G%26TShowJune%205.mp3" length="5572395" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/summer-genomics-festival-other-sports-genes-and-brain-surgery-fruit-flies/</guid>
 <pubDate>Fri, 05 Jun 2015 10:13:09 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/summer-festival.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>The Sports Genes with Jeremy Koenig, Athletigen</title>
 <link>https://mendelspod.com/podcasts/sports-genes-jeremy-koenig-athletigen/</link>
 <description>Jeremy Koenig is a molecular biologist and an athlete. His interest in both led him to found a new direct-to-consumer genetic testing company called Athletigen.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Jeremy%20Koenig%20Show.mp3" length="24341931" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/sports-genes-jeremy-koenig-athletigen/</guid>
 <pubDate>Wed, 03 Jun 2015 20:49:50 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/JeremyKoenig.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Woodstock for Genomics?  Richard Lumb and Carl Smith on this Month’s Festival</title>
 <link>https://mendelspod.com/podcasts/woodstock-genomics-richard-lumb-and-carl-smith-months-festival/</link>
 <description>If you haven’t already, check out the inaugural &lt;a href=&quot;http://www.festivalofgenomics.com&quot; target=&quot;_blank&quot;&gt;Festival of Genomics&lt;/a&gt; being held in Boston later this month.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/FLG%20Show_0.mp3" length="19655595" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/woodstock-genomics-richard-lumb-and-carl-smith-months-festival/</guid>
 <pubDate>Mon, 01 Jun 2015 20:21:13 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/FestivalofGenomics.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Geneticists Anonymous, the Sad State of Science Journalism, and New Kids on the Helix</title>
 <link>https://mendelspod.com/podcasts/geneticists-anonymous-sad-state-science-journalism-and-new-kids-helix/</link>
 <description>Gene and Tonic: May 29, 2015
Did you hear?  The Age of Genomics has come to an end.  
According to science journalist, David Dobbs, after 110 years of studying genomics, we have come up with almost nothing to improve human health, or as Dobbs put it so elegantly, we ain&#039;t got  &quot;&lt;a href=&quot;http://www.buzzfeed.com/daviddobbs/weighing-the-promises-of-big-genomics&quot; target=&quot;_blank&quot;&gt;diddly-squat&lt;/a&gt;.&quot;  
What will all of our geneticist friends do?  They don&#039;t want to be known as &quot;diddlly-squaticists.&quot;</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/G%26TShowMay29_0.mp3" length="5807835" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/geneticists-anonymous-sad-state-science-journalism-and-new-kids-helix/</guid>
 <pubDate>Fri, 29 May 2015 11:26:33 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/recovery_0.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> The 9 Billion People Problem:  Rod Wing on Plant Genomics</title>
 <link>https://mendelspod.com/podcasts/9-billion-people-problem-rod-wing-plant-genomics/</link>
 <description>By 2050, there will be 9 billion people on the planet. What will they eat?
This is the question that led Rod Wing, Director of the Arizona Genomics Institute, into the field of plant genomics. What has been accomplished so far in the mission to come up with some super green crops?  And how does Rod see anti-GMO sentiment and the recent trend toward gluten free diets factoring in? </description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Rod%20Wing%20Show.mp3" length="33518475" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/9-billion-people-problem-rod-wing-plant-genomics/</guid>
 <pubDate>Tue, 26 May 2015 19:48:49 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/rodwing.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Should We Hold Back the Reins on Biotechnology? with Chris Gunter</title>
 <link>https://mendelspod.com/podcasts/should-we-hold-back-reins-biotechnology-chris-gunter/</link>
 <description>A very unique biotechnology event took place this week.

BEINGS 2015, or the Biotech and the Ethical Imagination Global Summit, was held at The Tabernacle, a former church turned concert hall in Atlanta, Georgia.  The venue was not the only unusual thing for a summit about science.  Speakers at the meeting included a well known linguist, a famous Canadian novelist, and Catholic rector along with professors of bioethics, law, and, of course, biology.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Chris%20Gunter%20Show.mp3" length="28124955" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/should-we-hold-back-reins-biotechnology-chris-gunter/</guid>
 <pubDate>Thu, 21 May 2015 19:47:03 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/chrisgunterweb.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Are We Ready to Trust Liquid Biopsies? with Milena Cankovic, Henry Ford Hospital</title>
 <link>https://mendelspod.com/podcasts/are-we-ready-trust-liquid-biopsies-milena-cankovic-henry-ford-hospital/</link>
 <description>If you followed the news from the recent show of the American Association for Cancer Research (AACR), no doubt you heard about the exciting potential of liquid biopsies.  These new blood-based tests, made possible by better tools and analysis techniques, offer a non-invasive way of understanding various cancers.  Traditionally, with non-hematological cancers, solid tumor biopsies are obtained through surgical recession or an invasive needle.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Milena%20Cankovic%20Show.mp3" length="23465403" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/are-we-ready-trust-liquid-biopsies-milena-cankovic-henry-ford-hospital/</guid>
 <pubDate>Tue, 19 May 2015 08:03:00 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Milena_indiv1.JPG" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Gene and Tonic: Boxing for Cancer, Dubious Correlations, and When Should a Researcher Retire</title>
 <link>https://mendelspod.com/podcasts/gene-and-tonic-boxing-cancer-dubious-correlations-and-when-should-researcher-retire/</link>
 <description> 
In a keynote talk this week for the &lt;a href=&quot;http://labroots.com/virtual-event/id/5&quot; target=&quot;_blank&quot;&gt;online Genetics and Genomics conference&lt;/a&gt;, computational biology whiz, John Quackenbush, listed some pretty wild correlations found by a Harvard Business School student when he mixed some large data sets.  For example, U.S. spending on science, space, and technology corresponds directly with suicides by hanging, strangulation and suffocation.  We never would have guessed it without the help of big data.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/G%26TShowMay15.mp3" length="6346107" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/gene-and-tonic-boxing-cancer-dubious-correlations-and-when-should-researcher-retire/</guid>
 <pubDate>Fri, 15 May 2015 11:34:38 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/gin-and-tonic_7.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> New Patient Focused Genome Magazine Signing up Many Doctors Too</title>
 <link>https://mendelspod.com/podcasts/new-patient-focused-genome-magazine-signing-many-doctors-too/</link>
 <description>Just as biomedical research is experiencing a surge of translation into clinical application, so too must the stories of this research and its impact in the lives of patients be translated to a larger audience.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Jeanette%20McCarthy%20Show.mp3" length="18367803" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/new-patient-focused-genome-magazine-signing-many-doctors-too/</guid>
 <pubDate>Mon, 11 May 2015 20:00:00 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/JeanetteMcCarthyWeb.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Gene and Tonic: The Decline of Pseudoscience, An Atheist for President, and What to Do with a Sexist Reviewer</title>
 <link>https://mendelspod.com/podcasts/gene-and-tonic-decline-pseudoscience-atheist-president-and-what-do-sexist-reviewer/</link>
 <description>The New Republic argued in a pice entitled, &quot;&lt;a href=&quot;http://www.newrepublic.com/article/121704/decline-pseudoscience&quot; target=&quot;_blank&quot;&gt;The Decline of Pseudos&lt;/a&gt;&lt;a href=&quot;http://www.newrepublic.com/article/121704/decline-pseudoscience&quot; target=&quot;_blank&quot;&gt;cience&lt;/a&gt;,&quot; this week that now that the so called &quot;natural&quot; living industry has gone mainstream, &quot;it&#039;s days are numbered.&quot;  Surely Oprah&#039;s dumping of Dr. Oz backs this up.   But other events this week show a different story.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/G%26TShowMay8.mp3" length="6521931" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/gene-and-tonic-decline-pseudoscience-atheist-president-and-what-do-sexist-reviewer/</guid>
 <pubDate>Fri, 08 May 2015 10:55:03 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/gin-and-tonic_6.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title>Gene and Tonic: Sexism in Science, How to Spend an NIH Budget Increase, How Not to Spend It</title>
 <link>https://mendelspod.com/podcasts/gene-and-tonic-sexism-science-how-spend-nih-budget-increase-how-not-spend-it/</link>
 <description>Janitors have had a terribly busy time this week cleaning up all those jaws that were dropped on floors of research labs everywhere around the country.
Have you heard about this latest sexism scandal?
Two female co-authors of a scientific paper submitted their work to PLOS -- you know, the open access journal.   You won’t believe what they heard back from the lone peer reviewer.  They were told to go find “one or two male biologists” to be co-authors on the paper to increase its chances of being published.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/G%26TShowMay1.mp3" length="6147387" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/gene-and-tonic-sexism-science-how-spend-nih-budget-increase-how-not-spend-it/</guid>
 <pubDate>Fri, 01 May 2015 10:14:21 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/gin-and-tonic_5.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> Participation in Genomics Research a 21st Century Public Good, Says Paul Billings of Omicia</title>
 <link>https://mendelspod.com/podcasts/participation-genomics-research-21st-century-public-good-says-paul-billings-omicia/</link>
 <description>Pharma companies have always had their chief medical officers (CMOs).  Now, as the diagnostics industry grows, many kinds of life science companies are filling this important position as well.  Sequencing tool makers, direct-to-consumer firms, bioinformatics companies—they’re all appointing CMOs.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Paul%20Billings%20Show.mp3" length="29075355" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/participation-genomics-research-21st-century-public-good-says-paul-billings-omicia/</guid>
 <pubDate>Tue, 14 Apr 2015 21:52:19 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Paul_Billings_0.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Gene and Tonic: Competition for 23andMe, Four Tips for Attending AACR 2015, and &quot;Swab Stories&quot;</title>
 <link>https://mendelspod.com/podcasts/gene-and-tonic-competition-23andme-four-tips-attending-aacr-2015-and-swab-stories/</link>
 <description>An Old New DTC Co. on the Move
Let’s start with a bit of trivia.  What company has resorted to selling genetic ancestry testing online direct to consumers?  Hint:  the company is located in the San Francisco Bay area, has banked more than 800,000 samples from customers all over the world, and is slowly transforming itself into major biomedical player.
That’s right.  You got it.  It’s Ancestry.com.   </description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/G%26TShowApr10.mp3" length="5967675" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/gene-and-tonic-competition-23andme-four-tips-attending-aacr-2015-and-swab-stories/</guid>
 <pubDate>Fri, 10 Apr 2015 08:54:30 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/gin-and-tonic_3.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> Improving the Backbone of Clinical Genomics : Valerie Schneider, NCBI</title>
 <link>https://mendelspod.com/podcasts/improving-backbone-clinical-genomics-valerie-schneider-ncbi/</link>
 <description>When President Bill Clinton stood with Francis Collins and Craig Venter in 2001 to announce the sequencing of the genome, the genome wasn’t really done.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Valerie%20Schneider%20Show.mp3" length="26270379" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/improving-backbone-clinical-genomics-valerie-schneider-ncbi/</guid>
 <pubDate>Tue, 07 Apr 2015 18:28:29 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/ValerieSchneider.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Gene and Tonic: The ACA Turns Five, Ten Reasons to Have Your Genome Sequenced, and Humbled by the Ancients</title>
 <link>https://mendelspod.com/podcasts/gene-and-tonic-aca-turns-five-ten-reasons-have-your-genome-sequenced-and-humbled-ancients/</link>
 <description>Actually there was no news this week.  It turns out the whole industry took the week off to watch the stunning Ken Burns documentary on cancer.  
No, that’s not true.  We did find some news.  
How about this?  The Affordable Care Act turned five this past week.  Happy Birthday, ObamaCare!  So we thought we’d share some important numbers about the ACA:
11.7 million:   the number of Americans who have signed up for 2015 coverage.
46%:   the increase in enrollment from 2014 to 2015.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/G%26TShowApr3.mp3" length="5501115" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/gene-and-tonic-aca-turns-five-ten-reasons-have-your-genome-sequenced-and-humbled-ancients/</guid>
 <pubDate>Fri, 03 Apr 2015 12:18:34 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/gin-and-tonic_2.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> Behind the Sequencing Bench with Dale Yuzuki</title>
 <link>https://mendelspod.com/podcasts/behind-sequencing-bench-dale-yuzuki/</link>
 <description>Will tech companies like Google and Apple be good at life science applications? We pursue this question today with Dale Yuzuki, the avid life science blogger, scientist, and now a marketing manager at Thermo Fisher. (See his recent blog, &lt;a href=&quot;http://www.yuzuki.org/core-competency-google-not-life-sciences/&quot; target=&quot;_blank&quot;&gt;The Core Competency of Google Is Not Life Sciences.&lt;/a&gt;)</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Dale%20Yuzuki%20Show.mp3" length="24772203" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/behind-sequencing-bench-dale-yuzuki/</guid>
 <pubDate>Tue, 31 Mar 2015 18:14:54 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/DaleYuzuki.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Gene and Tonic: The Tenth Commandment of Science, Icelandic Treasure, and TechBio Babies</title>
 <link>https://mendelspod.com/podcasts/gene-and-tonic-tenth-commandment-science-icelandic-treasure-and-techbio-babies/</link>
 <description>We were off last week, so there’s plenty to talk about.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/G%26TShowMar27.mp3" length="6272667" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/gene-and-tonic-tenth-commandment-science-icelandic-treasure-and-techbio-babies/</guid>
 <pubDate>Fri, 27 Mar 2015 11:36:08 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/gin-and-tonic_1.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> It’s Pretty Bad:  Andy Brooks of RUCDR on Sample Quality</title>
 <link>https://mendelspod.com/podcasts/its-pretty-bad-andy-brooks-rucdr-sample-quality/</link>
 <description>The future of diagnostics is in the hands of those taking care of the biospecimen samples says, Andy Brooks our final guest in the series, Improving Biospecimen Standards. Andy is the Chief Operating Officer at Rutgers University Cell and DNA Repository, or RUCDR.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Andy%20Brooks%20Show%20Mar%202015.mp3" length="23137947" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/its-pretty-bad-andy-brooks-rucdr-sample-quality/</guid>
 <pubDate>Thu, 19 Mar 2015 16:30:26 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/AndyBrooks.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Knowing More about What We Don’t Know:  John McPherson on Cancer Genomics</title>
 <link>https://mendelspod.com/podcasts/knowing-more-about-what-we-dont-know-john-mcpherson-cancer-genomics/</link>
 <description>More than with any other major disease, the understanding and treatment of cancer is being transformed by genomics.  And these are early days.

John McPherson has been involved in sequencing since the original Human Genome Project.  He now directs the Genome Technologies Program at the Ontario Institute for Cancer Research.   John chaired a panel on cancer genomics at the recent AGBT, or Advances in Genome Biology and Technology conference, and shares his thoughts on this year&#039;s meeting.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/John%20McPherson%20Show.mp3" length="23409675" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/knowing-more-about-what-we-dont-know-john-mcpherson-cancer-genomics/</guid>
 <pubDate>Mon, 16 Mar 2015 21:38:43 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/JohnMcPherson.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Gene and Tonic: The iWatch and Research Kit, 23andMe Goes for the Big Time, No Spaceship</title>
 <link>https://mendelspod.com/podcasts/gene-and-tonic-iwatch-and-research-kit-23andme-goes-big-time-no-spaceship/</link>
 <description>Friday March 13th

It’s Friday already and time for Gene and Tonic, our wrap of the week’s headlines.

On Monday, Apple’s CEO, Tim Cook, announced that the iWatch is indeed a reality.  The iWatch has all the wearable techies and mobile health folks doing somersaults.  But it was what happened afterward that was so interesting.  Did you hear about this?</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/G%26TShowMar13.mp3" length="4666059" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/gene-and-tonic-iwatch-and-research-kit-23andme-goes-big-time-no-spaceship/</guid>
 <pubDate>Fri, 13 Mar 2015 12:37:03 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/gin-and-tonic_0.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> In Partnership with IBM’s Watson, Pathway Genomics Reinvents Itself</title>
 <link>https://mendelspod.com/podcasts/partnership-ibms-watson-pathway-genomics-reinvents-itself/</link>
 <description>Direct-to-consumer (DTC) genetic testing has had a bumpy ride.

Back in 2010, Pathway Genomics and Walgreens made a deal to sell DTC genetic tests in thousands of Walgreens drugstores.  Within 48 hours of the deal being announced, it collapsed.  The FDA sent a letter to Pathway basically asking them what the hell they were doing.  Walgreens quickly elected to put the kibosh on the partnership.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Ardy%20Arianpour%20Show_0.mp3" length="17322795" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/partnership-ibms-watson-pathway-genomics-reinvents-itself/</guid>
 <pubDate>Wed, 11 Mar 2015 21:48:23 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/ardy_0.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>  Affymetrix CEO, Frank Witney, on Arrays in the Age of Sequencing</title>
 <link>https://mendelspod.com/podcasts/affymetrix-ceo-frank-witney-arrays-age-sequencing/</link>
 <description>Go about anywhere in the life science industry, and you’ll run into someone who once worked at Affymetrix.  Since the founding of Affymetrix and the development of what’s come to be known simply as the Affy chip, the  company’s history has been intertwined with that of biotech and the genomics revolution.  But what has become of the company today?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Frank%20Witney%20Show_0.mp3" length="24476283" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/affymetrix-ceo-frank-witney-arrays-age-sequencing/</guid>
 <pubDate>Tue, 10 Mar 2015 09:39:30 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/frankwhitney.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Gene &amp; Tonic: Disruption in Sequencing, Scientist Politicians, Some Cool Synbio</title>
 <link>https://mendelspod.com/podcasts/gene-tonic-disruption-sequencing-scientist-politicians-some-cool-synbio/</link>
 <description>Join Theral for a quick wrap-up of the week&#039;s biotech news:

The biggest news this week has been the flow of  stories coming from last week’s AGBT conference held in Florida.  This is the annual all out party for the all out darling of our industry, the sequencing space.    Like a debutante ball, it’s where anybody who’s anybody comes out and does their curtsy to society.</description>
 <author>theral@verizon.net (Theral Timpson)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/G%26TShowMar6.mp3" length="5660523" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/gene-tonic-disruption-sequencing-scientist-politicians-some-cool-synbio/</guid>
 <pubDate>Fri, 06 Mar 2015 13:42:04 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/gin-and-tonic.jpg" />
 <itunes:author> theral@verizon.net (Theral Timpson)
</itunes:author>
</item>
 <item> <title> Changing the World with Color Changing Flowers</title>
 <link>https://mendelspod.com/podcasts/changing-world-color-changing-flowers/</link>
 <description>Keira Havens is the co-founder of Revolution Bioengineering, and this week the company launched a crowd funding campaign (see video below) to produce flowers that can change colors.

And what is the revolution?

“We want to change the world,” says Keira.  “We really want to make a difference in the way people think about biotechnology.  For a long time it’s been the realm of large companies and behind-the-scenes labs, and we want to make it a part of folks&#039; everyday lives.”</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Keira%20Havens%20Show.mp3" length="14020587" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/changing-world-color-changing-flowers/</guid>
 <pubDate>Wed, 04 Mar 2015 23:49:53 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/keirahavens.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Cancer Researcher at Mayo Says Illumina Platform Maxing Out, Looks to BGI/Complete</title>
 <link>https://mendelspod.com/podcasts/cancer-researcher-mayo-says-illumina-platform-maxing-out-looks-bgicomplete/</link>
 <description>Today we bring you a story which you probably wouldn’t have heard at last week’s AGBT conference at Marcos Island.  While PacBio and 10X Genomics were getting most of the buzz at the annual show on all things sequencing, it could be the new BGI/Complete Genomics platform that steals the show later this year, says David Smith, a cancer researcher at the Mayo Clinic.

In his research, David uses sequencing to analyze the connection between the human papillomavirus (HPV) with oropharyngeall cancer.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/David%20Smith%20Show.mp3" length="27064827" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/cancer-researcher-mayo-says-illumina-platform-maxing-out-looks-bgicomplete/</guid>
 <pubDate>Tue, 03 Mar 2015 09:16:17 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/DavidSmith.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Returning to Old Biotech Model, OncoMed Boasts of Seven Drugs in Clinical Trials by Mid 2015</title>
 <link>https://mendelspod.com/podcasts/returning-old-biotech-model-oncomed-boasts-seven-drugs-clinical-trials-mid-2015/</link>
 <description>For many years, the trend in biotech was for drug development companies to pursue one or maybe two drug candidates, or assets, as they’re called in industry parlance.  Go lean and attract the attention of big pharma or investors in the late stage trials.  But today’s guest says there is more innovation when the biotech organization invests in a technology platform that produces multiple drug candidates.  Paul Hastings is the CEO of OncoMed, a company developing drugs that target cancer stem cells.  He’s built OncoMed in what he says was the old model.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Paul%20Hastings%20Show.mp3" length="27336123" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/returning-old-biotech-model-oncomed-boasts-seven-drugs-clinical-trials-mid-2015/</guid>
 <pubDate>Mon, 23 Feb 2015 20:36:01 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/PaulHastings.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Cutting through the Hype in Healthcare Innovation with David Shaywitz and Lisa Suennen</title>
 <link>https://mendelspod.com/podcasts/cutting-through-hype-healthcare-innovation-david-shaywitz-and-lisa-suennen/</link>
 <description>In today’s special studio interview, the health tech duo, David Shaywitz and Lisa Suennen, walk us through the changing paradigms around healthcare.  They offer their thoughts on some of the new digital health and peer-to-peer social platforms which are becoming integrated in daily clinical care.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Lisa%26DavidShow.mp3" length="54831397" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/cutting-through-hype-healthcare-innovation-david-shaywitz-and-lisa-suennen/</guid>
 <pubDate>Thu, 19 Feb 2015 20:05:22 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Lisa%26David.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> A Call to Consumers to Lead the Shift in Healthcare:  Sharon Terry, Genetic Alliance</title>
 <link>https://mendelspod.com/podcasts/call-consumers-lead-shift-healthcare-sharon-terry-genetic-alliance/</link>
 <description>One of those attending the recent White House gathering where Obama announced the Precision Medicine Initiative was a woman who has worked tirelessly as a patient advocate for over twenty years.  She’s an award winning scientist and the CEO of the Genetic Alliance:  Sharon Terry joins us to kick off a new series, Personalized Medicine and the Consumerization of Healthcare.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Sharon%20Terry%20Show.mp3" length="17715051" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/call-consumers-lead-shift-healthcare-sharon-terry-genetic-alliance/</guid>
 <pubDate>Tue, 17 Feb 2015 10:52:09 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/SharonTerry_0.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>In Autoimmune Disease, Finding Clarity Beyond the Genome:  Stefan Muellner, Protagen</title>
 <link>https://mendelspod.com/podcasts/autoimmune-disease-finding-clarity-beyond-genome-stefan-muellner-protagen/</link>
 <description>Today we bring you a story which fits nicely in the vein of personalized medicine.   But this time with a twist.

We talk with the CEO of Protagen, a company that has developed a platform to find new biomarkers for disease, particularly autoimmune diseases such as SLE, or Systemic Lupus Erythematosus.  But the platform is based on the hunt for genetic mutations.  Rather the company is using antibodies, or proteins to better define disease and disease populations.  The company is able to stratify auto-immune diseases better than we’ve done with genomics.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Stefan%20Muellner%20Show.mp3" length="17204859" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/autoimmune-disease-finding-clarity-beyond-genome-stefan-muellner-protagen/</guid>
 <pubDate>Fri, 13 Feb 2015 09:21:08 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/StefanMuellner.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Myriad Settlements Mark End of an Era: Antoinette Konski on Gene Patents</title>
 <link>https://mendelspod.com/podcasts/myriad-settlements-mark-end-era-antoinette-konski-gene-patents/</link>
 <description>This past month one of the most successful genetic testing companies, Myriad Genetics, has been settling one gene patent case after another.  Also, the FDA has been attempting to regulate some very complicated lab testing.  So we figured we better talk to a lawyer about the devil in the details.  We’ve chosen Antoinette Konski of the law firm, Foley and Lardner.

Antoinette agrees that the Myriad settlements indicate the end of an era with gene patents.  So how is she advising her life science clients in securing IP?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Antoinette%20Konski%20Show.mp3" length="30672891" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/myriad-settlements-mark-end-era-antoinette-konski-gene-patents/</guid>
 <pubDate>Tue, 10 Feb 2015 09:12:08 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/AntoinetteKonskiSquare.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> David Schwartz on the Future of Sequencing</title>
 <link>https://mendelspod.com/podcasts/david-schwartz-future-sequencing/</link>
 <description>David Schwartz was focused on long read sequencing and the structural variations of the genome—the big picture—long before the current trend.  His lab at the University of Wisconsin at Madison developed optical mapping and posted the first optical map of the human genome several years ago.  And last year, they published the first optical map of a cancer genome.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/David%20Schwartz%20Show%20Feb%2015.mp3" length="32229819" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/david-schwartz-future-sequencing/</guid>
 <pubDate>Fri, 06 Feb 2015 09:12:12 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/DavidSchwartzSquare.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> Not a Stenographer to Power:  Luke Timmerman and the New &#039;Timmerman Report&#039;</title>
 <link>https://mendelspod.com/podcasts/not-stenographer-power-luke-timmerman-and-new-timmerman-report/</link>
 <description>Just less than a year ago, the national biotech editor at Xconomy, Luke Timmerman,  left his post.  Yeah, he just left it.   Gone was the regular Monday column that helped us all absorb  the newest trends in biotech.  Gone were the lists of companies to watch out for that made sense even if we weren&#039;t up to date on Luke&#039;s sports analogies.  One day the columns were here, then they were gone.  Luke said he was busy with a biography of Lee Hood, the guy who brought us automated DNA sequencing.  But we all knew Luke just wanted to go climb more mountains.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Luke%20Timmerman%20Feb%202015%20Show.mp3" length="19437867" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/not-stenographer-power-luke-timmerman-and-new-timmerman-report/</guid>
 <pubDate>Tue, 03 Feb 2015 08:57:17 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/LukeTimmermanSquare.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> FDA Will Take Time to Digest Comments on LDT Guidance, Says Liz Mansfield</title>
 <link>https://mendelspod.com/podcasts/fda-will-take-time-digest-comments-ldt-guidance-says-liz-mansfield/</link>
 <description>We’re very pleased to have Liz Mansfield of the FDA on the program to finish up our current Special Report on LDTs Series. Liz is part of the team at the FDA working on the new guidance for the regulation of LDTs, and she was at the recent meeting the FDA held to receive community feedback.
Today we get into some of the details of that feedback. Did Liz and the FDA hear any new issues that they had not already considered? What about the BRAF testing that was mentioned in the meeting? Is there a risk that patients will lose access to some important tests?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Liz%20Mansfield%20Jan%202015%20Show.mp3" length="29128491" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcasts/fda-will-take-time-digest-comments-ldt-guidance-says-liz-mansfield/</guid>
 <pubDate>Mon, 26 Jan 2015 20:48:42 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/LizMansfieldSquare.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Future of Personalized Medicine at Stake, says Amy Miller of PMC about LDT Regulation</title>
 <link>https://mendelspod.com/podcast/future-personalized-medicine-stake-says-amy-miller-pmc-about-ldt-regulation/</link>
 <description>Amy Miller is the Executive Vice President for the Personalized Medicine Coalition (PMC) and joins us in our Special Report on LDTs Series.  Though the PMC does not have a position on whether the FDA should regulate LDTs, Amy says that the stakes could not be higher.

“We see the future of personalized medicine is at stake. We urge the FDA to get this right the first time so that personalized medicine can continue to improve the quality of care that patients currently have access to,” she says at the outset of today’s interview.</description>
 <author>online@cglife.com (cglife)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/audio/Amy%20Miller%20Show.mp3" length="22828203" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/future-personalized-medicine-stake-says-amy-miller-pmc-about-ldt-regulation/</guid>
 <pubDate>Fri, 23 Jan 2015 16:17:30 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/AmyMillerSmall_0.jpeg" />
 <itunes:author> online@cglife.com (cglife)
</itunes:author>
</item>
 <item> <title>&#039;A Good Year&#039; with John LaMattina</title>
 <link>https://mendelspod.com/podcast/good-year-john-lamattina/</link>
 <description>Guest:

John LaMattina, Senior Partner, Pure Tech Ventures
   &lt;a href=&quot;/guests/john-lamattina&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/comparing-drug-approvals-2014-1996&quot;&gt; Listen (6:27)&lt;/a&gt; Comparing drug approvals: 2014 with 1996

&lt;a href=&quot;http://mendelspod.com/podcast/more-rational-drug-development&quot;&gt; Listen (7:10)&lt;/a&gt; More rational drug development?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/John%20LaMattina%20Show%202015.mp3" length="31206411" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/good-year-john-lamattina/</guid>
 <pubDate>Sun, 18 Jan 2015 21:47:52 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/JohnLaMattinaSmall_1.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> An Exciting Time for Mass Spec: Paul Beresford, Biodesix</title>
 <link>https://mendelspod.com/podcast/exciting-time-mass-spec-paul-beresford-biodesix/</link>
 <description>Guest:

Paul Beresford, VP of Bus Dev, Biodesix
   &lt;a href=&quot;http://mendelspod.com/guests/paul-beresford&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/veristrat-test-non-small-cell-lung-cancer&quot;&gt; Listen (4:47)&lt;/a&gt; VeriStrat - a test for non-small cell lung cancer

&lt;a href=&quot;http://mendelspod.com/podcast/what-do-you-anticipate-regulatory-front&quot;&gt; Listen (4:39)&lt;/a&gt; What do you anticipate on the regulatory front?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Paul%20Beresford%20Show.mp3" length="21799611" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/exciting-time-mass-spec-paul-beresford-biodesix/</guid>
 <pubDate>Thu, 15 Jan 2015 08:32:00 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/PaulBeresfordSmall_0.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Current Version of LDT Draft Guidance Means Much Fewer and Lower Quality Tests for Patients, Says Elaine Lyon of ARUP</title>
 <link>https://mendelspod.com/podcast/current-version-ldt-draft-guidance-means-much-fewer-and-lower-quality-tests-patients-says/</link>
 <description>Guest:

Elaine Lyon, Former President, AMP;  Medical Director of Molecular Genetics, ARUP Laboratories
   &lt;a href=&quot;http://mendelspod.com/guests/elaine-lyon&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/what-stake-here&quot;&gt; Listen (4:37)&lt;/a&gt; What is at stake here?

&lt;a href=&quot;http://mendelspod.com/podcast/your-message-being-heard&quot;&gt; Listen (6:16)&lt;/a&gt; Is your message being heard?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Elaine%20Lyon%202015%20Show.mp3" length="24277995" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/current-version-ldt-draft-guidance-means-much-fewer-and-lower-quality-tests-patients-says/</guid>
 <pubDate>Tue, 13 Jan 2015 08:50:30 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/ElaineLyon_0.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>The Sad State of Biospecimen Science with David Rimm, Yale</title>
 <link>https://mendelspod.com/podcast/sad-state-biospecimen-science-david-rimm-yale/</link>
 <description>Guest:

David Rimm, Professor of Pathology, Yale University School of Medicine 
   &lt;a href=&quot;http://mendelspod.com/guests/david-rimm&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/unsexy-science&quot;&gt; Listen (4:16)&lt;/a&gt; An unsexy science

&lt;a href=&quot;http://mendelspod.com/podcast/lack-certifications&quot;&gt; Listen (5:36)&lt;/a&gt; A lack of certifications</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/David%20Rimm%20Show.mp3" length="30738555" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/sad-state-biospecimen-science-david-rimm-yale/</guid>
 <pubDate>Thu, 08 Jan 2015 09:01:50 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/David_Rimm_2.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Cancer 2014: The Year in Review with Anna Barker</title>
 <link>https://mendelspod.com/podcast/cancer-2014-year-review-anna-barker/</link>
 <description>Guest:

Anna Barker, Co-Director, Complex Adaptive Systems Center, ASU
&lt;a href=&quot;http://mendelspod.com/guests/anna-barker&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/andys-challenge&quot;&gt; Listen (3:21)&lt;/a&gt; Andy&#039;s challenge

&lt;a href=&quot;http://mendelspod.com/podcast/year-immunotherapy&quot;&gt; Listen (4:39)&lt;/a&gt; The year of immunotherapy</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Anna%20Barker%20Dec%202014%20Show.mp3" length="35820171" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/cancer-2014-year-review-anna-barker/</guid>
 <pubDate>Mon, 29 Dec 2014 19:22:25 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/Anna%20Barker%20Small.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Faces of Leadership in Diagnostics: Surbhi Sarna</title>
 <link>https://mendelspod.com/podcast/faces-leadership-diagnostics-surbhi-sarna/</link>
 <description>Guest:

Surbhi Sarna, Founder, CEO, nVision Medical

&lt;a href=&quot;http://mendelspod.com/guests/surbhi-sarna&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/filling-void-female-health-innovation&quot;&gt; Listen (4:43)&lt;/a&gt; Filling a void in female health innovation

&lt;a href=&quot;http://mendelspod.com/podcast/addressing-leading-cause-infertility&quot;&gt; Listen (4:31)&lt;/a&gt; Addressing the leading cause of infertility</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Surbhi%20Sarna%20Show.mp3" length="25660395" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/faces-leadership-diagnostics-surbhi-sarna/</guid>
 <pubDate>Wed, 17 Dec 2014 21:30:02 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/SurbhiSarna_0.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Historic Consensus Reached on Biospecimen Standards:  Carolyn Compton, NBDA</title>
 <link>https://mendelspod.com/podcast/historic-consensus-reached-biospecimen-standards-carolyn-compton-nbda/</link>
 <description>Guest:

Carolyn Compton, Professor of Pathology, ASU 
   &lt;a href=&quot;http://mendelspod.com/guests/carolyn-compton&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/historic-new-consensus&quot;&gt; Listen (4:54)&lt;/a&gt; A historic new consensus

&lt;a href=&quot;http://mendelspod.com/podcast/cap-committed-enforcement&quot;&gt; Listen (6:33)&lt;/a&gt; CAP committed to enforcement</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Carolyn%20Compton%20Dec%202014%20Show.mp3" length="36586971" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/historic-consensus-reached-biospecimen-standards-carolyn-compton-nbda/</guid>
 <pubDate>Mon, 15 Dec 2014 22:36:17 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/CarolynComptonSmall2_1.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Setting Better Expectations for Genomic Medicine:  Geoff Ginsburg, Duke University</title>
 <link>https://mendelspod.com/podcast/setting-better-expectations-genomic-medicine-geoff-ginsburg-duke-university/</link>
 <description>Guest:

Geoffrey Ginsburg, Director, Duke Center for Applied Genomics and Precision Medicine
   &lt;a href=&quot;http://mendelspod.com/guests/geoff-ginsburg&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/genomic-medicine-occuring-across-lifespan&quot;&gt; Listen (6:58)&lt;/a&gt; Genomic medicine occuring across the lifespan</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Geoff%20Ginsburg%20Show.mp3" length="33500763" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/setting-better-expectations-genomic-medicine-geoff-ginsburg-duke-university/</guid>
 <pubDate>Tue, 09 Dec 2014 13:15:03 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/GeoffGinsburgSmall.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Test Driving Genomic Medicine:  Thomas Quertermous, Stanford</title>
 <link>https://mendelspod.com/podcast/test-driving-genomic-medicine-thomas-quertermous-stanford/</link>
 <description>Guest:

Thomas Quertermous, Director of Research, Division of Cardiovascular Medicine, Stanford University
   &lt;a href=&quot;http://mendelspod.com/guests/thomas-quertermous&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/close-not-quite-there&quot;&gt; Listen (7:45)&lt;/a&gt; Close, but not quite there</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Thomas%20Quertermous%20Show.mp3" length="36139419" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/test-driving-genomic-medicine-thomas-quertermous-stanford/</guid>
 <pubDate>Tue, 02 Dec 2014 21:09:00 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/ThomasQuertermousSmall.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>The Silicon Valley Fantasy Trip:  Sci-fi Author Kim Stanley Robinson Talks Life Science</title>
 <link>https://mendelspod.com/podcast/silicon-valley-fantasy-trip-sci-fi-author-kim-stanley-robinson-talks-life-science/</link>
 <description>Guest:

Kim Stanley Robinson, Sci-Fi Author 
   &lt;a href=&quot;http://mendelspod.com/guests/robinson-kim-stanley&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/creating-plot-when-science-wants-be-boring&quot;&gt; Listen (3:30)&lt;/a&gt; Creating plot when science wants to be boring

&lt;a href=&quot;http://mendelspod.com/podcast/genetics-and-distant-past&quot;&gt; Listen (3:22)&lt;/a&gt; Genetics and the distant past</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/KSR%202014%20Show.mp3" length="41460363" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/silicon-valley-fantasy-trip-sci-fi-author-kim-stanley-robinson-talks-life-science/</guid>
 <pubDate>Tue, 25 Nov 2014 07:51:33 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/KSRemail.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Faces of Leadership in Diagnostics: Mara Aspinall</title>
 <link>https://mendelspod.com/podcast/faces-leadership-diagnostics-mara-aspinall/</link>
 <description>Guest:

Mara Aspinall, Founder, DxInsights

&lt;a href=&quot;http://mendelspod.com/guests/aspinall-mara&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/dxinsight-and-epemed&quot;&gt; Listen (2:43)&lt;/a&gt; DxInsights and EPEMED

&lt;a href=&quot;http://mendelspod.com/podcast/diagnostics-50&quot;&gt; Listen (3:53)&lt;/a&gt; Diagnostics 5.0</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Mara%20Aspinall%202014%20Show.mp3" length="27306315" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/faces-leadership-diagnostics-mara-aspinall/</guid>
 <pubDate>Thu, 20 Nov 2014 11:01:05 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/MaraAspinallSmall.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>The Daunting Task of Managing Biospecimens at the World&#039;s Largest CRO: Diane Farhi, Quintiles</title>
 <link>https://mendelspod.com/podcast/daunting-task-managing-biospecimens-worlds-largest-cro-diane-farhi-quintiles/</link>
 <description>Guest:

Diane C. Farhi,, MD, Senior Medical Director, Quintiles Laboratories 
   &lt;a href=&quot;http://mendelspod.com/guests/diane-farhi&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/tracking-clinical-samples-around-world&quot;&gt; Listen (6:37)&lt;/a&gt; Tracking clinical samples around the world

&lt;a href=&quot;http://mendelspod.com/podcast/how-measure-sample-stability&quot;&gt; Listen (5:34)&lt;/a&gt; How to measure sample stability</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Diane%20Farhi%20Show.mp3" length="29291355" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/daunting-task-managing-biospecimens-worlds-largest-cro-diane-farhi-quintiles/</guid>
 <pubDate>Tue, 18 Nov 2014 08:40:16 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/QuintilesSmall.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>  Janet Woodcock, FDA, on Biomarker Development and the Future of Clinical Trials</title>
 <link>https://mendelspod.com/podcast/janet-woodcock-fda-biomarker-development-and-future-clinical-trials/</link>
 <description>Guest:

Janet, Woodcock, MD, Director, CDER, FDA&lt;br /&gt;
   &lt;a href=&quot;http://mendelspod.com/guests/woodcock-janet-md&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/no-agency-charged-better-translational-outcomes&quot;&gt; Listen (4:41)&lt;/a&gt; No agency charged with better translational outcomes</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Janet%20Woodcock%202014%20Show.mp3" length="29793339" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/janet-woodcock-fda-biomarker-development-and-future-clinical-trials/</guid>
 <pubDate>Thu, 13 Nov 2014 12:05:09 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/JanetWoodcockSmall.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> Biosampling Basics with Scott Jewell, Van Andel Institute</title>
 <link>https://mendelspod.com/podcast/biosampling-basics-scott-jewell-van-andel-institute/</link>
 <description>Guest:

Scott Jewell, Senior Scientific Investigator and Director of Program for Biospecimen Science, Van Andel Institute 
   &lt;a href=&quot;http://mendelspod.com/guests/scott-jewell&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/do-you-see-more-creativity-sample-consent-area&quot;&gt; Listen (3:30)&lt;/a&gt; Do you see more creativity in the sample consent area?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Scott%20Jewell%20Show.mp3" length="37559835" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/biosampling-basics-scott-jewell-van-andel-institute/</guid>
 <pubDate>Tue, 11 Nov 2014 06:19:59 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/ScottJewellSmall.JPG" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> Faces of Leadership in Diagnostics:  Bonnie Anderson, Veracyte</title>
 <link>https://mendelspod.com/podcast/faces-leadership-diagnostics-bonnie-anderson-veracyte/</link>
 <description>Guest:

Bonnie Anderson, CEO, Veracyte 
   &lt;a href=&quot;http://mendelspod.com/guests/bonnie-anderson&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/what-secret-your-success&quot;&gt; Listen (5:58)&lt;/a&gt; What is the secret to your success?

&lt;a href=&quot;http://mendelspod.com/podcast/building-case-reimbursement&quot;&gt; Listen (4:30)&lt;/a&gt; Building the case for reimbursement</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Bonnie%20Anderson%20Show.mp3" length="34964379" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/faces-leadership-diagnostics-bonnie-anderson-veracyte/</guid>
 <pubDate>Mon, 03 Nov 2014 11:13:59 -0600</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/BonnieAndersonSmall_0.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Biotech’s Gentleman Lawyer: Alan Mendelson</title>
 <link>https://mendelspod.com/podcast/biotechs-gentleman-lawyer-alan-mendelson/</link>
 <description>Guest:  Alan Mendelson, Partner, Latham &amp; Watkins
&lt;a href=&quot;http://mendelspod.com/guests/alan-mendelson&quot;&gt;Bio and Contact Info&lt;/a&gt;

Alan Mendelson, a partner at Latham &amp; Watkins, is the first service provider--as opposed to a scientist, entrepreneur, or venture capitalist--to receive one of BayBio’s prestigious Pantheon Lifetime Achievement Awards. We talk to him a month before the awards ceremony which will be held in San Francisco on December 11th, 2014.</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Alan%20Mendelson.mp3" length="53585852" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/biotechs-gentleman-lawyer-alan-mendelson/</guid>
 <pubDate>Thu, 30 Oct 2014 13:49:25 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/AlanMendelsonSmall.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>The Open Secret about the HER2 Assay with Jim Vaught</title>
 <link>https://mendelspod.com/podcast/open-secret-about-her2-assay-jim-vaught/</link>
 <description>Guest:

Jim Vaught, Editor-in-Chief, Biopreservation and Biobanking Journal 
   &lt;a href=&quot;http://mendelspod.com/guests/jim-vaught&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/importance-better-biosamples-only-recognized-past-10-15-years&quot;&gt; Listen (6:50)&lt;/a&gt; The importance of better biosamples only recognized in the past 10 to 15 years</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Jim%20Vaught%20Show.mp3" length="32014251" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/open-secret-about-her2-assay-jim-vaught/</guid>
 <pubDate>Tue, 28 Oct 2014 09:38:28 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/JimVaughtSmall.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>What a Physicist Can Tell Us about Cancer</title>
 <link>https://mendelspod.com/podcast/what-physicist-can-tell-us-about-cancer/</link>
 <description>Guest:

Paul Davies, Principal Investigator, Center for the Convergence of Physical Science and Cancer Biology, ASU 
   &lt;a href=&quot;http://mendelspod.com/guests/paul-davies&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/phone-call&quot;&gt; Listen (4:05)&lt;/a&gt; The phone call

&lt;a href=&quot;http://mendelspod.com/podcast/too-focused-cure&quot;&gt; Listen (3:39)&lt;/a&gt; Too focused on a cure</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Paul%20Davies%20Show.mp3" length="34139691" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/what-physicist-can-tell-us-about-cancer/</guid>
 <pubDate>Thu, 23 Oct 2014 11:42:54 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/PaulDaviesSmall.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> &#039;Moving Target Science:&#039; Jonathan Brody on Pancreatic Cancer</title>
 <link>https://mendelspod.com/podcast/moving-target-science-jonathan-brody-pancreatic-cancer/</link>
 <description>Guest:

Jonathan Brody, Assoc Professor of Surgery, Thomas Jefferson University
   &lt;a href=&quot;http://mendelspod.com/guests/jonathan-brody&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/brca-testing-being-used-prostate-cancer-well&quot;&gt; Listen (8:17)&lt;/a&gt; BRCA testing being used for pancreatic cancer as well</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Jonathan%20Brody%20Show.mp3" length="34832187" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/moving-target-science-jonathan-brody-pancreatic-cancer/</guid>
 <pubDate>Tue, 21 Oct 2014 09:27:13 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/JonathanBrodySmall.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>The Progress of Clinical Genomics in Sweden with Ulf Gyllensten</title>
 <link>https://mendelspod.com/podcast/progress-clinical-genomics-sweden-ulf-gyllensten/</link>
 <description>Guest:

Ulf Gyllensten, Professor, Department of Immunology, Genetics, and Pathology, Uppsala University, Sweden
   &lt;a href=&quot;http://mendelspod.com/guests/ulf-gyllensten&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/what-are-your-goals-national-genomics-infrastructure&quot;&gt; Listen (4:24)&lt;/a&gt; What are your goals at the National Genomics Infrastructure?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Ulf%20Gyllensten%20Show.mp3" length="33148251" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/progress-clinical-genomics-sweden-ulf-gyllensten/</guid>
 <pubDate>Thu, 16 Oct 2014 11:30:28 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/UlfGyllenstenSmall_0.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Proteins Are Where It&#039;s At:  Chip Petricoin, George Mason University</title>
 <link>https://mendelspod.com/podcast/proteins-are-where-its-chip-petricoin-george-mason-university/</link>
 <description>Guest:

Emanuel &quot;Chip&quot; Petricoin, Co-Director, CAPMM, George Mason University 
   &lt;a href=&quot;http://mendelspod.com/guests/chip-petricoin&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/beyond-genome&quot;&gt; Listen (4:00)&lt;/a&gt; Beyond the genome

&lt;a href=&quot;http://mendelspod.com/podcast/challenges-mapping-proteome&quot;&gt; Listen (5:30)&lt;/a&gt; Challenges to mapping the proteome</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Chip%20Petricoin%20Show.mp3" length="38861451" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/proteins-are-where-its-chip-petricoin-george-mason-university/</guid>
 <pubDate>Tue, 14 Oct 2014 23:04:16 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/ChipPetricoinSmall.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>After a Decade on the Sidelines, Gene Myers Back into Sequencing, Excited about Long Reads</title>
 <link>https://mendelspod.com/podcast/after-decade-sidelines-gene-myers-back-sequencing-excited-about-long-reads/</link>
 <description>Guest:

Gene Myers , Founding Director, Systems Biology Center, Max Planck Institute
   &lt;a href=&quot;http://mendelspod.com/guests/gene-myers&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/what-have-you-been-celera-days&quot;&gt; Listen (6:10)&lt;/a&gt; What have you been up to since the Celera days?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Gene%20Myers%20Show.mp3" length="30147579" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/after-decade-sidelines-gene-myers-back-sequencing-excited-about-long-reads/</guid>
 <pubDate>Thu, 09 Oct 2014 09:18:35 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/GeneMyers_0.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> The Story of Aubrey de Grey and How the Study of Aging Became Mainstream</title>
 <link>https://mendelspod.com/podcast/story-aubrey-de-grey-and-how-study-aging-became-mainstream/</link>
 <description>Guest:  Aubrey de Grey, CoFounder, CSO, SENS Research Foundation
&lt;a href=&quot;http://mendelspod.com/guests/aubrey-de-grey&quot;&gt;Bio and Contact Info&lt;/a&gt;



Chapters: (Advance the marker)

0:35  First Rejuvenation Biotechnology Conference

4:50  Shackled by “short-termism”

6:00  Aging was not a topic for biologists

11:32  A serious nuisance

17:13  Smoking out the opposition</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Aubrey%20de%20Grey.mp3" length="69797792" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/story-aubrey-de-grey-and-how-study-aging-became-mainstream/</guid>
 <pubDate>Tue, 07 Oct 2014 09:46:14 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/AubreydeGreySmallSquare.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>#ScienceHack with Connor Dickie, Synbiota</title>
 <link>https://mendelspod.com/podcast/sciencehack-connor-dickie-synbiota/</link>
 <description>Guest:

Connor Dickie, CEO, Synbiota
   &lt;a href=&quot;http://mendelspod.com/guests/connor-dickie&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/has-open-science-really-taken-life-sciences&quot;&gt; Listen (5:13)&lt;/a&gt; Has open science really taken off in the life sciences?

&lt;a href=&quot;http://mendelspod.com/podcast/sciencehack&quot;&gt; Listen (4:58)&lt;/a&gt; #ScienceHack</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Connor%20Dickie%20Show.mp3" length="24624027" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/sciencehack-connor-dickie-synbiota/</guid>
 <pubDate>Fri, 03 Oct 2014 08:47:43 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/SmallConnorDickie.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> What Translational Gap? Michael Pishvaian on Advances in Tumor Profiling</title>
 <link>https://mendelspod.com/podcast/what-translational-gap-michael-pishvaian-advances-tumor-profiling/</link>
 <description>Guest:

Michael Pishvaian, Assistant Professor, Georgetown University; CMO, Perthera 
   &lt;a href=&quot;http://mendelspod.com/guests/michael-pishvaian&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/untapped-potential&quot;&gt; Listen (4:08)&lt;/a&gt; Untapped potential</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Michael%20Pishvaian%20Show.mp3" length="27730539" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/what-translational-gap-michael-pishvaian-advances-tumor-profiling/</guid>
 <pubDate>Wed, 01 Oct 2014 11:02:25 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/MikePishvaianSmall.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>A Dangerous Book?  Science Historian Nathaniel Comfort Discusses “A Troublesome Inheritance”</title>
 <link>https://mendelspod.com/podcast/dangerous-book-science-historian-nathaniel-comfort-discusses-%E2%80%9C-troublesome-inheritance%E2%80%9D/</link>
 <description>Guest:

Comfort, Nathaniel, PhD, Author, Professor, History of Science, Technology and Medicine, Johns Hopkins University
   &lt;a href=&quot;http://mendelspod.com/guests/nathaniel-comfort&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/debate-about-race-and-genetics-really-about-social-justice&quot;&gt; Listen (4:20)&lt;/a&gt; Debate about race and genetics is really about social justice</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Nathaniel%20Comfort%20Show%202014_0.mp3" length="29434779" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/dangerous-book-science-historian-nathaniel-comfort-discusses-%E2%80%9C-troublesome-inheritance%E2%80%9D/</guid>
 <pubDate>Thu, 25 Sep 2014 09:42:00 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/ComfortSmall.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> Eric Schadt on Long Read Sequencing and Clinical Genomics</title>
 <link>https://mendelspod.com/podcast/eric-schadt-long-read-sequencing-and-clinical-genomics/</link>
 <description>Guest:

Eric Schadt, Professor &amp; Chair Genetics and Genomic Sciences, Director Icahn Institute for Genomics and Multiscale Biology
   &lt;a href=&quot;http://mendelspod.com/guests/eric-schadt&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/getting-buy-few-lead-doctors&quot;&gt; Listen (5:01)&lt;/a&gt; Getting buy-in from a few lead doctors</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Eric%20Schadt%20Show.mp3" length="30678507" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/eric-schadt-long-read-sequencing-and-clinical-genomics/</guid>
 <pubDate>Tue, 23 Sep 2014 08:50:32 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/EricSchadt2Small.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> George Church at 60</title>
 <link>https://mendelspod.com/podcast/george-church-60/</link>
 <description>Guest:

George Church, Professor of Genetics, Harvard Medical School 
   &lt;a href=&quot;http://mendelspod.com/guests/church-george-phd&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/churchs-law&quot;&gt; Listen (6:11)&lt;/a&gt; Church&#039;s Law

&lt;a href=&quot;http://mendelspod.com/podcast/colbert-der-spiegel-and-regenesis&quot;&gt; Listen (6:45)&lt;/a&gt; Colbert, Der Spiegel and Regenesis</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/George%20Church%202014%20Show.mp3" length="49099419" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/george-church-60/</guid>
 <pubDate>Wed, 17 Sep 2014 20:42:26 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/GeorgeChurch%20square.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Major Sequencing Projects Should Be Done with Long Reads, Says Dan Geraghty</title>
 <link>https://mendelspod.com/podcast/major-sequencing-projects-should-be-done-long-reads-says-dan-geraghty/</link>
 <description>Guest:

Dan Geraghty, Researcher, Fred Hutchinson Cancer Center; CEO, Scisco Genetics
   &lt;a href=&quot;http://mendelspod.com/guests/dan-geraghty&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/unable-so-far-find-causal-linkages-mhc-region-genome&quot;&gt; Listen (4:43)&lt;/a&gt; Unable so far to find causal linkages in MHC region of the genome</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Dan%20Geraghty%20Show.mp3" length="35579547" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/major-sequencing-projects-should-be-done-long-reads-says-dan-geraghty/</guid>
 <pubDate>Tue, 16 Sep 2014 09:25:23 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/DanGeraghtySmall.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Test Driving Illumina&#039;s  X Ten with Shawn Baker, AllSeq</title>
 <link>https://mendelspod.com/podcast/test-driving-illuminas-x-ten-shawn-baker-allseq/</link>
 <description>Guest:

Shawn Baker, CSO, AllSeq 
   &lt;a href=&quot;http://mendelspod.com/guests/baker-shawn-ph-d&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/taking-x-ten-test-drive&quot;&gt; Listen (5:27)&lt;/a&gt; Taking the X Ten for a test drive

&lt;a href=&quot;http://mendelspod.com/podcast/what-latest-price-genome-through-allseq&quot;&gt; Listen (6:56)&lt;/a&gt; What is the latest price for a whole human genome sequence through Allseq?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Shawn%20Baker%20X%20Ten%20Show.mp3" length="34401915" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/test-driving-illuminas-x-ten-shawn-baker-allseq/</guid>
 <pubDate>Fri, 12 Sep 2014 08:31:39 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/ShawnBaker2Small.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> Short Read Sequencing Not Up to the Task of Characterizing Transcriptome Says Mike Snyder of Stanford</title>
 <link>https://mendelspod.com/podcast/short-read-sequencing-not-task-characterizing-transcriptome-says-mike-snyder-stanford/</link>
 <description>Guest:

Mike Snyder, Director, Center for Genomics &amp; Personalized Medicine, Stanford
   &lt;a href=&quot;http://mendelspod.com/guests/mike-snyder&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/current-method-figuring-out-transcriptomes-crazy&quot;&gt; Listen (5:44)&lt;/a&gt; Current method for figuring out transcriptomes is crazy</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Mike%20Snyder%20Long%20Reads%20Show.mp3" length="28900827" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/short-read-sequencing-not-task-characterizing-transcriptome-says-mike-snyder-stanford/</guid>
 <pubDate>Wed, 10 Sep 2014 10:32:26 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/MikeSnyderSm.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> U.K. Life Science Update with Eliot Forster, MedCity</title>
 <link>https://mendelspod.com/podcast/uk-life-science-update-eliot-forster-medcity/</link>
 <description>Guest:

Eliot Forster, Executive Chair, MedCity 
   &lt;a href=&quot;http://mendelspod.com/guests/eliot-forster&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/cashing-strong-life-science-tradition&quot;&gt; Listen (2:54)&lt;/a&gt; Cashing in on illustrious life science tradition

&lt;a href=&quot;http://mendelspod.com/podcast/culture-collaboration-strong-uk&quot;&gt; Listen (2:56)&lt;/a&gt; Culture of collaboration strong in the UK</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Eliot%20Forster%20Show.mp3" length="27172827" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/uk-life-science-update-eliot-forster-medcity/</guid>
 <pubDate>Sun, 07 Sep 2014 19:59:52 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/EliotForsterSmall.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> Paperwork, Not Algorithms the Biggest Challenge for Large Bioinformatics Projects, Says David Haussler, UCSC</title>
 <link>https://mendelspod.com/podcast/paperwork-not-algorithms-biggest-challenge-large-bioinformatics-projects-says-david-haussler/</link>
 <description>Guest:

David Haussler, Director, Center for Biomolecular Science and Engineering, UCSC&lt;br /&gt;
   &lt;a href=&quot;http://mendelspod.com/guests/david-haussler&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/paperwork-not-algorithms-biggest-challenge-bioinformatics&quot;&gt; Listen (8:08)&lt;/a&gt; Paperwork not algorithms the biggest challenge with bioinformatics</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/David%20Haussler%20Show.mp3" length="35131563" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/paperwork-not-algorithms-biggest-challenge-large-bioinformatics-projects-says-david-haussler/</guid>
 <pubDate>Thu, 28 Aug 2014 09:56:13 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/DavidHaussler_0.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Big Pharma Does Some Farming: Pearl Huang, GSK</title>
 <link>https://mendelspod.com/podcast/big-pharma-does-some-farming-pearl-huang-gsk/</link>
 <description>Guest:

Pearl Huang, VP, Global Head of DPAc, GSK 
   &lt;a href=&quot;http://mendelspod.com/guests/pearl-huang&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/what-discovery-fast-track-challenge&quot;&gt; Listen (6:28)&lt;/a&gt; What is the Discovery Fast Track Challenge?

&lt;a href=&quot;http://mendelspod.com/podcast/how-do-reseachers-benefit-if-they-are-chosen&quot;&gt; Listen (4:25)&lt;/a&gt; How do the reseachers benefit if they are chosen?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Pearl%20Huang%20Show.mp3" length="20619819" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/big-pharma-does-some-farming-pearl-huang-gsk/</guid>
 <pubDate>Tue, 19 Aug 2014 09:26:53 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/PearlHuangSmall.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Why Internet Traffic Directors Should Sit Down with Biologists:  George Poste Talks Complex Systems</title>
 <link>https://mendelspod.com/podcast/why-internet-traffic-directors-should-sit-down-biologists-george-poste-talks-complex-systems/</link>
 <description>Guest:

George Poste, Chief Scientist, Complex Adaptive Systems; Regents’ Professor and Del E. Webb Chair in Health Innovation, ASU&lt;br /&gt;
   &lt;a href=&quot;http://mendelspod.com/guests/george-poste&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/paradigm-shift-systems-thinking&quot;&gt; Listen (5:51)&lt;/a&gt; A paradigm shift to systems thinking</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/George%20Poste%20Show.mp3" length="44702091" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/why-internet-traffic-directors-should-sit-down-biologists-george-poste-talks-complex-systems/</guid>
 <pubDate>Thu, 14 Aug 2014 12:18:26 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/GeorgePosteSmall.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Pioneering Use of the Microbiome:  Colleen Cutcliffe, Whole Biome</title>
 <link>https://mendelspod.com/podcast/pioneering-use-microbiome-colleen-cutcliffe-whole-biome/</link>
 <description>Guest:

Colleen Cutcliffe, CEO, Whole Biome&lt;br /&gt;
   &lt;a href=&quot;http://mendelspod.com/guests/colleen-cutcliffe&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/do-we-know-enough-about-microbiome-yet-commercialize-it&quot;&gt; Listen (2:32)&lt;/a&gt; Do we know enough about the microbiome yet to commercialize it?

&lt;a href=&quot;http://mendelspod.com/podcast/complete-biome-test&quot;&gt; Listen (5:58)&lt;/a&gt; The Complete Biome Test</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Colleen%20Cutcliffe%20Show.mp3" length="24411051" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/pioneering-use-microbiome-colleen-cutcliffe-whole-biome/</guid>
 <pubDate>Mon, 11 Aug 2014 20:23:43 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/ColleenCutcliffeSmall.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> The FDA on LDT Draft Guidance Notice to Congress</title>
 <link>https://mendelspod.com/podcast/fda-ldt-draft-guidance-notice-congress/</link>
 <description>Guests:

Liz Mansfield, Deputy Office Director of Personalized Medicine, OIR, FDA&lt;br /&gt;
   &lt;a href=&quot;http://mendelspod.com/guests/liz-mansfield&quot;&gt;Bio and Contact Info&lt;/a&gt;

Katie Serrano, Deputy Director of the Division of Chemistry and Toxicology, OIR, FDA&lt;br /&gt;
   &lt;a href=&quot;http://mendelspod.com/guests/katie-serrano&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/what-was-submitted-congress&quot;&gt; Listen (4:08)&lt;/a&gt; What was submitted to Congress?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/FDA%20LDT%20Show%202014.mp3" length="31890267" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/fda-ldt-draft-guidance-notice-congress/</guid>
 <pubDate>Thu, 07 Aug 2014 09:27:50 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/FDASmall.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> NIH Goes Lean with Steve Blank</title>
 <link>https://mendelspod.com/podcast/nih-goes-lean-steve-blank/</link>
 <description>Guest:  Steve Blank,  Author, Entrepreneur, Educator 
&lt;a href=&quot;http://mendelspod.com/guests/steve-blank&quot;&gt;Bio and Contact Info&lt;/a&gt;



Chapters:  (Advance the marker)

Intro

0:59        What are you up to with the NIH?

4:39        The scientific method for entrepreneurship

8:14        Do scientists resist learning about business?

10:50   &quot;I’m from the U.S. Government, and we need your help!&quot;</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Steve%20Blank.mp3" length="64469094" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/nih-goes-lean-steve-blank/</guid>
 <pubDate>Sun, 03 Aug 2014 22:11:46 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/SmSteveBlank.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>The Perfect 46 with Brett Ryan Bonowicz, Filmmaker</title>
 <link>https://mendelspod.com/podcast/perfect-46-brett-ryan-bonowicz-filmmaker/</link>
 <description>Guest:

Brett Ryan Bonowicz, Filmmaker&lt;br /&gt;
   &lt;a href=&quot;http://mendelspod.com/guests/brett-ryan-bonowicz&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/where-fiction-your-science-fiction&quot;&gt; Listen (4:00)&lt;/a&gt; Where is the &quot;fiction&quot; in your science fiction?

&lt;a href=&quot;http://mendelspod.com/podcast/upcoming-screenings&quot;&gt; Listen (4:47)&lt;/a&gt; Upcoming screenings</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Brett%20Ryan%20Bonowicz%20Show.mp3" length="29573019" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/perfect-46-brett-ryan-bonowicz-filmmaker/</guid>
 <pubDate>Thu, 31 Jul 2014 11:34:51 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/BrettRyanBonowiczSmall.png" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>The Lowdown on Adaptive Clinical Trials with Don Berry</title>
 <link>https://mendelspod.com/podcast/adaptive-clinical-trials-don-berry/</link>
 <description>Guest:

Don Berry, Prof of Statistics, MD Anderson Cancer Center&lt;br /&gt;
   &lt;a href=&quot;http://mendelspod.com/guests/don-berry&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/what-goal-i-spy-trials&quot;&gt; Listen (5:39)&lt;/a&gt; What is the goal of I-SPY trials?

&lt;a href=&quot;http://mendelspod.com/podcast/why-were-adaptive-trials-not-introduced-sooner&quot;&gt; Listen (8:31)&lt;/a&gt; Why were adaptive trials not introduced sooner?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Don%20Berry%20Show.mp3" length="34855515" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/adaptive-clinical-trials-don-berry/</guid>
 <pubDate>Mon, 28 Jul 2014 09:24:28 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/DonBerry_1.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Are We Driving Innovation without the Quality?  Pete Kissinger, Purdue</title>
 <link>https://mendelspod.com/podcast/are-we-driving-innovation-without-quality-pete-kissinger-purdue/</link>
 <description>Guest:

Pete Kissinger, Chemist, Purdue University&lt;br /&gt;
   &lt;a href=&quot;http://mendelspod.com/guests/pete-kissinger&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/many-problems-life-science-traced-back-poor-measurements&quot;&gt; Listen (4:43)&lt;/a&gt; Many problems in life science traced back to poor measurements

&lt;a href=&quot;http://mendelspod.com/podcast/innovation-without-quality&quot;&gt; Listen (2:50)&lt;/a&gt; Innovation without quality</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Pete%20Kissinger%20Show.mp3" length="38175003" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/are-we-driving-innovation-without-quality-pete-kissinger-purdue/</guid>
 <pubDate>Wed, 23 Jul 2014 22:03:05 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/PeteKissingerSmall.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>The Basic Biology Lab Goes into the Cloud:  Brian Frezza, Emerald Therapeutics</title>
 <link>https://mendelspod.com/podcast/basic-biology-lab-goes-cloud-brian-frezza-emerald-therapeutics/</link>
 <description>Guest:  Brian Frezza, Co-Founder, Co-CEO, Emerald Therapeutics
&lt;a href=&quot;http://mendelspod.com/guests/brian-frezza&quot;&gt;Bio and Contact Info&lt;/a&gt;



Chapters:  (Advance the marker)

0:50  What is the Emerald Cloud Lab?

4:16  Does this impact the scientific method?

10:00  Pulling the labor, not the scientist out

14:20  Much more data detail

19:52  A chance to improve reproducibility</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Brian%20Frezza%202014.mp3" length="58984555" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/basic-biology-lab-goes-cloud-brian-frezza-emerald-therapeutics/</guid>
 <pubDate>Sun, 20 Jul 2014 18:30:54 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/BrianFrezzaSmall.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Bio-Sample Quality Matters! Carolyn Compton, ASU</title>
 <link>https://mendelspod.com/podcast/bio-sample-quality-matters-carolyn-compton-asu/</link>
 <description>Guest:

Carolyn Compton, Professor of Pathology, ASU&lt;br /&gt;
   &lt;a href=&quot;http://mendelspod.com/guests/carolyn-compton&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/qualitymof-biomarker-data-limited-quality-biospecimen&quot;&gt; Listen (5:40)&lt;/a&gt; Quality of biomarker data limited by quality of biospecimen

&lt;a href=&quot;http://mendelspod.com/podcast/degradation-samples&quot;&gt; Listen (5:24)&lt;/a&gt; Degradation of samples</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Carolyn%20Compton%20Show_0.mp3" length="31031019" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/bio-sample-quality-matters-carolyn-compton-asu/</guid>
 <pubDate>Thu, 10 Jul 2014 17:59:32 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/CarolynComptonSmall2.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> Rare Disease Horizons, Part IV: Biobanking and Disease Registries with Liz Horn</title>
 <link>https://mendelspod.com/podcast/rare-disease-horizons-part-iv-biobanking-and-disease-registries-liz-horn/</link>
 <description>Guest:

 Liz Horn, PhD, Patient Advocate 
&lt;a href=&quot;http://mendelspod.com/guests/liz-horn&quot;&gt; Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/what-biobanking&quot;&gt; Listen (8:22)&lt;/a&gt; What is biobanking?

&lt;a href=&quot;http://mendelspod.com/podcast/sample-collection-and-diagnostic-odyssee&quot;&gt; Listen (4:05)&lt;/a&gt; Sample collection and the diagnostic odyssey</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Liz%20Horn%20Show.mp3" length="22975515" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/rare-disease-horizons-part-iv-biobanking-and-disease-registries-liz-horn/</guid>
 <pubDate>Tue, 01 Jul 2014 15:19:35 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/LizHorn-port.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Can We Do DTC Genomics Right?  Misha Angrist, Part II</title>
 <link>https://mendelspod.com/podcast/can-we-do-dtc-genomics-right-misha-angrist-part-ii/</link>
 <description>Guest:

Misha Angrist, Author, Assoc. Professor, Duke Institute for Genomic Sciences
   &lt;a href=&quot;http://mendelspod.com/guests/angrist-misha-phd-mfa&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/presidential-bioethics-commissions-do-not-have-good-record&quot;&gt; Listen (7:03)&lt;/a&gt; Presidential bioethics commissions do not have a good record</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Misha%20Angrist%20Show%20Part%20II.mp3" length="32890779" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/can-we-do-dtc-genomics-right-misha-angrist-part-ii/</guid>
 <pubDate>Sat, 21 Jun 2014 14:36:59 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/MishaAngristSmall_1.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> The Impossible Job of Genetic Counseling: Misha Angrist Part I</title>
 <link>https://mendelspod.com/podcast/impossible-job-genetic-counseling-misha-angrist-part-i/</link>
 <description>Guest:

Misha Angrist, Author, Assoc. Professor, Duke Institute for Genomic Sciences
   &lt;a href=&quot;http://mendelspod.com/guests/angrist-misha-phd-mfa&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/new-ma-bioethics-and-science-policy&quot;&gt; Listen (7:25)&lt;/a&gt; New MA in Bioethics and Science Policy</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Misha%20Angrist%20Show%20Part%20I.mp3" length="29619675" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/impossible-job-genetic-counseling-misha-angrist-part-i/</guid>
 <pubDate>Tue, 17 Jun 2014 12:00:48 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/MishaAngristSmall.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Pre-Leukemic Stem Cells with Liran Shlush</title>
 <link>https://mendelspod.com/podcast/pre-leukemic-stem-cells-liran-shlush/</link>
 <description>Guest:  Liran Shlush, Researcher, Princess Margaret Cancer Center
   &lt;a href=&quot;http://mendelspod.com/guests/liran-shlush&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/preleukemic-stem-cells&quot;&gt; Listen (4:44)&lt;/a&gt; Preleukemic stem cells

&lt;a href=&quot;http://mendelspod.com/podcast/implications-aml-therapy-and-diagnosis&quot;&gt; Listen (7:42)&lt;/a&gt; Implications for AML therapy and diagnosis</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Liran%20Shlush%20Show.mp3" length="23763915" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/pre-leukemic-stem-cells-liran-shlush/</guid>
 <pubDate>Tue, 10 Jun 2014 11:31:02 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/LiranShlushSmall.jpeg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Training the Next Generation of Bioinformaticians: Russ Altman, Stanford</title>
 <link>https://mendelspod.com/podcast/training-next-generation-bioinformaticians-russ-altman-stanford/</link>
 <description>Guest:

Russ Altman, Dept Chair, Bioengineering, Stanford University
   &lt;a href=&quot;http://mendelspod.com/guests/altman-russ-md-phd&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/bioinformatician-bottleneck&quot;&gt; Listen (5:32)&lt;/a&gt; A bioinformatician bottleneck?

&lt;a href=&quot;http://mendelspod.com/podcast/does-engineer-or-coder-have-enough-basic-biology&quot;&gt; Listen (4:19)&lt;/a&gt; Does the engineer or coder have enough basic biology?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Russ%20Altman%20Show%202014.mp3" length="31372731" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/training-next-generation-bioinformaticians-russ-altman-stanford/</guid>
 <pubDate>Wed, 04 Jun 2014 22:52:51 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/RussAltman.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title> Rare Disease Horizons: The Hope of New Research and Technology, Part III: Stem Cells with Larry Goldstein, UCSD</title>
 <link>https://mendelspod.com/podcast/rare-disease-horizons-hope-new-research-and-technology-part-iii-stem-cells-larry-goldstein/</link>
 <description>Guests:

Larry Goldstein, PhD, Director, UCSD Stem Cell Program&lt;br /&gt;
&lt;a href=&quot;http://mendelspod.com/guests/larry-goldstein&quot;&gt; Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/where-are-we-today-stem-cell-research&quot;&gt; Listen (3:16)&lt;/a&gt; Where are we at today with stem cell research?

&lt;a href=&quot;http://mendelspod.com/podcast/one-step-beyond-animal-models&quot;&gt; Listen (5:14)&lt;/a&gt; One step beyond animal models</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Larry%20Goldstein%20Show_0.mp3" length="29713851" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/rare-disease-horizons-hope-new-research-and-technology-part-iii-stem-cells-larry-goldstein/</guid>
 <pubDate>Sun, 01 Jun 2014 20:53:18 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/stemcells.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
 <item> <title>Clinical Genomics Takes Hold in Iowa: Colleen Campbell, IIHG</title>
 <link>https://mendelspod.com/podcast/clinical-genomics-takes-hold-iowa-colleen-campbell-iihg/</link>
 <description>Guest:

Colleen Campbell, Assistant Director, University of Iowa - Iowa Institute for Human Genetics
   &lt;a href=&quot;http://mendelspod.com/guests/colleen-campbell&quot;&gt;Bio and Contact Info&lt;/a&gt;

&lt;a href=&quot;http://mendelspod.com/podcast/how-are-you-implementing-genomic-medicine&quot;&gt; Listen (2:35)&lt;/a&gt; How are you implementing genomic medicine?</description>
 <author>ayannamv@gmail.com (Ayanna Monteverdi)</author>
 <enclosure url="https://mendelspod.com/sites/default/files/Colleen%20Campbell%20Show.mp3" length="31808619" type="audio/mpeg" />
 <guid isPermaLink="false">https://mendelspod.com/podcast/clinical-genomics-takes-hold-iowa-colleen-campbell-iihg/</guid>
 <pubDate>Tue, 27 May 2014 16:19:32 -0500</pubDate>
 <source url="https://mendelspod.com/feed.xml">Mendelspod Podcast</source>
 <itunes:image href="https://mendelspod.com/sites/default/files/CollenCampbellSmall.jpg" />
 <itunes:author> ayannamv@gmail.com (Ayanna Monteverdi)
</itunes:author>
</item>
</channel>
</rss>